US20080199510A1 - Thermo-mechanically controlled implants and methods of use - Google Patents
Thermo-mechanically controlled implants and methods of use Download PDFInfo
- Publication number
- US20080199510A1 US20080199510A1 US12/033,586 US3358608A US2008199510A1 US 20080199510 A1 US20080199510 A1 US 20080199510A1 US 3358608 A US3358608 A US 3358608A US 2008199510 A1 US2008199510 A1 US 2008199510A1
- Authority
- US
- United States
- Prior art keywords
- implant
- implant according
- electromagnetic radiation
- particles
- exposing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/12—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L31/125—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L31/128—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix containing other specific inorganic fillers not covered by A61L31/126 or A61L31/127
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/12—Mammary prostheses and implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/28—Bones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/148—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- G—PHYSICS
- G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
- G21K—TECHNIQUES FOR HANDLING PARTICLES OR IONISING RADIATION NOT OTHERWISE PROVIDED FOR; IRRADIATION DEVICES; GAMMA RAY OR X-RAY MICROSCOPES
- G21K5/00—Irradiation devices
- G21K5/02—Irradiation devices having no beam-forming means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0004—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0071—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof thermoplastic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0001—Means for transferring electromagnetic energy to implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0004—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof adjustable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0004—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof adjustable
- A61F2250/0012—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof adjustable for adjusting elasticity, flexibility, spring rate or mechanical tension
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/04—Materials or treatment for tissue regeneration for mammary reconstruction
Definitions
- This invention relates generally to medical apparatus and methods, and more specifically to implants and biodegradable implants for use in the vascular system as well as other body lumens and cavities.
- Implants are also used as matrices for tissue growth (e.g. orthopedic bone fusion procedures), to control unwanted tissue growth and for delivery of therapeutic agents to tissue. Implants may also be employed to join tissue surfaces together or for isolating or protecting tissue lesions in order to enable or mediate healing. Implants are also used to mediate the rate of substances or energy passing into, out of, or through tissue.
- implants are fabricated using various metals and/or polymers.
- common metals include stainless steel, titanium, nickel-titanium alloys like Nitinol and polymers such as PTFE (e.g. Teflon®), polyethylene, polyurethane and polyester are often used in implants.
- PTFE e.g. Teflon®
- polyethylene e.g. polyethylene
- polyurethane polyurethane
- polyester e.g. Teflon®
- a potential disadvantage of these permanent implants is that the implant materials may be harder and stiffer than the surrounding tissues, thus anatomical or physiological mismatch may occur, potentially resulting in tissue damage or causing unwanted biological responses. Some materials may fatigue over time and break which can disrupt the layer of endothelial cells potentially causing thrombosis. Additionally, a permanent implant is not always required.
- biodegradable polymeric implants include the aliphatic polyester polylactic acid or polylactide (PLA) and polyglycolide (PGA).
- PLA aliphatic polyester polylactic acid or polylactide
- PGA polyglycolide
- PLA was originally proposed for use in suture material in the late 1960's.
- PLA was proposed as a suture material including both the optically active poly-L-lactide (PLLA) and the racemic mixture poly-DL-lactide (PDLA).
- PLLA has also been used in biodegradable stents, as reported by Igaki and Tamai.
- a co-polymer of PLA and PGA, known as PLGA has also been proposed for use in implants.
- Another material which has recently been proposed (in the 1980's) for use in sutures and orthopedic implants is polydioxanone.
- implantable drug delivery systems using polyanhydrides were proposed by Langer et al. at the Massachusetts Institute of Technology, and more recently tyrosine derived polyarylate has seen use in hernia repair and companies are developing biodegradable stents composed of materials such as a tyrosine derived polycarbonate, poly(DTE carbonate).
- additives may be mixed with the biodegradable polymers to decrease the glass transition temperature, for example 2-10% ⁇ -caprolactone added to 90-98% PLLA can reduce the glass transition temperature down to about 38°-55° C., but a heat source hotter than the glass transition temperature may still be required due to heat transfer inefficiencies or non-uniform heating, therefore, similar complications may still arise.
- One proposed solution to the challenge of non-uniform heating is to coat the implant with a radiation absorbing material which converts radiation to heat.
- exemplary coatings include chromophores like indocyanine green, vital blue, carbon black and methylene blue.
- the radiation often ultraviolet or visible light must therefore be supplied in situ from a second device due to the poor penetration of the radiation through the tissue. Additionally, production of sufficient and uniform heat using this technique remains a challenge.
- the chromophores may degrade into unwanted chemicals that are toxic to the body. Therefore, there exists a need for an easier, less toxic and less invasive way to heat implants, including biodegradable polymer implants, to an elevated temperature so that they may be shaped or molded in situ. Furthermore, such techniques should also be able to heat the implant uniformly.
- biodegradable implants will degrade over time, it would also be desirable to be able to control the rate of degradation. For example, when an implant is no longer required, it would be desirable to be able to accelerate the degradation rate so that the implant breaks down faster than its normal in situ rate. For this reason, there is also need for a way to control the degradation rate of a biodegradable implant.
- Prior patents describing nanoshells for converting incident radiation into heat include: U.S. Pat. Nos. 6,344,272; 6,428,811; 6,530,944; 6,645,517; 6,660,381; 6,685,730; 6,699,724; 6,778,316; and 6,852,252.
- Prior patents describing thermo-mechanically expansion of stents include: U.S. Pat. Nos. 5,670,161; 5,741,323; 6,607,553; 6,736,842.
- Prior patents describing meltable stents include: U.S. Pat. Nos. 4,690,684 and 4,770,176.
- Prior patent describing bioerodable polyanhydrides for controlled drug delivery include: U.S. Pat. No.
- Prior patents describing tyrosine derived polycarbonate as an implant include: U.S. Pat. Nos. 6,951,053; 7,101,840; and 7,005,454.
- Prior patents describing biodegradable stents include: U.S. Pat. Nos. 5,733,327; 5,762,625; 5,817,100; 6,045,568; 6,080,177, 6,200,335; 6,413,272; 6,500,204; 6,632,242; RE38,653; RE38,711; 7,066,952; and 7,070,615. The full disclosure of each of these patents is incorporated herein by reference.
- the invention generally provides for an implant having a plurality of particles dispersed therein.
- the particles are adapted to convert incident radiation into heat energy when the particles are irradiated with electromagnetic radiation.
- the particles are in thermal contact with the implant and therefore the heat generated by the particles raises the temperature of the implant.
- the increased temperature changes a material property of the implant.
- an implant for use in tissue comprises a structure that is adapted for implantation into the tissue and that has a first material property at normal body temperature.
- the material property is variable at an elevated temperature above normal body temperature.
- the implant also comprises a plurality of particles that are dispersed in the structure and that are adapted to convert incident radiation into heat energy when the particles are irradiated with electromagnetic radiation. The particles are in thermal contact with the structure and thus exposure of the particles to incident radiation raises the temperature of the structure thereby changing the first material property.
- an expandable implant for use in tissue comprises a structure that is adapted for implantation into the tissue and that is not plastically deformable at normal body temperature but that is plastically deformable at an elevated temperature above normal body temperature.
- the implant also has a plurality of particles dispersed in the structure and that are adapted to convert incident radiation into heat energy when irradiated with electromagnetic radiation. The particles are in thermal contact with the structure such that exposure of the particles to the incident radiation raises the temperature of the structure allowing it to be plastically deformed.
- an expandable, biodegradable implant for use in tissue comprises a biodegradable structure that is adapted for implantation into the tissue and that degrades at a first rate when implanted in the tissue at normal body temperature.
- the implant also comprises a plurality of particles that are dispersed in the structure with the particles adapted to convert incident radiation into heat energy when they are irradiated with electromagnetic radiation. The particles are in thermal contact with the structure such that exposure of the particles to the incident radiation raises the temperature of the structure thereby increasing the degradation rate of the structure relative to the first rate.
- the degradation rate of an implant may also be controlled by using an additional reagent such as a catalyst or enzyme.
- the reagent is adapted to react with the structure so as to increase the structure's degradation rate relative to the first rate at normal body temperature.
- the reagent is dispersed in a carrier such as a microsphere along with particles such as nanoshells.
- the microsphere which may be a hydrogel, is distributed in the implant structure and exposure of the particles to incident radiation raises the temperature of the carrier or microsphere, thereby releasing the reagent.
- the structure is biodegradable and is composed of a polymer or copolymer, either synthetic or natural, that is not plastically expandable at normal body temperature but is thermo-mechanically expandable at an elevated temperature above normal body temperature.
- the structure is often composed of one or more of the following materials including, polyhydroxyalkanoates, polyalphahydroxy acids, polysaccharides, proteins, hydrogels, lignin, shellac, natural rubber, polyanhydrides, polyamide esters, polyvinyl esters, polyvinyl alcohols, polyalkylene esters, polyethylene oxide, polyvinylpyrrolidone, polyethylene maleic anhydride and poly(glycerol-sibacate).
- the structure may also comprise poly-L-lactide, poly- ⁇ -caprolactone or a biological fluid in the solid state such as blood plasma.
- the material property may be the biodegradation rate of the structure, viscosity or the property may be the ability of the structure to be plastically expanded.
- the structure may be a stent which may be tubular and that is radially expandable at the elevated temperature.
- the stent may comprise a tube having a sidewall and the sidewall may define a plurality of openings therein.
- the structure may also have a therapeutic agent that is adapted to be released therefrom.
- the therapeutic agent may be an anti-restenosis agent or it may be at least one of the following, including antibiotics, thrombolytics, anti-thrombotics, anti-inflammatories, cytotoxic agents, anti-proliferative agents, vasodilators, gene therapy agents, radioactive agents, immunosuppressants, chemotherapeutics, endothelial cell attractors, endothelial cell promoters, stem cells and combinations thereof.
- the structure may be adapted to be implanted into a breast or it may be used to deliver a drug to the tissue.
- the structure may also be used to exclude aneurysms or it may be an orthopedic implant.
- the particles may comprise nanoparticles or nanoshells and often the particles have a non-conducting core layer such as silicon dioxide, with a first thickness and a conducting outer shell layer, such as gold, adjacent to the core layer with a second thickness.
- the ratio of the first thickness to the second thickness defines a maximum wavelength of electromagnetic radiation converted by the particles into heat.
- the particles are substantially spherical.
- the elevated temperature is in the range from about 38° C. to about 60° C. and the electromagnetic radiation often is ultraviolet, visible, near infrared or infrared light.
- a method of controlling a material property of an implant comprises the steps of providing an implant having a plurality of particles dispersed therein.
- the implant has a first material property when implanted in tissue at normal body temperature and the material property is variable at an elevated temperature above normal body temperature.
- Exposing the implant to electromagnetic radiation results in the incident radiation being converted into heat energy thus raising the temperature of the implant above normal body temperature and thereby changing the material property relative to the first material property.
- a method of delivering an expandable implant to a treatment site in a body comprises providing an implant having a plurality of particles dispersed therein and positioning the implant at the treatment site. Positioning may include advancing a catheter through a body lumen with the implant disposed on the catheter. Exposing the implant to electromagnetic radiation allows the particles to convert the incident radiation into heat energy. The heat energy raises the implant temperature above its glass transition temperature such that the implant may be plastically deformed so as to change its shape. Expanding the implant may include expanding a balloon.
- a method of controlling the degradation rate of an implant comprises providing a biodegradable implant having a plurality of particles dispersed therein.
- the implant degrades at a first rate when implanted in tissue at normal body temperature.
- Exposing the implant to electromagnetic radiation allows the particles to convert the incident radiation into heat energy which raises the temperature of the implant above normal body temperature.
- the elevated temperature changes the biodegradation rate of the implant relative to the first rate.
- Exposing the implant may include irradiating a carrier such as a microsphere, dispersed in the implant and containing a reagent and particles. The carrier heats up and releases the reagent when irradiated and the reagent reacts with the implant to degrade it.
- the reagent may be an enzyme or catalyst.
- the method may also comprise discontinuing exposure of the implant to the electromagnetic radiation in order to allow the implant to cool down so that it returns to body temperature so that the implant is substantially undeformable plastically at body temperature.
- the method may also include monitoring the temperature of implant. Exposing the implant to electromagnetic radiation may include exposing the implant from outside the body or from within the body. Sometimes a catheter may be used to deliver the radiation to the implant. The radiation may be delivered for a fixed duration of time, continuously for a defined period or over periodic intervals until a desired temperature obtained in the implant.
- FIGS. 1A-1B show nanoshells having various outer shell thicknesses.
- FIG. 2 illustrates the optical resonances of metal nanoshells having various ratios of core radius to shell thickness.
- FIG. 3A shows a biodegradable stent having nanoshells dispersed therein.
- FIG. 3B shows a nanoshell generating heat in a section of the stent shown in FIG. 3A .
- FIG. 3C shows an implant made from frozen biological fluid and having nanoshells dispersed therein.
- FIG. 3D shows the implant of FIG. 3C used to facilitate creation of an anastomosis.
- FIGS. 4A-4B illustrate a preferred embodiment of a stent in the unexpanded and expanded state.
- FIGS. 5A-5E illustrate stent expansion in accordance with an exemplary embodiment.
- FIGS. 6A-6E illustrate stent biodegradation in accordance with an exemplary embodiment.
- FIG. 7 illustrates a microsphere containing nanoshells and a chemical reagent dispersed therein.
- FIGS. 8A-8D illustrate expansion of a breast implant in accordance with an exemplary embodiment.
- FIGS. 1A and 1B illustrate nanoshells having various outer shell thicknesses.
- Nanoshells are nanoparticles having a diameter ranging from a few nanometers up to about 5 microns.
- the nanoshells are composed of a non-conducting, semiconductor or dielectric inner core layer and an ultra thin conducting outer shell layer.
- nanoshell 100 is spherically shaped and has an outer spherical shell 102 made from gold.
- a portion 104 of outer shell 102 has been removed in FIG. 1A so that the inner spherical core 106 is visible.
- Inner core 106 is made from silicon dioxide.
- Nanoshells may be made with various inner core diameters and outer shell thicknesses.
- FIG. 1B illustrates another nanoshell 110 having a thinner outer shell 112 compared with the outer shell 102 of FIG. 1A .
- the nanoshell in FIG. 1B also has a section 114 of outer shell 112 removed so that the inner core 106 is visible.
- Nanoshells have a unique ability to interact with specific wavelengths of electromagnetic radiation and effectively convert the incident radiation into heat energy. By adjusting the relative core and shell thicknesses, and choice of materials, nanoshells can be fabricated that will react with or scatter light at any wavelength across much of the ultraviolet, visible and infrared range of the electromagnetic spectrum. The nanoshell may therefore be tuned to specific wavelengths of electromagnetic radiation and the conversion of incident radiation to heat energy can be optimized.
- FIG. 2 shows a graph 200 of the optical resonances of metal nanoshells having various ratios of core radius to shell thickness.
- nanoshells 202 and 204 both have a 60 nm inner core made from silicon dioxide.
- Nanoshell 202 has a gold outer shell, 20 nm thick and the resulting maximum absorption wavelength is approximately 740 nm. As the shell thickness decreases, the maximum absorption wavelength increases.
- Nanoshell 204 has a gold shell layer 5 nm thick and the resulting maximum absorption wavelength is approximately 1010 nm.
- the tunability of nanoshells, including the relationship between the ratio of core diameter to shell thickness and maximum absorption wavelength is more fully discussed in U.S. Pat. No. 6,344,272 which has previously been incorporated herein by reference.
- Nanoshells are well described in the scientific and patent literature. Other aspects of nanoshells such as manufacturing methods, materials and principles of operation are described in U.S. Pat. Nos. 6,428,811; 6,530,944; 6,645,517; 6,660,381; 6,685,730; 6,699,724; 6,778,316; and 6,852,252, the entire contents of which have previously been incorporated herein by reference.
- nanoshells are efficient at converting incident radiation into heat, they may be dispersed in implants and light or other forms of electromagnetic radiation may be used to heat up the implant. Furthermore, since a nanoshell may be tuned to certain wavelengths, a nanoshell that preferentially interacts with light at near infrared wavelengths between approximately 700 and approximately 2500 nm is desirable, and more preferably between about 800 nm and 1200 nm, since this range of wavelengths is transmitted through tissue with very little absorption and therefore relatively little attenuation. Thus the majority of the light is delivered to the nanoparticles, converted into heat and transferred to the implant in which the nanoparticles are dispersed. This makes external access to an implanted device possible and heating of the tissue surrounding the implant is substantially avoided.
- a Nd:YAG laser emits light at a wavelength of 1064 nm and hence is ideal for irradiating an implant from outside the body.
- a biodegradable implant as the implant breaks down the nanoshells are released into surrounding tissue. Due to their small size, the nanoshells are easily purged by body systems such as the kidneys. Nanoshells therefore present a unique way of allowing an implant to be heated from outside the body with minimal biocompatibility issues.
- FIG. 3A shows an implantable stent 300 .
- Stents are defined to include any of the array of expandable prostheses and scaffolds which are introduced into a lumen at a target treatment site and expanded in situ thereby exerting a radially outward force against the lumen wall to restore patency.
- Stents may be implanted in a number of lumens including the coronary and peripheral vasculature, biliary ducts, urethra and ureter, as well as other body cavities.
- Urethral and ureter stents are well reported in the patent literature, including for example U.S. Pat. Nos. 7,112,226 and 7,044,981, the entire contents of which are incorporated herein by reference.
- Stent 300 is a tubular prosthesis made from any material 302 that is solid at normal body temperature and that may be plastically deformed at an elevated temperature. Examples include standard engineering thermoplastics such as polyurethane and others well known to those skilled in the art, including biodegradable polymers like polylactide. Stent 300 may optionally be a copolymer containing 2-10% of poly- ⁇ -caprolactone so as to adjust the mechanical properties of the stent, including lowering the glass transition temperature to just above normal body temperature. In preferred embodiments, the copolymer stent 300 has a glass transition temperature in the range from about 40° to about 60° C. Stent 300 may also comprise plasticizers to further soften the implant.
- the plasticizers should be biocompatible such as oleic acid and linoleic acid which are classified under Food and Drug Administration (FDA) guidelines for food additives as being Generally Recognized as Safe (GRAS).
- FDA Food and Drug Administration
- GRAS Generally Recognized as Safe
- the stent 300 may be delivered to the site of a stenotic lesion or an intimal dissection and expanded in situ in order to restore patency of a vessel.
- nanoparticles 304 preferably 0.0001 to 1% nanoparticles 304 , more preferably 0.00025% to 0.5%, and most preferably 0.0005% to 0.1% nanoparticles are dispersed in the stent 300 .
- the nanoparticles 304 may be tuned to interact with many forms of electromagnetic radiation including microwaves, ultrasound, magnetic fields, electric fields, radiofrequency, infrared, visible, ultraviolet, laser, x-rays, gamma rays and cosmic rays.
- the nanoparticles 304 are preferably tuned to interact with near infrared radiation having a wavelength approximately 1064 nm so that that a Nd:YAG laser may be used to irradiate stent 300 from outside the body.
- the nanoparticles 304 in this embodiment are preferably nanoshells having an outer shell composed of gold and an inner core composed of silicon dioxide.
- the nanoparticles 304 convert the incident radiation into heat, thereby heating the polymer matrix above its glass transition temperature and allowing stent 300 to be plastically deformed into a lesion with a balloon or other expandable member in situ.
- stent 300 may also include quantum dots dispersed therein. Quantum dots have many desirable characteristics, including favorable optical properties. The quantum dots may be used to help visualize stent 300 while in situ since they fluoresce when irradiated with certain wavelengths of light. Examples of materials used to fabricate quantum dots include cadmium selenide, cadmium sulfide, zinc sulfide and zinc selenide.
- FIG. 3B illustrates a section 308 of FIG. 3A which has been enlarged to show how incident radiation 312 interacts with nanoparticle 304 such that the radiation 312 is converted into heat by nanoparticle 304 and the heat 310 is emitted to the surrounding polymer matrix 302 .
- stent 300 is a tubular prosthesis without any apertures in the sidewalls and therefore it could also be used to exclude an aneurysm. However, this is not meant to be limiting and stent 300 may be modified to include apertures in the sidewalls.
- near infrared light is used to irradiate the nanoparticles and generate heat.
- many wavelengths of electromagnetic radiation may also be used, including a magnetic field.
- the nanoparticles may be magnetically responsive so that they produce heat upon exposure to a magnetic field. Examples of magnetically responsive materials include iron oxides, magnetite (Fe 3 O 4 ) and maghemite ( ⁇ -Fe 3 O 3 ).
- FIGS. 4A and 4B illustrate a preferred embodiment of one possible stent geometry.
- Stent segment 32 comprises parallel rows 122 A, 122 B and 122 C of 1-shaped cells 124 formed into a cylindrical shape around axial axis A.
- Cells 124 have upper and lower axial slots 126 and a connecting circumferential slot 128 .
- Upper and lower slots 126 are bounded by upper axial struts 132 , lower axial struts 130 , curved outer ends 134 , and curved inner ends 136 .
- Circumferential slots 128 are bounded by outer circumferential strut 138 and inner circumferential strut 140 .
- Each I-shaped cell 124 is connected to the adjacent I-shaped cell 124 in the same row 122 by a circumferential connecting strut 142 .
- Row 122 A is connected to row 122 B by the merger or joining of curved inner ends 136 of at least one of upper and lower slots 126 in each cell 124 .
- the stent includes a bulge 144 in upper and lower axial struts 130 , 132 extending circumferentially outwardly from axial slots 126 . These give axial slots 126 an arrowhead or cross shape at their inner and outer ends.
- the bulge 144 in each upper axial strut 130 extends toward the bulge 144 in a lower axial strut 132 in the same cell 124 or in an adjacent cell 124 , thus creating a concave abutment 146 in the space between each axial slot 126 .
- Concave abutments 146 are configured to receive and engage curved outer ends 134 of cells 124 in the adjacent stent segment, thereby maintaining spacing between the stent segments.
- the axial location of bulges 144 along upper and lower axial struts 130 , 132 may be selected to provide the desired degree of inter-segment spacing.
- FIG. 4B shows a stent 32 of FIG. 4A in an expanded condition. It may be seen that axial slots 124 are deformed into a circumferentially widened modified diamond shape with bulges 144 on the now diagonal upper and lower axial struts 130 , 132 . Circumferential slots 128 are generally the same size and shape as in the unexpanded configuration. Bulges 144 have been pulled away from each other to some extent, but still provide a concave abutment 146 to maintain a minimum degree of spacing between adjacent stent segments. As in the earlier embodiment, some axial shortening of each segment occurs upon expansion and stent geometry can be optimized to provide the ideal intersegment spacing.
- FIGS. 4A-4B also enables access to vessel side branches blocked by stent segment 32 .
- a dilatation catheter may be inserted into circumferential slot 128 and expanded to provide an enlarged opening through which a side branch may be entered.
- stent 300 may also comprise a therapeutic agent 306 .
- stent 300 may be coated, impregnated, infused or otherwise coupled with one or more drugs that inhibit restenosis, such as Rapamycin, Everolimus, Biolimus A9, Paclitaxel, prodrugs, or derivatives of the aforementioned, or other suitable agents, preferably carried in a durable or bioerodable carrier of polymeric or other suitable material.
- drugs that inhibit restenosis such as Rapamycin, Everolimus, Biolimus A9, Paclitaxel, prodrugs, or derivatives of the aforementioned, or other suitable agents, preferably carried in a durable or bioerodable carrier of polymeric or other suitable material.
- stent 300 may be coated with other types of drugs or therapeutic materials such as antibiotics, thrombolytics, anti-thrombotics, anti-inflammatories, cytotoxic agents, anti-proliferative agents, vasodilators, gene therapy agents, radioactive agents, immunosuppressants, chemotherapeutics, endothelial cell attractors or promoters and/or stem cells.
- drugs or therapeutic materials such as antibiotics, thrombolytics, anti-thrombotics, anti-inflammatories, cytotoxic agents, anti-proliferative agents, vasodilators, gene therapy agents, radioactive agents, immunosuppressants, chemotherapeutics, endothelial cell attractors or promoters and/or stem cells.
- drugs or therapeutic materials such as antibiotics, thrombolytics, anti-thrombotics, anti-inflammatories, cytotoxic agents, anti-proliferative agents, vasodilators, gene therapy agents, radioactive agents, immunosuppressants, chemo
- FIG. 3C illustrates an implant where nanoshells may be used to control the degradation of the implant.
- a stent 325 is adapted for creating an anastomosis.
- the stent 325 may be made from a variety of meltable materials including polymers, frozen blood plasma or other biological fluids in the solid state.
- Nanoshells 330 are dispersed in the stent 325 .
- FIG. 3D shows the stent 325 placed into the ends V 1 , V 2 of the two vessels to be connected together, thereby aligning the ends together so that they may be sutured or thermally bonded together, creating an anastomosis 352 .
- stent 325 may be irradiated with near infrared light from outside the body.
- the nanoshells 330 convert the incident radiation into heat.
- the resulting heat melts the stent 325 thereby creating a patent lumen for fluid flow. Further details on meltable stents are disclosed in U.S. Pat. Nos. 4,690,684 and 4,770,176, the entire contents of which are fully incorporated herein by reference.
- FIGS. 5A-5E the deployment of a stent to treat a stenotic lesion is shown in accordance with an exemplary embodiment. While the embodiment will be described in the context of a femoral artery stent procedure, it should be understood that the invention may be employed in any variety of coronary or peripheral arteries, blood vessels and other body lumens in which stents or tubular prostheses are deployed, including the carotid and iliac arteries, blood vessels in the brain, other arteries or veins, as well as non-vascular body lumens such as the ureter, urethra, fallopian tubes, the hepatic and biliary duct and the like.
- FIG. 1 the deployment of a stent to treat a stenotic lesion is shown in accordance with an exemplary embodiment. While the embodiment will be described in the context of a femoral artery stent procedure, it should be understood that the invention may be employed in any variety of coronary or peripheral arteries, blood vessels and other body
- a stent delivery catheter 500 includes a stent 502 having a plurality of nanoshells 512 dispersed therein and mounted over an expandable balloon 506 attached to the distal end of catheter shaft 504 .
- a single biodegradable stent 502 is disposed on the delivery catheter 500 , although multiple stents may also be disposed on the delivery catheter 500 .
- Stent 502 is preferably composed of a copolymer containing approximately 90 to 99% polylactide with 1 to 10% poly- ⁇ -caprolactone, and more preferably 95 to 99% polylactide with 1 to 5% poly- ⁇ -caprolactone, uniformly blended with preferably 0.0001 to 1% gold nanoshells, more preferably 0.00025% to 0.5%, and most preferably 0.0005% to 0.1% gold nanoshells that are tuned to convert near infrared light into heat.
- Stent 502 may also be fabricated from any material that is solid at normal body temperature and that can be plastically deformed at an elevated temperature, thus many other polymers such as polyurethanes as well as other biodegradable materials may be used to fabricate the stent 502 . Delivery catheters such as over-the-wire systems and rapid exchange systems are well known in the art and may be used to deliver stent 502 to the lesion L.
- the delivery catheter 500 is introduced into a treatment vessel first, by placing an introducer sheath (not illustrated) into the target peripheral artery, typically using a percutaneous procedure such as the Seldinger technique or by surgical cutdown.
- the target vessel is a femoral artery.
- the introducer sheath is then advanced slightly into the femoral artery.
- a guidewire GW is then inserted through the introducer and advanced into the target vessel V where a lesion L to be treated is located.
- guidewire GW is then inserted through the distal end of catheter shaft 504 , through a lumen in catheter shaft 504 , exiting at the proximal end of catheter shaft 504 , which is outside the patient's body.
- Stent delivery catheter 500 is then slidably advanced over the guidewire GW into the vessel V so that stent 502 traverses the lesion L.
- Optional radiopaque markers may be placed on the catheter shaft 504 in order to facilitate visualization of the delivery catheter under fluoroscopy. Once the delivery catheter has been properly positioned in the vessel, the stent 502 may be heated up to facilitate its expansion.
- an external source of electromagnetic radiation 508 is used to irradiate stent 502 so as to heat it up.
- the external source of radiation is preferably a Nd:YAG laser which emits a wavelength of light approximately 1064 nm. This wavelength is applied extracorporally and the light 510 is transmitted through the tissue T to the stent 502 .
- Nanoshells 512 dispersed in the stent 502 are tuned to convert the light into heat. Heat generated by nanoshells 512 is transferred to the polymer which makes up stent 502 , thereby heating it up.
- radiation may be applied in situ.
- fiber optic catheter 514 shows a fiber optic catheter 514 deployed alongside delivery catheter 500 .
- the fiber optic catheter 514 is adapted to deliver the Nd:YAG laser light 516 directly to stent 502 .
- the delivery catheter 500 and the fiber optic catheter 514 may be combined into a single device that heats and deploys stent 502 .
- fiber optic catheter 514 includes an optional diffuser (not shown). The diffuser is adapted to spread out and scatter the radiation so as to cover a larger area of the stent 502 .
- T g glass transition temperature
- the exposure time is dependent upon many factors, including but not limited to, area of radiation coverage, wavelength and intensity of the radiation, type and mass of the implant material and nanoshell concentration. Therefore, exposure time could range from a few seconds to a few hours, and more preferably from about 10 seconds to about an hour. Longer exposure times are not desirable due to patient inconvenience.
- Stent 502 is fabricated from a material having a glass transition temperature above normal body temperature. Therefore, stent 502 is solid at or below normal body temperature. Normal body temperature is approximately 37° C., therefore the stent 502 material is selected to have a T g slightly higher than 37° C., yet not so high that the temperature required to heat the stent above T g results in tissue damage.
- stent 502 Once the temperature of stent 502 is raised above the glass transition temperature, it's viscosity decreases, permitting stent 502 to be plastically deformed.
- balloon 506 is expanded, typically with contrast media and/or saline and an inflation device such an IndeflatorTM, manufactured by Abbott (formerly Guidant Corp., Santa Clara, Calif.). Stent 502 is soft and therefore expands with balloon 506 to an expanded state 518 , covering lesion L.
- application of radiation may be discontinued, allowing stent 518 to cool down to body temperature. When stent 518 cools down, it solidifies and permanently retains its expanded shape.
- balloon 506 is then deflated and delivery catheter 500 is withdrawn from the vessel, leaving stent 518 with nanoshells 512 in place.
- Stent 518 is composed of biodegradable materials and therefore, over time will degrade, releasing nanoshells 512 into the vascular system where they will be filtered and purged out of the body by the kidneys.
- an implant 804 having nanoparticles 814 dispersed therein is implanted using standard surgical or minimally invasive techniques into a breast 802 .
- the implant may be any biocompatible thermoplastic or material that is solid at normal body temperature and that may be plastically deformed upon heating. Examples of such materials include, but are not limited to polyurethanes, polyethylene, and PVC.
- Nanoparticles 814 may be tuned to convert any wavelength of electromagnetic radiation into heat, however, in this exemplary embodiment, nanoparticles 814 are tuned to near infrared light, such as that provided by a Nd:YAG laser.
- the breast 802 is irradiated with near infrared light 808 from an Nd:YAG laser 806 .
- This wavelength of light is easily transmitted through tissue without being attenuated.
- the light 808 therefore irradiates the nanoparticles 814 , here preferably nanoshells having a gold outer shell and a silicon dioxide inner core, such that the incident radiation is converted into heat.
- the heat raises the temperature of implant 802 above its glass transition temperature, lowering its viscosity and softening the implant 802 .
- a syringe 810 may then be used to fill the implant 804 with a fluid such as saline in order to expand the implant to a larger volume as seen in FIG. 8C .
- irradiation 808 may be suspended allowing the implant 804 to cool down and solidify and permanently retain the expanded shape.
- Syringe 810 may then be removed as shown in FIG. 8D .
- other expandable members such as a balloon catheter could be used to expand the implant.
- repeat treatments may be applied as required in order to fine tune the implant to obtain a more desirable clinical result, or to accommodate changes in breast size or shape that occur with aging.
- Similar implants may also be used in other areas of the body, such as for shaping the chin, nose, lips, face, buttocks, calf, legs, thighs, legs, or any part of the body.
- Nanoshells may also be used to control the degradation rate of a biodegradable implant.
- FIGS. 6A-6E illustrate a method of controlling the degradation rate of a biodegradable implant by using nanoshells to heat up the implant, thereby accelerating the rate at which the implant degrades in situ.
- degradation of a stent is described.
- this is not meant to be limiting, as biodegradation of a number of other implants may be controlled in a similar manner.
- ureteral implants, ocular implants or drug delivery devices e.g. for treatment of cancer or diabetes
- a stent 602 has been expanded and implanted at the site of a stenotic lesion L in a vessel V.
- the vessel may be a coronary artery, a peripheral artery or any body lumen or cavity.
- Stent 602 is composed of a biodegradable polymer having a plurality of nanoshells 604 dispersed therein.
- stent 602 is preferably composed of a copolymer having approximately 90 to 99% polylactide and 1 to 10% poly- ⁇ -caprolactone, and more preferably 95 to 99% polylactide and 1 to 5% poly- ⁇ -caprolactone, uniformly blended with 0.0001 to 1%, more preferably 0.00025% to 0.5% and most preferably 0.0005% to 0.1% gold nanoshells that are tuned to convert near infrared light having a wavelength in the range from about 700 nm to about 2500 nm, and more preferably between about 800 nm and 1200 nm into heat.
- Other biodegradable polymers and nanoshells are possible, and this exemplary embodiment is not intended to be limiting.
- biodegradable materials include polyesters such as polyhydroxyalkanoates (PHA) and polyalphahydroxy acids (AHA).
- PHAs include, but are not limited to polymers of 3-hydroxypropionate, 3-hydroxybutyrate, 3-hydroxyvalerate, 3-hydroxycaproate, 3-hydroxyheptanoate, 3-hydroxyoctanoate, 3-hydroxynonanoate, 3-hydroxydecanoate, 3-hydroxyundecanoate, 3-hydroxydodecanoate, 4-hydroxybutyrate and 5-hydroxyvalerate.
- AHAs include, but are not limited to various forms of polylactide or polylactic acid including PLA, PLLA or PDLLA, polyglycolic acid and polyglycolide, poly(lactic-co-glycolic acid), poly(lactide-co-glycolide), poly( ⁇ -caprolactone) and polydioxanone.
- Polysaccharides including starch, glycogen, cellulose and chitin may also be used as a biodegradable material. It is also feasible that proteins such as zein, resilin, collagen, gelatin, casein, silk or wool could be used as a biodegradable implant material.
- Still other materials such as hydrogels including poly(hydroxyethyl methylacrylate), polyethylene glycol, poly(N-isopropylacrylamide), poly(N-vinyl-2-pyrrolidone), cellulose polyvinyl alcohol, silicone hydrogels, polyacrylamides, and polyacrylic acid are potential biodegradable implant materials.
- Other potential biodegradable materials include lignin, shellac, natural rubber, polyanhydrides, polyamide esters, polyvinyl esters, polyvinyl alcohol, polyalkylene esters, polyethylene oxide, polyvinylpyrrolidone, polyethylene maleic anhydride and poly(glycerol-sibacate).
- Still another potential biodegradable material include the polyphosphazenes developed by Harry R. Allcock at Pennsylvania State University.
- a Nd:YAG laser 610 is used to extracorporally irradiate stent 602 with near infrared light 612 .
- Light 612 supplied from laser 610 is at a wavelength approximately 1064 nm which can pass through tissues T without being significantly absorbed.
- the light 612 irradiates stent 602 and nanoshells 604 dispersed in the stent 602 interact with the light 612 and convert it into heat which raises the temperature of stent 602 .
- a fiber optic catheter 606 may be advanced to the site of the stent 602 using standard catheter delivery techniques and near infrared light 608 from a Nd:YAG laser may be intravascularly delivered to stent 602 to further irradiate stent 602 .
- the exposure time is dependent upon many factors, including but not limited to, area of radiation coverage, wavelength and intensity of the radiation, type and mass of biodegradable material, nanoshell concentration, and concentration of any catalysts or enzymes in the implant. Therefore, exposure time could range from a few seconds to a few hours, and more preferably from about 10 seconds to about an hour.
- Stent 602 is irradiated to a temperature above the glass transition temperature, which as described above is selected to be slightly higher than normal body temperature and low enough to minimize potential tissue thermal damage.
- stent 602 As stent 602 temperature increases, naturally occurring chemical reactions between the body and the stent 602 are accelerated, thereby increasing the rate at which stent 602 breaks down. In FIG. 6C , stent 602 has partially degraded. Continued irradiation of stent 602 with near infrared light 608 and 612 maintains the stent 602 at an elevated temperature and the stent continues to break down as shown in FIG. 6D . This process continues until the entire stent 602 has degraded into low molecular weight, non-toxic products and therefore is removed from lesion L, as shown in FIG. 6E . Nanoshells 604 in the stent 602 are released into the vascular system during degradation and they are small enough to be filtered out of the body by the kidneys.
- a microsphere containing nanoshells and a chemical reagent may be dispersed in the implant and used to accelerate biodegradation even more than previously described.
- FIG. 7 illustrates a microsphere 700 , having a diameter approximately in the range of 1-10 ⁇ m and made from a hydrogel 704 such as polyvinyl alcohol, sodium polyacrylate, acrylate polymers and copolymers having an abundance of hydrophilic groups. Other hydrogels have been previously discussed.
- Nanoshells 702 are dispersed within the microsphere 700 along with a chemical reagent 706 .
- the reagent may be any substance which reacts with an implant to degrade it.
- reagents examples include, but are not limited to hydrolases that catalyze hyrolysis of various bonds, lyases that cleave various bonds by means other than hydrolysis or oxidation and oxidases that cause oxidation.
- hydrolases that catalyze hyrolysis of various bonds
- lyases that cleave various bonds by means other than hydrolysis or oxidation and oxidases that cause oxidation.
- the use of these reagents can accelerate the rate of biodegradation relative to the method described above with respect to FIGS. 6A-6E .
- the nanoshells 702 convert the incident radiation into heat thereby raising the temperature of microsphere 700 .
- the irradiation time is dependent upon many factors, including but not limited to, area of radiation coverage, intensity of the radiation, type and mass of biodegradable polymer, nanoshell concentration, hydrogel water concentration, and concentration of any catalysts or enzymes in the implant. Therefore, exposure time could range from a few seconds to a few hours, and more preferably from about 10 seconds to about an hour. In some embodiments, it may be desirable to spread the implant irradiation over multiple sessions, such a weekly, monthly or daily either for patient convenience or to control the bioerosion process.
- an implant having different layers of degradable materials could be independently degraded by selectively releasing various reagents E from the microsphere 700 at different temperatures.
- the various layers could be bioeroded away at the same time during a single treatment session, or the layers may be selectively bioeroded away with multiple exposures to electromagnetic radiation at different times.
Abstract
An implant comprises a structure that may be implanted into tissue and that has a first material property at normal body temperature. The first material property is variable at elevated temperatures above normal body temperature. The implant also has a plurality of particles dispersed in the structure that are adapted to convert incident radiation into heat energy when irradiated with electromagnetic radiation. The particles are in thermal contact with the structure such that exposure of the particles to incident radiation raises the temperature of the structure thereby changing the first material property relative to the first material property at normal body temperature.
Description
- The present application claims the benefit of U.S. Provisional Application No. 60/890,703 (Attorney Docket No. 021629-004500US), filed Feb. 20, 2007, the full disclosure of which is incorporated herein by reference.
- 1. Field of the Invention
- This invention relates generally to medical apparatus and methods, and more specifically to implants and biodegradable implants for use in the vascular system as well as other body lumens and cavities.
- The use of implants in body tissue is becoming increasingly important in medical treatment. Examples of implant usage include alteration of tissue in cosmetic or reconstructive procedures such as breast augmentation as well as creation, preservation or closure of lumens, channels or fluid reservoirs (e.g. stenting stenotic lesions, exclusion of aneurysms or embolic coils). Implants are also used as matrices for tissue growth (e.g. orthopedic bone fusion procedures), to control unwanted tissue growth and for delivery of therapeutic agents to tissue. Implants may also be employed to join tissue surfaces together or for isolating or protecting tissue lesions in order to enable or mediate healing. Implants are also used to mediate the rate of substances or energy passing into, out of, or through tissue.
- Often, implants are fabricated using various metals and/or polymers. Examples of common metals include stainless steel, titanium, nickel-titanium alloys like Nitinol and polymers such as PTFE (e.g. Teflon®), polyethylene, polyurethane and polyester are often used in implants. A potential disadvantage of these permanent implants is that the implant materials may be harder and stiffer than the surrounding tissues, thus anatomical or physiological mismatch may occur, potentially resulting in tissue damage or causing unwanted biological responses. Some materials may fatigue over time and break which can disrupt the layer of endothelial cells potentially causing thrombosis. Additionally, a permanent implant is not always required. An implant may only be required for a limited time period, therefore the implant often must be surgically explanted when it is no longer needed. To overcome some of these challenges, the use of biodegradable polymeric implants has been proposed. Examples of implantable biodegradable polymers include the aliphatic polyester polylactic acid or polylactide (PLA) and polyglycolide (PGA). PGA was originally proposed for use in suture material in the late 1960's. By the early 1970's PLA was proposed as a suture material including both the optically active poly-L-lactide (PLLA) and the racemic mixture poly-DL-lactide (PDLA). PLLA has also been used in biodegradable stents, as reported by Igaki and Tamai. A co-polymer of PLA and PGA, known as PLGA has also been proposed for use in implants. Another material which has recently been proposed (in the 1980's) for use in sutures and orthopedic implants is polydioxanone. In the mid-1990's implantable drug delivery systems using polyanhydrides were proposed by Langer et al. at the Massachusetts Institute of Technology, and more recently tyrosine derived polyarylate has seen use in hernia repair and companies are developing biodegradable stents composed of materials such as a tyrosine derived polycarbonate, poly(DTE carbonate).
- While these newer biodegradable implant materials have overcome some of the challenges of earlier implant materials, other potential drawbacks still exist. For example, it is often desirable to adjust the shape of some implants in situ so that the implant conforms more accurately to the anatomy of the treatment site. However, the biodegradable polymers cannot be plastically deformed, molded or shaped at normal body temperatures since they must be solid at body temperature. The implant must therefore be heated above its glass transition temperature, Tg. Often the glass transition temperature is fairly high, for example PDLLA and PLLA have a Tg approximately 50°-80° C., therefore in situ heating may result in localized tissue damage, thrombosis or patient discomfort. It is well known that adding an impurity to a material will change some of the material's properties such as increasing its boiling point and reducing its freezing point. Therefore, additives may be mixed with the biodegradable polymers to decrease the glass transition temperature, for example 2-10% ε-caprolactone added to 90-98% PLLA can reduce the glass transition temperature down to about 38°-55° C., but a heat source hotter than the glass transition temperature may still be required due to heat transfer inefficiencies or non-uniform heating, therefore, similar complications may still arise.
- One proposed solution to the challenge of non-uniform heating is to coat the implant with a radiation absorbing material which converts radiation to heat. Exemplary coatings include chromophores like indocyanine green, vital blue, carbon black and methylene blue. The radiation, often ultraviolet or visible light must therefore be supplied in situ from a second device due to the poor penetration of the radiation through the tissue. Additionally, production of sufficient and uniform heat using this technique remains a challenge. Furthermore, the chromophores may degrade into unwanted chemicals that are toxic to the body. Therefore, there exists a need for an easier, less toxic and less invasive way to heat implants, including biodegradable polymer implants, to an elevated temperature so that they may be shaped or molded in situ. Furthermore, such techniques should also be able to heat the implant uniformly.
- Additionally, while biodegradable implants will degrade over time, it would also be desirable to be able to control the rate of degradation. For example, when an implant is no longer required, it would be desirable to be able to accelerate the degradation rate so that the implant breaks down faster than its normal in situ rate. For this reason, there is also need for a way to control the degradation rate of a biodegradable implant.
- 2. Description of the Background Art
- Prior patents describing nanoshells for converting incident radiation into heat include: U.S. Pat. Nos. 6,344,272; 6,428,811; 6,530,944; 6,645,517; 6,660,381; 6,685,730; 6,699,724; 6,778,316; and 6,852,252. Prior patents describing thermo-mechanically expansion of stents include: U.S. Pat. Nos. 5,670,161; 5,741,323; 6,607,553; 6,736,842. Prior patents describing meltable stents include: U.S. Pat. Nos. 4,690,684 and 4,770,176. Prior patent describing bioerodable polyanhydrides for controlled drug delivery include: U.S. Pat. No. 4,891,225. Prior patents describing tyrosine derived polycarbonate as an implant include: U.S. Pat. Nos. 6,951,053; 7,101,840; and 7,005,454. Prior patents describing biodegradable stents include: U.S. Pat. Nos. 5,733,327; 5,762,625; 5,817,100; 6,045,568; 6,080,177, 6,200,335; 6,413,272; 6,500,204; 6,632,242; RE38,653; RE38,711; 7,066,952; and 7,070,615. The full disclosure of each of these patents is incorporated herein by reference.
- The invention generally provides for an implant having a plurality of particles dispersed therein. The particles are adapted to convert incident radiation into heat energy when the particles are irradiated with electromagnetic radiation. The particles are in thermal contact with the implant and therefore the heat generated by the particles raises the temperature of the implant. The increased temperature changes a material property of the implant.
- In a first aspect of the present invention, an implant for use in tissue comprises a structure that is adapted for implantation into the tissue and that has a first material property at normal body temperature. The material property is variable at an elevated temperature above normal body temperature. The implant also comprises a plurality of particles that are dispersed in the structure and that are adapted to convert incident radiation into heat energy when the particles are irradiated with electromagnetic radiation. The particles are in thermal contact with the structure and thus exposure of the particles to incident radiation raises the temperature of the structure thereby changing the first material property.
- In another aspect of the present invention, an expandable implant for use in tissue comprises a structure that is adapted for implantation into the tissue and that is not plastically deformable at normal body temperature but that is plastically deformable at an elevated temperature above normal body temperature. The implant also has a plurality of particles dispersed in the structure and that are adapted to convert incident radiation into heat energy when irradiated with electromagnetic radiation. The particles are in thermal contact with the structure such that exposure of the particles to the incident radiation raises the temperature of the structure allowing it to be plastically deformed.
- In yet another aspect of the present invention, an expandable, biodegradable implant for use in tissue comprises a biodegradable structure that is adapted for implantation into the tissue and that degrades at a first rate when implanted in the tissue at normal body temperature. The implant also comprises a plurality of particles that are dispersed in the structure with the particles adapted to convert incident radiation into heat energy when they are irradiated with electromagnetic radiation. The particles are in thermal contact with the structure such that exposure of the particles to the incident radiation raises the temperature of the structure thereby increasing the degradation rate of the structure relative to the first rate.
- The degradation rate of an implant may also be controlled by using an additional reagent such as a catalyst or enzyme. The reagent is adapted to react with the structure so as to increase the structure's degradation rate relative to the first rate at normal body temperature. Often, the reagent is dispersed in a carrier such as a microsphere along with particles such as nanoshells. The microsphere, which may be a hydrogel, is distributed in the implant structure and exposure of the particles to incident radiation raises the temperature of the carrier or microsphere, thereby releasing the reagent.
- Often the structure is biodegradable and is composed of a polymer or copolymer, either synthetic or natural, that is not plastically expandable at normal body temperature but is thermo-mechanically expandable at an elevated temperature above normal body temperature. The structure is often composed of one or more of the following materials including, polyhydroxyalkanoates, polyalphahydroxy acids, polysaccharides, proteins, hydrogels, lignin, shellac, natural rubber, polyanhydrides, polyamide esters, polyvinyl esters, polyvinyl alcohols, polyalkylene esters, polyethylene oxide, polyvinylpyrrolidone, polyethylene maleic anhydride and poly(glycerol-sibacate). The structure may also comprise poly-L-lactide, poly-ε-caprolactone or a biological fluid in the solid state such as blood plasma. The material property may be the biodegradation rate of the structure, viscosity or the property may be the ability of the structure to be plastically expanded.
- Sometimes the structure may be a stent which may be tubular and that is radially expandable at the elevated temperature. The stent may comprise a tube having a sidewall and the sidewall may define a plurality of openings therein. Sometimes the structure may also have a therapeutic agent that is adapted to be released therefrom. The therapeutic agent may be an anti-restenosis agent or it may be at least one of the following, including antibiotics, thrombolytics, anti-thrombotics, anti-inflammatories, cytotoxic agents, anti-proliferative agents, vasodilators, gene therapy agents, radioactive agents, immunosuppressants, chemotherapeutics, endothelial cell attractors, endothelial cell promoters, stem cells and combinations thereof. Sometimes the structure may be adapted to be implanted into a breast or it may be used to deliver a drug to the tissue. The structure may also be used to exclude aneurysms or it may be an orthopedic implant.
- The particles may comprise nanoparticles or nanoshells and often the particles have a non-conducting core layer such as silicon dioxide, with a first thickness and a conducting outer shell layer, such as gold, adjacent to the core layer with a second thickness. The ratio of the first thickness to the second thickness defines a maximum wavelength of electromagnetic radiation converted by the particles into heat. Sometimes the particles are substantially spherical. Often the elevated temperature is in the range from about 38° C. to about 60° C. and the electromagnetic radiation often is ultraviolet, visible, near infrared or infrared light.
- In another aspect of the present invention, a method of controlling a material property of an implant comprises the steps of providing an implant having a plurality of particles dispersed therein. The implant has a first material property when implanted in tissue at normal body temperature and the material property is variable at an elevated temperature above normal body temperature. Exposing the implant to electromagnetic radiation results in the incident radiation being converted into heat energy thus raising the temperature of the implant above normal body temperature and thereby changing the material property relative to the first material property.
- In yet another aspect of the present invention, a method of delivering an expandable implant to a treatment site in a body comprises providing an implant having a plurality of particles dispersed therein and positioning the implant at the treatment site. Positioning may include advancing a catheter through a body lumen with the implant disposed on the catheter. Exposing the implant to electromagnetic radiation allows the particles to convert the incident radiation into heat energy. The heat energy raises the implant temperature above its glass transition temperature such that the implant may be plastically deformed so as to change its shape. Expanding the implant may include expanding a balloon.
- In another aspect of the present invention, a method of controlling the degradation rate of an implant comprises providing a biodegradable implant having a plurality of particles dispersed therein. The implant degrades at a first rate when implanted in tissue at normal body temperature. Exposing the implant to electromagnetic radiation allows the particles to convert the incident radiation into heat energy which raises the temperature of the implant above normal body temperature. The elevated temperature changes the biodegradation rate of the implant relative to the first rate. Exposing the implant may include irradiating a carrier such as a microsphere, dispersed in the implant and containing a reagent and particles. The carrier heats up and releases the reagent when irradiated and the reagent reacts with the implant to degrade it. The reagent may be an enzyme or catalyst.
- The method may also comprise discontinuing exposure of the implant to the electromagnetic radiation in order to allow the implant to cool down so that it returns to body temperature so that the implant is substantially undeformable plastically at body temperature. The method may also include monitoring the temperature of implant. Exposing the implant to electromagnetic radiation may include exposing the implant from outside the body or from within the body. Sometimes a catheter may be used to deliver the radiation to the implant. The radiation may be delivered for a fixed duration of time, continuously for a defined period or over periodic intervals until a desired temperature obtained in the implant.
- These and other embodiments are described in further detail in the following description related to the appended drawing figures.
-
FIGS. 1A-1B show nanoshells having various outer shell thicknesses. -
FIG. 2 illustrates the optical resonances of metal nanoshells having various ratios of core radius to shell thickness. -
FIG. 3A shows a biodegradable stent having nanoshells dispersed therein. -
FIG. 3B shows a nanoshell generating heat in a section of the stent shown inFIG. 3A . -
FIG. 3C shows an implant made from frozen biological fluid and having nanoshells dispersed therein. -
FIG. 3D shows the implant ofFIG. 3C used to facilitate creation of an anastomosis. -
FIGS. 4A-4B illustrate a preferred embodiment of a stent in the unexpanded and expanded state. -
FIGS. 5A-5E illustrate stent expansion in accordance with an exemplary embodiment. -
FIGS. 6A-6E illustrate stent biodegradation in accordance with an exemplary embodiment. -
FIG. 7 illustrates a microsphere containing nanoshells and a chemical reagent dispersed therein. -
FIGS. 8A-8D illustrate expansion of a breast implant in accordance with an exemplary embodiment. -
FIGS. 1A and 1B illustrate nanoshells having various outer shell thicknesses. Nanoshells are nanoparticles having a diameter ranging from a few nanometers up to about 5 microns. The nanoshells are composed of a non-conducting, semiconductor or dielectric inner core layer and an ultra thin conducting outer shell layer. In the exemplary embodiment ofFIG. 1A , nanoshell 100 is spherically shaped and has an outerspherical shell 102 made from gold. Aportion 104 ofouter shell 102 has been removed inFIG. 1A so that the innerspherical core 106 is visible.Inner core 106 is made from silicon dioxide. Other common materials that may be utilized for the inner core include, but are not limited to, gold sulfide, titanium dioxide, polymethyl methacrylate, polystyrene and macromolecules such as dendrimers. Metals which are well suited for use in the outer shell also include, but are not limited to silver, copper, platinum, palladium, lead, iron and the like. Nanoshells may be made with various inner core diameters and outer shell thicknesses.FIG. 1B illustrates anothernanoshell 110 having a thinnerouter shell 112 compared with theouter shell 102 ofFIG. 1A . The nanoshell inFIG. 1B also has asection 114 ofouter shell 112 removed so that theinner core 106 is visible. - Nanoshells have a unique ability to interact with specific wavelengths of electromagnetic radiation and effectively convert the incident radiation into heat energy. By adjusting the relative core and shell thicknesses, and choice of materials, nanoshells can be fabricated that will react with or scatter light at any wavelength across much of the ultraviolet, visible and infrared range of the electromagnetic spectrum. The nanoshell may therefore be tuned to specific wavelengths of electromagnetic radiation and the conversion of incident radiation to heat energy can be optimized.
-
FIG. 2 shows agraph 200 of the optical resonances of metal nanoshells having various ratios of core radius to shell thickness. InFIG. 2 ,nanoshells Nanoshell 202 has a gold outer shell, 20 nm thick and the resulting maximum absorption wavelength is approximately 740 nm. As the shell thickness decreases, the maximum absorption wavelength increases.Nanoshell 204 has agold shell layer 5 nm thick and the resulting maximum absorption wavelength is approximately 1010 nm. The tunability of nanoshells, including the relationship between the ratio of core diameter to shell thickness and maximum absorption wavelength is more fully discussed in U.S. Pat. No. 6,344,272 which has previously been incorporated herein by reference. - Nanoshells are well described in the scientific and patent literature. Other aspects of nanoshells such as manufacturing methods, materials and principles of operation are described in U.S. Pat. Nos. 6,428,811; 6,530,944; 6,645,517; 6,660,381; 6,685,730; 6,699,724; 6,778,316; and 6,852,252, the entire contents of which have previously been incorporated herein by reference.
- Because nanoshells are efficient at converting incident radiation into heat, they may be dispersed in implants and light or other forms of electromagnetic radiation may be used to heat up the implant. Furthermore, since a nanoshell may be tuned to certain wavelengths, a nanoshell that preferentially interacts with light at near infrared wavelengths between approximately 700 and approximately 2500 nm is desirable, and more preferably between about 800 nm and 1200 nm, since this range of wavelengths is transmitted through tissue with very little absorption and therefore relatively little attenuation. Thus the majority of the light is delivered to the nanoparticles, converted into heat and transferred to the implant in which the nanoparticles are dispersed. This makes external access to an implanted device possible and heating of the tissue surrounding the implant is substantially avoided. One particular source of near infrared light, a Nd:YAG laser emits light at a wavelength of 1064 nm and hence is ideal for irradiating an implant from outside the body. Additionally, in the case of a biodegradable implant, as the implant breaks down the nanoshells are released into surrounding tissue. Due to their small size, the nanoshells are easily purged by body systems such as the kidneys. Nanoshells therefore present a unique way of allowing an implant to be heated from outside the body with minimal biocompatibility issues.
-
FIG. 3A shows animplantable stent 300. Stents are defined to include any of the array of expandable prostheses and scaffolds which are introduced into a lumen at a target treatment site and expanded in situ thereby exerting a radially outward force against the lumen wall to restore patency. Stents may be implanted in a number of lumens including the coronary and peripheral vasculature, biliary ducts, urethra and ureter, as well as other body cavities. Urethral and ureter stents are well reported in the patent literature, including for example U.S. Pat. Nos. 7,112,226 and 7,044,981, the entire contents of which are incorporated herein by reference. Other stents are discussed and incorporated below.Stent 300 is a tubular prosthesis made from any material 302 that is solid at normal body temperature and that may be plastically deformed at an elevated temperature. Examples include standard engineering thermoplastics such as polyurethane and others well known to those skilled in the art, including biodegradable polymers like polylactide.Stent 300 may optionally be a copolymer containing 2-10% of poly-ε-caprolactone so as to adjust the mechanical properties of the stent, including lowering the glass transition temperature to just above normal body temperature. In preferred embodiments, thecopolymer stent 300 has a glass transition temperature in the range from about 40° to about 60°C. Stent 300 may also comprise plasticizers to further soften the implant. The plasticizers should be biocompatible such as oleic acid and linoleic acid which are classified under Food and Drug Administration (FDA) guidelines for food additives as being Generally Recognized as Safe (GRAS). Thestent 300 may be delivered to the site of a stenotic lesion or an intimal dissection and expanded in situ in order to restore patency of a vessel. - In
FIG. 3A , preferably 0.0001 to 1% nanoparticles 304, more preferably 0.00025% to 0.5%, and most preferably 0.0005% to 0.1% nanoparticles are dispersed in thestent 300. Thenanoparticles 304 may be tuned to interact with many forms of electromagnetic radiation including microwaves, ultrasound, magnetic fields, electric fields, radiofrequency, infrared, visible, ultraviolet, laser, x-rays, gamma rays and cosmic rays. However, in this exemplary embodiment, thenanoparticles 304 are preferably tuned to interact with near infrared radiation having a wavelength approximately 1064 nm so that that a Nd:YAG laser may be used to irradiatestent 300 from outside the body. Thenanoparticles 304 in this embodiment are preferably nanoshells having an outer shell composed of gold and an inner core composed of silicon dioxide. Thenanoparticles 304 convert the incident radiation into heat, thereby heating the polymer matrix above its glass transition temperature and allowingstent 300 to be plastically deformed into a lesion with a balloon or other expandable member in situ. Optionally,stent 300 may also include quantum dots dispersed therein. Quantum dots have many desirable characteristics, including favorable optical properties. The quantum dots may be used to help visualizestent 300 while in situ since they fluoresce when irradiated with certain wavelengths of light. Examples of materials used to fabricate quantum dots include cadmium selenide, cadmium sulfide, zinc sulfide and zinc selenide. -
FIG. 3B illustrates asection 308 ofFIG. 3A which has been enlarged to show howincident radiation 312 interacts withnanoparticle 304 such that theradiation 312 is converted into heat bynanoparticle 304 and theheat 310 is emitted to the surroundingpolymer matrix 302. In this exemplary embodiment,stent 300 is a tubular prosthesis without any apertures in the sidewalls and therefore it could also be used to exclude an aneurysm. However, this is not meant to be limiting andstent 300 may be modified to include apertures in the sidewalls. - In many of the embodiments described herein, near infrared light is used to irradiate the nanoparticles and generate heat. However, it should be obvious to one of ordinary skill in the art that many wavelengths of electromagnetic radiation may also be used, including a magnetic field. The nanoparticles may be magnetically responsive so that they produce heat upon exposure to a magnetic field. Examples of magnetically responsive materials include iron oxides, magnetite (Fe3O4) and maghemite (γ-Fe3O3).
-
FIGS. 4A and 4B illustrate a preferred embodiment of one possible stent geometry. InFIG. 4A a portion ofstent segment 32 is shown in a planar shape for clarity.Stent segment 32 comprisesparallel rows cells 124 formed into a cylindrical shape around axialaxis A. Cells 124 have upper and loweraxial slots 126 and a connectingcircumferential slot 128. Upper andlower slots 126 are bounded by upperaxial struts 132, loweraxial struts 130, curved outer ends 134, and curved inner ends 136.Circumferential slots 128 are bounded by outercircumferential strut 138 and innercircumferential strut 140. Each I-shapedcell 124 is connected to the adjacent I-shapedcell 124 in the same row 122 by acircumferential connecting strut 142.Row 122A is connected to row 122B by the merger or joining of curved inner ends 136 of at least one of upper andlower slots 126 in eachcell 124. - In
FIGS. 4A-4B , the stent includes abulge 144 in upper and loweraxial struts axial slots 126. These giveaxial slots 126 an arrowhead or cross shape at their inner and outer ends. Thebulge 144 in each upperaxial strut 130 extends toward thebulge 144 in a loweraxial strut 132 in thesame cell 124 or in anadjacent cell 124, thus creating aconcave abutment 146 in the space between eachaxial slot 126.Concave abutments 146 are configured to receive and engage curved outer ends 134 ofcells 124 in the adjacent stent segment, thereby maintaining spacing between the stent segments. The axial location ofbulges 144 along upper and loweraxial struts -
FIG. 4B shows astent 32 ofFIG. 4A in an expanded condition. It may be seen thataxial slots 124 are deformed into a circumferentially widened modified diamond shape withbulges 144 on the now diagonal upper and loweraxial struts Circumferential slots 128 are generally the same size and shape as in the unexpanded configuration.Bulges 144 have been pulled away from each other to some extent, but still provide aconcave abutment 146 to maintain a minimum degree of spacing between adjacent stent segments. As in the earlier embodiment, some axial shortening of each segment occurs upon expansion and stent geometry can be optimized to provide the ideal intersegment spacing. - It should also be noted that the embodiment of
FIGS. 4A-4B also enables access to vessel side branches blocked bystent segment 32. Should such side branch access be desired, a dilatation catheter may be inserted intocircumferential slot 128 and expanded to provide an enlarged opening through which a side branch may be entered. - A number of other stent geometries are applicable and have been reported in the scientific and patent literature. Other stent geometries include, but are not limited to those disclosed in the following U.S. patents, the full disclosures of which are incorporated herein by reference: U.S. Pat. Nos. 6,315,794; 5,980,552; 5,836,964; 5,527,354; 5,421,955; 4,886,062; and 4,776,337.
- Referring back to
FIG. 3A ,stent 300 may also comprise atherapeutic agent 306. In preferred embodiments,stent 300 may be coated, impregnated, infused or otherwise coupled with one or more drugs that inhibit restenosis, such as Rapamycin, Everolimus, Biolimus A9, Paclitaxel, prodrugs, or derivatives of the aforementioned, or other suitable agents, preferably carried in a durable or bioerodable carrier of polymeric or other suitable material. Alternatively,stent 300 may be coated with other types of drugs or therapeutic materials such as antibiotics, thrombolytics, anti-thrombotics, anti-inflammatories, cytotoxic agents, anti-proliferative agents, vasodilators, gene therapy agents, radioactive agents, immunosuppressants, chemotherapeutics, endothelial cell attractors or promoters and/or stem cells. Such materials may be coated over all or a portion of the surface ofstent 300, orstent 300 may have a porous structure or include apertures, holes, channels, or other features in which such materials may be deposited. -
FIG. 3C illustrates an implant where nanoshells may be used to control the degradation of the implant. In an exemplary embodiment, astent 325 is adapted for creating an anastomosis. Thestent 325 may be made from a variety of meltable materials including polymers, frozen blood plasma or other biological fluids in the solid state. Nanoshells 330 are dispersed in thestent 325.FIG. 3D shows thestent 325 placed into the ends V1, V2 of the two vessels to be connected together, thereby aligning the ends together so that they may be sutured or thermally bonded together, creating ananastomosis 352. In this embodiment, after thestent 325 has been placed into the vessel ends, V1, V2, and the ends have been connected together,stent 325 may be irradiated with near infrared light from outside the body. Thenanoshells 330 convert the incident radiation into heat. The resulting heat melts thestent 325 thereby creating a patent lumen for fluid flow. Further details on meltable stents are disclosed in U.S. Pat. Nos. 4,690,684 and 4,770,176, the entire contents of which are fully incorporated herein by reference. - Referring now to
FIGS. 5A-5E , the deployment of a stent to treat a stenotic lesion is shown in accordance with an exemplary embodiment. While the embodiment will be described in the context of a femoral artery stent procedure, it should be understood that the invention may be employed in any variety of coronary or peripheral arteries, blood vessels and other body lumens in which stents or tubular prostheses are deployed, including the carotid and iliac arteries, blood vessels in the brain, other arteries or veins, as well as non-vascular body lumens such as the ureter, urethra, fallopian tubes, the hepatic and biliary duct and the like. InFIG. 5A , astent delivery catheter 500 includes astent 502 having a plurality ofnanoshells 512 dispersed therein and mounted over anexpandable balloon 506 attached to the distal end ofcatheter shaft 504. In this exemplary embodiment, a singlebiodegradable stent 502 is disposed on thedelivery catheter 500, although multiple stents may also be disposed on thedelivery catheter 500.Stent 502 is preferably composed of a copolymer containing approximately 90 to 99% polylactide with 1 to 10% poly-ε-caprolactone, and more preferably 95 to 99% polylactide with 1 to 5% poly-ε-caprolactone, uniformly blended with preferably 0.0001 to 1% gold nanoshells, more preferably 0.00025% to 0.5%, and most preferably 0.0005% to 0.1% gold nanoshells that are tuned to convert near infrared light into heat.Stent 502 may also be fabricated from any material that is solid at normal body temperature and that can be plastically deformed at an elevated temperature, thus many other polymers such as polyurethanes as well as other biodegradable materials may be used to fabricate thestent 502. Delivery catheters such as over-the-wire systems and rapid exchange systems are well known in the art and may be used to deliverstent 502 to the lesion L. - Having multiple stents allows the physician operator to select the number of stents to deliver and thus customization of stent length is possible, as disclosed in U.S. Patent Publication Nos. 2006/0282150 and 2007/0027521, the entire contents of which are incorporated herein by reference. Additionally, other customizable-length stent delivery systems have been proposed for delivering multiple stent segments and these may also be used to deliver one or
more stents 502. Prior publications describing catheters for delivering multiple segmented stents include: U.S. Pat. Nos. 7,309,350; 7,326,236; 7,137,993; and 7,182,779; U.S. Patent Publication Nos. 2005/0038505; 2004/0186551; and 2003/0135266. Prior related U.S. patent applications, Publications and Provisionals include Ser. Nos. 2006/0282150; 2006/0282147; 2007/0179587; 2007/0067012; 60/784,309; and 11/462,951. The full disclosures of each of these patents and applications are incorporated herein by reference. - In.
FIG. 5A , thedelivery catheter 500 is introduced into a treatment vessel first, by placing an introducer sheath (not illustrated) into the target peripheral artery, typically using a percutaneous procedure such as the Seldinger technique or by surgical cutdown. In this exemplary embodiment, the target vessel is a femoral artery. The introducer sheath is then advanced slightly into the femoral artery. A guidewire GW is then inserted through the introducer and advanced into the target vessel V where a lesion L to be treated is located. The proximal end of guidewire GW is then inserted through the distal end ofcatheter shaft 504, through a lumen incatheter shaft 504, exiting at the proximal end ofcatheter shaft 504, which is outside the patient's body. -
Stent delivery catheter 500 is then slidably advanced over the guidewire GW into the vessel V so thatstent 502 traverses the lesion L. Optional radiopaque markers (not illustrated) may be placed on thecatheter shaft 504 in order to facilitate visualization of the delivery catheter under fluoroscopy. Once the delivery catheter has been properly positioned in the vessel, thestent 502 may be heated up to facilitate its expansion. - In
FIG. 5B , an external source ofelectromagnetic radiation 508 is used to irradiatestent 502 so as to heat it up. InFIG. 5B , the external source of radiation is preferably a Nd:YAG laser which emits a wavelength of light approximately 1064 nm. This wavelength is applied extracorporally and the light 510 is transmitted through the tissue T to thestent 502. Nanoshells 512 dispersed in thestent 502 are tuned to convert the light into heat. Heat generated by nanoshells 512 is transferred to the polymer which makes upstent 502, thereby heating it up. In addition or as an alternative to applying extracorporeal radiation, radiation may be applied in situ.FIG. 5C shows afiber optic catheter 514 deployed alongsidedelivery catheter 500. Thefiber optic catheter 514 is adapted to deliver the Nd:YAG laser light 516 directly tostent 502. In some embodiments, thedelivery catheter 500 and thefiber optic catheter 514 may be combined into a single device that heats and deploysstent 502. In some embodiments,fiber optic catheter 514 includes an optional diffuser (not shown). The diffuser is adapted to spread out and scatter the radiation so as to cover a larger area of thestent 502. - Radiation is applied until the temperature of
stent 502 is above its glass transition temperature, Tg, which is approximately 40°-60° C. in this exemplary embodiment. The exposure time is dependent upon many factors, including but not limited to, area of radiation coverage, wavelength and intensity of the radiation, type and mass of the implant material and nanoshell concentration. Therefore, exposure time could range from a few seconds to a few hours, and more preferably from about 10 seconds to about an hour. Longer exposure times are not desirable due to patient inconvenience. -
Stent 502 is fabricated from a material having a glass transition temperature above normal body temperature. Therefore,stent 502 is solid at or below normal body temperature. Normal body temperature is approximately 37° C., therefore thestent 502 material is selected to have a Tg slightly higher than 37° C., yet not so high that the temperature required to heat the stent above Tg results in tissue damage. - Once the temperature of
stent 502 is raised above the glass transition temperature, it's viscosity decreases, permittingstent 502 to be plastically deformed. InFIG. 5D ,balloon 506 is expanded, typically with contrast media and/or saline and an inflation device such an Indeflator™, manufactured by Abbott (formerly Guidant Corp., Santa Clara, Calif.).Stent 502 is soft and therefore expands withballoon 506 to an expandedstate 518, covering lesion L. Afterstent 502 has been enlarged to its expandedstate 518, application of radiation may be discontinued, allowingstent 518 to cool down to body temperature. Whenstent 518 cools down, it solidifies and permanently retains its expanded shape. InFIG. 5E ,balloon 506 is then deflated anddelivery catheter 500 is withdrawn from the vessel, leavingstent 518 withnanoshells 512 in place.Stent 518 is composed of biodegradable materials and therefore, over time will degrade, releasingnanoshells 512 into the vascular system where they will be filtered and purged out of the body by the kidneys. - Referring now to
FIGS. 8A-8D , the expansion of an implant for breast augmentation during cosmetic and reconstructive procedures (e.g. after mastectomy) is shown in accordance with an exemplary embodiment. InFIG. 8A , animplant 804 havingnanoparticles 814 dispersed therein is implanted using standard surgical or minimally invasive techniques into abreast 802. The implant may be any biocompatible thermoplastic or material that is solid at normal body temperature and that may be plastically deformed upon heating. Examples of such materials include, but are not limited to polyurethanes, polyethylene, and PVC.Nanoparticles 814 may be tuned to convert any wavelength of electromagnetic radiation into heat, however, in this exemplary embodiment,nanoparticles 814 are tuned to near infrared light, such as that provided by a Nd:YAG laser. - In
FIG. 8B , thebreast 802 is irradiated with near infrared light 808 from an Nd:YAG laser 806. As previously discussed, this wavelength of light is easily transmitted through tissue without being attenuated. The light 808 therefore irradiates thenanoparticles 814, here preferably nanoshells having a gold outer shell and a silicon dioxide inner core, such that the incident radiation is converted into heat. The heat raises the temperature ofimplant 802 above its glass transition temperature, lowering its viscosity and softening theimplant 802. Asyringe 810 may then be used to fill theimplant 804 with a fluid such as saline in order to expand the implant to a larger volume as seen inFIG. 8C . Once thebreast 802 has been enlarged to a desired size and/or shape,irradiation 808 may be suspended allowing theimplant 804 to cool down and solidify and permanently retain the expanded shape.Syringe 810 may then be removed as shown inFIG. 8D . In alternative embodiments, other expandable members, such as a balloon catheter could be used to expand the implant. Additionally, repeat treatments may be applied as required in order to fine tune the implant to obtain a more desirable clinical result, or to accommodate changes in breast size or shape that occur with aging. Similar implants may also be used in other areas of the body, such as for shaping the chin, nose, lips, face, buttocks, calf, legs, thighs, legs, or any part of the body. - Nanoshells may also be used to control the degradation rate of a biodegradable implant.
FIGS. 6A-6E illustrate a method of controlling the degradation rate of a biodegradable implant by using nanoshells to heat up the implant, thereby accelerating the rate at which the implant degrades in situ. In this exemplary embodiment, degradation of a stent is described. However, this is not meant to be limiting, as biodegradation of a number of other implants may be controlled in a similar manner. For example, ureteral implants, ocular implants or drug delivery devices (e.g. for treatment of cancer or diabetes), need only be implanted for a limited time, therefore it is desirable to be able to accelerate their degradation so as to avoid having to surgically remove them. InFIG. 6A , astent 602 has been expanded and implanted at the site of a stenotic lesion L in a vessel V. The vessel may be a coronary artery, a peripheral artery or any body lumen or cavity.Stent 602 is composed of a biodegradable polymer having a plurality ofnanoshells 604 dispersed therein. In this exemplary embodiment,stent 602 is preferably composed of a copolymer having approximately 90 to 99% polylactide and 1 to 10% poly-ε-caprolactone, and more preferably 95 to 99% polylactide and 1 to 5% poly-ε-caprolactone, uniformly blended with 0.0001 to 1%, more preferably 0.00025% to 0.5% and most preferably 0.0005% to 0.1% gold nanoshells that are tuned to convert near infrared light having a wavelength in the range from about 700 nm to about 2500 nm, and more preferably between about 800 nm and 1200 nm into heat. Other biodegradable polymers and nanoshells are possible, and this exemplary embodiment is not intended to be limiting. - Some examples of other biodegradable materials include polyesters such as polyhydroxyalkanoates (PHA) and polyalphahydroxy acids (AHA). Exemplary PHAs include, but are not limited to polymers of 3-hydroxypropionate, 3-hydroxybutyrate, 3-hydroxyvalerate, 3-hydroxycaproate, 3-hydroxyheptanoate, 3-hydroxyoctanoate, 3-hydroxynonanoate, 3-hydroxydecanoate, 3-hydroxyundecanoate, 3-hydroxydodecanoate, 4-hydroxybutyrate and 5-hydroxyvalerate. Examples of AHAs include, but are not limited to various forms of polylactide or polylactic acid including PLA, PLLA or PDLLA, polyglycolic acid and polyglycolide, poly(lactic-co-glycolic acid), poly(lactide-co-glycolide), poly(ε-caprolactone) and polydioxanone. Polysaccharides including starch, glycogen, cellulose and chitin may also be used as a biodegradable material. It is also feasible that proteins such as zein, resilin, collagen, gelatin, casein, silk or wool could be used as a biodegradable implant material. Still other materials such as hydrogels including poly(hydroxyethyl methylacrylate), polyethylene glycol, poly(N-isopropylacrylamide), poly(N-vinyl-2-pyrrolidone), cellulose polyvinyl alcohol, silicone hydrogels, polyacrylamides, and polyacrylic acid are potential biodegradable implant materials. Other potential biodegradable materials include lignin, shellac, natural rubber, polyanhydrides, polyamide esters, polyvinyl esters, polyvinyl alcohol, polyalkylene esters, polyethylene oxide, polyvinylpyrrolidone, polyethylene maleic anhydride and poly(glycerol-sibacate). Still another potential biodegradable material include the polyphosphazenes developed by Harry R. Allcock at Pennsylvania State University.
- In
FIG. 6B , a Nd:YAG laser 610 is used to extracorporallyirradiate stent 602 with nearinfrared light 612.Light 612 supplied fromlaser 610 is at a wavelength approximately 1064 nm which can pass through tissues T without being significantly absorbed. The light 612 irradiatesstent 602 andnanoshells 604 dispersed in thestent 602 interact with the light 612 and convert it into heat which raises the temperature ofstent 602. Optionally, as an alternative or supplement to light 612 fromlaser 610, afiber optic catheter 606 may be advanced to the site of thestent 602 using standard catheter delivery techniques and near infrared light 608 from a Nd:YAG laser may be intravascularly delivered tostent 602 to further irradiatestent 602. The exposure time is dependent upon many factors, including but not limited to, area of radiation coverage, wavelength and intensity of the radiation, type and mass of biodegradable material, nanoshell concentration, and concentration of any catalysts or enzymes in the implant. Therefore, exposure time could range from a few seconds to a few hours, and more preferably from about 10 seconds to about an hour. Exposure times greater than an hour, such as those seen in phototherapy regimes used to treat neonatal jaundice or in Crigler-Najjar syndrome (e.g. 12 hours/day) become impractical due to patient inconvenience.Stent 602 is irradiated to a temperature above the glass transition temperature, which as described above is selected to be slightly higher than normal body temperature and low enough to minimize potential tissue thermal damage. - As
stent 602 temperature increases, naturally occurring chemical reactions between the body and thestent 602 are accelerated, thereby increasing the rate at whichstent 602 breaks down. InFIG. 6C ,stent 602 has partially degraded. Continued irradiation ofstent 602 with nearinfrared light stent 602 at an elevated temperature and the stent continues to break down as shown inFIG. 6D . This process continues until theentire stent 602 has degraded into low molecular weight, non-toxic products and therefore is removed from lesion L, as shown inFIG. 6E . Nanoshells 604 in thestent 602 are released into the vascular system during degradation and they are small enough to be filtered out of the body by the kidneys. - In alternative embodiments, a microsphere containing nanoshells and a chemical reagent may be dispersed in the implant and used to accelerate biodegradation even more than previously described.
FIG. 7 illustrates amicrosphere 700, having a diameter approximately in the range of 1-10 μm and made from ahydrogel 704 such as polyvinyl alcohol, sodium polyacrylate, acrylate polymers and copolymers having an abundance of hydrophilic groups. Other hydrogels have been previously discussed. Nanoshells 702 are dispersed within themicrosphere 700 along with achemical reagent 706. The reagent may be any substance which reacts with an implant to degrade it. Examples of possible reagents include, but are not limited to hydrolases that catalyze hyrolysis of various bonds, lyases that cleave various bonds by means other than hydrolysis or oxidation and oxidases that cause oxidation. The use of these reagents can accelerate the rate of biodegradation relative to the method described above with respect toFIGS. 6A-6E . When themicrosphere 700 is irradiated, thenanoshells 702 convert the incident radiation into heat thereby raising the temperature ofmicrosphere 700. As described previously, the irradiation time is dependent upon many factors, including but not limited to, area of radiation coverage, intensity of the radiation, type and mass of biodegradable polymer, nanoshell concentration, hydrogel water concentration, and concentration of any catalysts or enzymes in the implant. Therefore, exposure time could range from a few seconds to a few hours, and more preferably from about 10 seconds to about an hour. In some embodiments, it may be desirable to spread the implant irradiation over multiple sessions, such a weekly, monthly or daily either for patient convenience or to control the bioerosion process. - As the
microsphere 700 is irradiated and heats up, it expands and releases the reagent E into the implant material. The reagent begins to chemically react with the implant material, breaking it down, thus accelerating the in situ biodegradation rate. Additional information on methods of use, materials and principles of operation of controlled drug delivery systems are reported in the scientific and patent literature including U.S. Pat. Nos. 6,645,517 (West et al.) and 4,891,225 (Langer et al.), the entire contents of which are incorporated herein by reference. In other embodiments, an implant having different layers of degradable materials could be independently degraded by selectively releasing various reagents E from themicrosphere 700 at different temperatures. The various layers could be bioeroded away at the same time during a single treatment session, or the layers may be selectively bioeroded away with multiple exposures to electromagnetic radiation at different times. - While the exemplary embodiments have been described in some details for clarity of understanding and by way of example, a variety of additional modifications, adaptations and changes may be clear to those of skill in the art. Hence, the scope of the present invention is limited solely by the appended claims.
Claims (171)
1. An implant for use in tissue, the implant comprising:
a structure adapted for implantation into the tissue, the structure having a first material property at normal body temperature, the material property being variable at an elevated temperature above normal body temperature; and
a plurality of particles dispersed in the structure, the particles adapted to convert incident radiation into heat energy when irradiated with electromagnetic radiation, and wherein the particles are in thermal contact with the structure such that exposure of the particles to the incident radiation raises the temperature of the structure thereby changing the first material property.
2. An implant according to claim 1 , wherein the material property is the ability of the structure to be plastically expanded and wherein the structure is not plastically expandable at normal body temperatures but is plastically deformable at an elevated temperature above normal body temperature.
3. An implant according to claim 1 , wherein the structure is biodegradable and the material property is the biodegradation rate of the structure.
4. An implant according to claim 1 , wherein the material property is the viscosity of the structure, the structure having a lower viscosity at an elevated temperature above normal body temperature.
5. An implant according to claim 1 , wherein the particles comprise nanoparticles.
6. An implant according to claim 1 , wherein the particles comprise a non-conducting core layer having a first thickness and a conducting outer shell layer adjacent to the core layer having a second thickness.
7. An implant according to claim 6 , wherein the ratio of the first thickness to the second thickness defines a maximum wavelength of electromagnetic radiation converted by the particles into heat.
8. An implant according to claim 6 , wherein the outer layer comprises gold.
9. An implant according to claim 6 , wherein the core layer comprises silicon dioxide.
10. An implant according to claim 1 , wherein the particles comprise nanoshells.
11. An implant according to claim 1 , wherein the particles are substantially spherical.
12. An implant according to claim 1 , wherein the structure is biodegradable.
13. An implant according to claim 1 , wherein the structure comprises a polymer.
14. An implant according to claim 1 , wherein the structure comprises a natural polymer.
15. An implant according to claim 1 , wherein the structure comprises a synthetic polymer.
16. An implant according to claim 1 , wherein the structure comprises a copolymer.
17. An implant according to claim 1 , wherein the structure comprises a material selected from the group consisting of polyhydroxyalkanoates, polyalphahydroxy acids, polysaccharides, proteins, hydrogels, lignin, shellac, natural rubber, polyanhydrides, polyamide esters, polyvinyl esters, polyvinyl alcohols, polyalkylene esters, polyethylene oxide, polyvinylpyrrolidone, polyethylene maleic anhydride, poly(glycerol-sibacate) and polyphosphazenes.
18. An implant according to claim 1 , wherein the structure comprises poly-L-lactide.
19. An implant according to claim 1 , wherein the structure comprises poly-DL-lactide.
20. An implant according to claim 1 , wherein the structure comprises poly-ε-caprolactone.
21. An implant according to claim 1 , wherein the structure comprises a plasticizer adapted to soften the structure.
22. An implant according to claim 1 , wherein the structure comprises a biological fluid in the solid state.
23. An implant according to claim 22 , wherein the biological fluid comprises blood plasma.
24. An implant according to claim 1 , wherein the structure is a stent.
25. An implant according to claim 24 , wherein the stent is tubular and is radially expandable at the elevated temperature.
26. An implant according to claim 24 , wherein the stent comprises a tube having a sidewall, the sidewall defining a plurality of openings therein.
27. An implant according to claim 1 , wherein the structure is adapted to be implanted into a breast.
28. An implant according to claim 1 , wherein the structure is adapted to exclude an aneurysm.
29. An implant according to claim 1 , wherein the structure is an orthopedic implant.
30. An implant according to claim 1 , wherein the elevated temperature is in the range from about 38° C. to about 60° C.
31. An apparatus according to claim 1 , wherein the electromagnetic radiation is one of ultraviolet, visible, near infrared and infrared light.
32. An implant according to claim 1 , wherein the structure carries a therapeutic agent adapted to be released therefrom in a controlled manner.
33. An implant according to claim 32 , wherein the therapeutic agent inhibits restenosis.
34. An implant according to claim 32 , wherein the therapeutic agent comprises at least one of antibiotics, thrombolytics, anti-thrombotics, anti-inflammatories, cytotoxic agents, anti-proliferative agents, vasodilators, gene therapy agents, radioactive agents, immunosuppressants, chemotherapeutics, endothelial cell attractors, endothelial cell promoters, stem cells and combinations thereof.
35. An expandable implant for use in tissue, the implant comprising:
a structure adapted for implantation into the tissue, wherein the structure is not plastically deformable at normal body temperatures but is plastically deformable at an elevated temperature above normal body temperature; and
a plurality of particles dispersed in the structure, the particles adapted to convert incident radiation into heat energy when irradiated with electromagnetic radiation, and wherein the particles are in thermal contact with the structure such that exposure of the particles to the incident radiation raises the temperature of the structure allowing plastic deformation thereof.
36. An implant according to claim 35 , wherein the particles comprise nanoparticles.
37. An implant according to claim 35 , wherein the particles comprise a non-conducting core layer having a first thickness and a conducting outer shell layer adjacent to the core layer having a second thickness.
38. An implant according to claim 37 , wherein the ratio of the first thickness to the second thickness defines a maximum wavelength of electromagnetic radiation converted into heat by the particles.
39. An implant according to claim 37 , wherein the outer layer comprises gold.
40. An implant according to claim 37 , wherein the core layer comprises silicon dioxide.
41. An implant according to claim 35 , wherein the particles comprise nanoshells.
42. An implant according to claim 35 , wherein the particles are substantially spherical.
43. An implant according to claim 35 , wherein the structure is biodegradable.
44. An implant according to claim 35 , wherein the structure comprises a polymer.
45. An implant according to claim 35 , wherein the structure comprises a copolymer.
46. An implant according to claim 35 , wherein the structure comprises a natural polymer.
47. An implant according to claim 35 , wherein the structure comprises a synthetic polymer.
48. An implant according to claim 35 , wherein the structure comprises a material selected from the group consisting of polyhydroxyalkanoates, polyalphahydroxy acids, polysaccharides, proteins, hydrogels, lignin, shellac, natural rubber, polyanhydrides, polyamide esters, polyvinyl esters, polyvinyl alcohols, polyalkylene esters, polyethylene oxide, polyvinylpyrrolidone, polyethylene maleic anhydride and poly(glycerol-sibacate) and polyphosphazenes.
49. An implant according to claim 35 , wherein the structure comprises poly-L-lactide.
50. An implant according to claim 35 , wherein the structure comprises poly-DL-lactide.
51. An implant according to claim 35 , wherein the structure comprises poly-ε-caprolactone.
52. An implant according to claim 35 , wherein the structure comprises a plasticizer adapted to soften the structure.
53. An implant according to claim 35 , wherein the structure is a stent.
54. An implant according to claim 53 , wherein the stent is tubular and is radially expandable at the elevated temperature.
55. An implant according to claim 53 , wherein the stent comprises a tube having a sidewall, the sidewall defining a plurality of openings therein.
56. An implant according to claim 35 , wherein the structure is adapted to be implanted into a breast.
57. An implant according to claim 35 , wherein the structure is adapted to exclude an aneurysm.
58. An implant according to claim 35 , wherein the structure is an orthopedic implant.
59. An implant according to claim 35 , wherein the elevated temperature is in the range from about 38° C. to about 60° C.
60. An apparatus according to claim 35 , wherein the electromagnetic radiation is one of ultraviolet, visible, near infrared and infrared light.
61. An implant according to claim 35 , wherein the structure carries a therapeutic agent adapted to be released therefrom in a controlled manner.
62. An implant according to claim 61 , wherein the therapeutic agent inhibits restenosis.
63. An implant according to claim 61 , wherein the therapeutic agent comprises at least one of antibiotics, thrombolytics, anti-thrombotics, anti-inflammatories, cytotoxic agents, anti-proliferative agents, vasodilators, gene therapy agents, radioactive agents, immunosuppressants, chemotherapeutics, endothelial cell attractors, endothelial cell promoters, stem cells and combinations thereof.
64. An expandable, biodegradable implant for use in tissue, the implant comprising:
a biodegradable structure adapted for implantation into the tissue, wherein the structure degrades at a first rate when implanted in the tissue at normal body temperature; and
a plurality of particles dispersed in the structure, the particles adapted to convert incident radiation into heat energy when irradiated with electromagnetic radiation, and wherein the particles are in thermal contact with the structure such that exposure of the particles to the incident radiation raises the temperature of the structure thereby increasing the degradation rate of the structure relative to the first rate.
65. An implant according to claim 64 , wherein the particles comprise nanoparticles.
66. An implant according to claim 64 , wherein the particles comprise a non-conducting core layer having a first thickness and a conducting outer shell layer adjacent to the core layer having a second thickness.
67. An implant according to claim 66 , wherein the ratio of the first thickness to the second thickness defines a maximum wavelength of electromagnetic radiation converted into heat by the particles.
68. An implant according to claim 66 , wherein the outer layer comprises gold.
69. An implant according to claim 66 , wherein the core layer comprises silicon dioxide.
70. An implant according to claim 64 , wherein the particles comprise nanoshells.
71. An implant according to claim 64 , wherein the particles are substantially spherical.
72. An implant according to claim 64 , wherein the structure comprises a polymer.
73. An implant according to claim 64 , wherein the structure comprises a copolymer.
74. An implant according to claim 64 , wherein the structure comprises a natural polymer.
75. An implant according to claim 64 , wherein the structure comprises a synthetic polymer.
76. An implant according to claim 64 , wherein the structure comprises a material selected from the group consisting of polyhydroxyalkanoates, polyalphahydroxy acids, polysaccharides, proteins, hydrogels, lignin, shellac, natural rubber, polyanhydrides, polyamide esters, polyvinyl esters, polyvinyl alcohols, polyalkylene esters, polyethylene oxide, polyvinylpyrrolidone, polyethylene maleic anhydride and poly(glycerol-sibacate) and polyphosphazenes.
77. An implant according to claim 64 , wherein the structure comprises poly-L-lactide.
78. An implant according to claim 64 , wherein the structure comprises poly-DL-lactide.
79. An implant according to claim 64 , wherein the structure comprises poly-ε-caprolactone.
80. An implant according to claim 64 , wherein the structure is a stent.
81. An implant according to claim 80 , wherein the stent is tubular and is radially expandable at the elevated temperature.
82. An implant according to claim 80 , wherein the stent comprises a tube having a sidewall, the sidewall defining a plurality of openings therein.
83. An implant according to claim 64 , wherein the structure is adapted to be implanted into a breast.
84. An implant according to claim 64 , wherein the structure is adapted to exclude an aneurysm.
85. An implant according to claim 64 , wherein the structure is an orthopedic implant.
86. An implant according to claim 64 , wherein the elevated temperature is in the range from about 38° C. to about 60° C.
87. An apparatus according to claim 64 , wherein the electromagnetic radiation is one of ultraviolet, visible, near infrared and infrared light.
88. An apparatus according to claim 64 , further comprising a carrier dispersed in the structure and carrying a reagent, wherein exposure of the particles to the incident radiation raises the temperature of the carrier thereby releasing the reagent therefrom, the reagent adapted to react with the structure so as to increase the degradation rate of the structure relative to the first rate.
89. An apparatus according to claim 88 , wherein the carrier comprises a microsphere.
90. An apparatus according to claim 88 , wherein the carrier comprises a hydrogel.
91. An apparatus according to claim 88 , wherein the carrier comprises a catalyst.
92. An apparatus according to claim 88 , wherein the reagent comprises an enzyme.
93. An implant according to claim 64 , wherein the implant carries a therapeutic agent adapted to be released therefrom in a controlled manner.
94. An implant according to claim 93 , wherein the therapeutic agent inhibits restensosis.
95. An implant according to claim 93 , wherein the therapeutic agent comprises at least one of antibiotics, thrombolytics, anti-thrombotics, anti-inflammatories, cytotoxic agents, anti-proliferative agents, vasodilators, gene therapy agents, radioactive agents, immunosuppressants, chemotherapeutics, endothelial cell attractors, endothelial promoters, stem cells and combinations thereof.
96. A method of controlling a material property of an implant, the method comprising:
providing an implant having a plurality of particles dispersed therein and wherein the implant has a first material property when implanted in tissue at normal body temperature, the material property being variable at an elevated temperature above normal body temperature; and
exposing the implant to electromagnetic radiation, the incident radiation being converted into heat energy thus raising the temperature of the implant above normal body temperature, thereby changing the material property relative to the first material property.
97. The method of claim 96 , wherein the material property is the ability of the structure to be plastically deformed and wherein the structure is not plastically deformable at normal body temperatures but is plastically deformable at an elevated temperature above normal body temperature.
98. The method of claim 96 , wherein the implant is biodegradable and the first material property is the biodegradation rate of the implant.
99. The method of claim 96 , wherein the material property is the viscosity of the structure, the structure having a lower viscosity at an elevated temperature above normal body temperature.
100. The method of claim 96 , further comprising discontinuing exposure of the implant to the electromagnetic radiation thereby allowing the implant to cool down so that it returns to body temperature, the implant being substantially undeformable plastically at body temperature.
101. The method of claim 96 , further comprising monitoring the temperature of the implant.
102. The method of claim 96 , wherein the implant temperature is raised to a temperature in the range from about 38° C. to about 60° C.
103. The method of claim 96 , wherein the implant is a stent.
104. The method of claim 96 , further comprising implanting the implant into a breast.
105. The method of claim 96 , further comprising excluding an aneurysm with the implant.
106. The method of claim 96 , wherein the implant is an orthopedic implant.
107. The method of claim 96 , wherein the particles are nanoparticles.
108. The method of claim 96 , wherein the particles are nanoshells.
109. The method of claim 108 , wherein the nanoshells comprise a non-conducting core layer and a conducting outer shell layer.
110. The method of claim 96 , wherein the electromagnetic radiation is one of ultraviolet, visible, near infrared and infrared light.
111. The method of claim 96 , wherein exposing the implant to electromagnetic radiation comprises exposing the implant to the electromagnetic radiation extracorporally.
112. The method of claim 96 , wherein exposing the implant to electromagnetic radiation comprises exposing the implant to the electromagnetic radiation from within the body.
113. The method of claim 96 , wherein exposing the implant to electromagnetic radiation comprises delivering electromagnetic radiation to the implant with a catheter.
114. The method of claim 96 , wherein exposing the implant to electromagnetic radiation comprises delivering the radiation for a fixed duration of time.
115. The method of claim 96 , wherein exposing the implant to electromagnetic radiation comprises delivering the radiation until a desired temperature is obtained in the implant.
116. The method of claim 96 , wherein exposing the implant to electromagnetic radiation comprises delivering the radiation over periodic intervals.
117. The method of claim 96 , wherein exposing the implant to electromagnetic radiation comprises delivering the radiation continuously during a defined period.
118. The method of claim 96 , wherein the implant is biodegradable.
119. The method of claim 96 , further comprising releasing a therapeutic agent from the implant in a controlled manner.
120. The method of claim 119 , wherein the therapeutic agent inhibits restenosis.
121. The method of claim 119 , wherein the therapeutic agent comprises at least one of antibiotics, thrombolytics, anti-thrombotics, anti-inflammatories, cytotoxic agents, anti-proliferative agents, vasodilators, gene therapy agents, radioactive agents, immunosuppressants, chemotherapeutics, endothelial cell attractors, endothelial cell promoters, stem cells and combinations thereof.
122. A method of delivering an expandable implant to a treatment site in a body, the method comprising:
providing an implant having a plurality of particles dispersed therein;
positioning the implant at the treatment site;
exposing the implant to electromagnetic radiation, the particles converting the incident radiation into heat energy thereby raising the temperature of the implant above the implant glass transition temperature; and
plastically deforming the implant so as to change the shape of the implant.
123. The method of claim 122 , further comprising discontinuing exposure of the implant to the electromagnetic radiation thereby allowing the implant to cool down so that it returns to body temperature, the implant being substantially undeformable plastically at body temperature.
124. The method of claim 122 , wherein expanding the implant comprises expanding a balloon.
125. The method of claim 122 , further comprising monitoring the temperature of the implant.
126. The method of claim 122 , wherein positioning the implant comprises advancing a catheter through a body lumen, the implant disposed on the catheter.
127. The method of claim 122 , wherein the implant temperature is raised to a temperature in the range from about 38° C. to about 60° C.
128. The method of claim 122 , wherein the implant is a stent.
129. The method of claim 122 , further comprising implanting the implant into a breast.
130. The method of claim 122 , further comprising excluding an aneurysm with the implant.
131. The method of claim 122 , wherein the implant is an orthopedic implant.
132. The method of claim 122 , wherein the particles are nanoparticles.
133. The method of claim 122 , wherein the particles are nanoshells.
134. The method of claim 133 , wherein the nanoshells comprise a non-conducting core layer and a conducting outer shell layer.
135. The method of claim 122 , wherein the electromagnetic radiation is one of ultraviolet, visible, near infrared and infrared light.
136. The method of claim 122 , wherein exposing the implant to electromagnetic radiation comprises exposing the implant to electromagnetic radiation extracorporally.
137. The method of claim 122 , wherein exposing the implant to electromagnetic radiation comprises exposing the implant to electromagnetic radiation from within the body.
138. The method of claim 122 , wherein exposing the implant to electromagnetic radiation comprises delivering electromagnetic radiation to the implant with a catheter.
139. The method of claim 122 , wherein exposing the implant to electromagnetic radiation comprises delivering the radiation for a fixed duration of time.
140. The method of claim 122 , wherein exposing the implant to electromagnetic radiation comprises delivering the radiation until a desired temperature is obtained in the implant.
141. The method of claim 122 , wherein exposing the implant to electromagnetic radiation comprises delivering the radiation over periodic intervals.
142. The method of claim 122 , wherein exposing the implant to electromagnetic radiation comprises delivering the radiation continuously during a defined period.
143. The method of claim 122 , wherein the implant is biodegradable.
144. The method of claim 122 , further comprising releasing a therapeutic agent from the implant in a controlled manner.
145. The method of claim 144 , wherein the therapeutic agent inhibits restenosis.
146. The method of claim 144 , wherein the therapeutic agent comprises at least one of antibiotics, thrombolytics, anti-thrombotics, anti-inflammatories, cytotoxic agents, anti-proliferative agents, vasodilators, gene therapy agents, radioactive agents, immunosuppressants, chemotherapeutics, endothelial cell attractors, endothelial cell promoters, stem cells and combinations thereof.
147. A method of controlling degradation of an implant, the method comprising:
providing a biodegradable implant having a plurality of particles dispersed therein and wherein the implant degrades at a first rate when implanted in tissue at normal body temperature; and
exposing the implant to electromagnetic radiation, the incident radiation being converted into heat energy thus raising the temperature of the implant above normal body temperature, thereby changing the biodegradation rate of the implant relative to the first rate.
148. The method of claim 147 , further comprising discontinuing exposure of the implant to the electromagnetic radiation thereby allowing the implant to cool down so that it returns to body temperature.
149. The method of claim 147 , further comprising monitoring the temperature of the implant.
150. The method of claim 147 , wherein the implant temperature is raised to a temperature in the range from about 38° C. to about 60° C.
151. The method of claim 147 , wherein the implant is a stent.
152. The method of claim 147 , further comprising implanting the implant into a breast.
153. The method of claim 147 , further comprising excluding an aneurysm with the implant.
154. The method of claim 147 , wherein the implant is an orthopedic implant.
155. The method of claim 147 , wherein the particles comprise nanoparticles.
156. The method of claim 147 , wherein the particles comprise nanoshells.
157. The method of claim 147 , wherein the particles comprise a non-conducting core layer and a conducting outer shell layer adjacent to the core layer.
158. The method of claim 147 , wherein the electromagnetic radiation is one of ultraviolet, visible, near infrared and infrared light.
159. The method of claim 147 , wherein exposing the implant to electromagnetic radiation comprises exposing the implant to electromagnetic radiation extracorporally.
160. The method of claim 147 , wherein exposing the implant to electromagnetic radiation comprises exposing the implant to electromagnetic radiation from within the body.
161. The method of claim 147 , wherein exposing the implant to electromagnetic radiation comprises delivering electromagnetic radiation to the implant with a catheter.
162. The method of claim 147 , wherein exposing the implant to electromagnetic radiation comprises delivering the radiation for a fixed duration of time.
163. The method of claim 147 , wherein exposing the implant to electromagnetic radiation comprises delivering the radiation until a desired temperature is obtained in the implant.
164. The method of claim 147 , wherein exposing the implant to electromagnetic radiation comprises delivering the radiation over periodic intervals.
165. The method of claim 147 , wherein exposing the implant to electromagnetic radiation comprises delivering the radiation continuously during a defined period.
166. The method of claim 147 , wherein exposing the implant comprises irradiating a carrier containing a reagent, the carrier releasing the reagent and wherein the reagent reacts with the implant to degrade it.
167. The method of claim 166 , wherein the reagent is an enzyme.
168. The method of claim 166 , wherein the reagent is a catalyst.
169. The method of claim 147 , further comprising releasing a therapeutic agent from the implant in a controlled manner.
170. The method of claim 169 , wherein the therapeutic agent inhibits restenosis.
171. The method of claim 169 , wherein the therapeutic agent comprises at least one of antibiotics, thrombolytics, anti-thrombotics, anti-inflammatories, cytotoxic agents, anti-proliferative agents, vasodilators, gene therapy agents, radioactive agents, immunosuppressants, chemotherapeutics, endothelial cell attractors, endothelial cell promoters, stem cells and combinations thereof.
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/033,586 US20080199510A1 (en) | 2007-02-20 | 2008-02-19 | Thermo-mechanically controlled implants and methods of use |
JP2009550987A JP2010518980A (en) | 2007-02-20 | 2008-02-20 | Thermomechanically controlled implant and method of use |
CA002678814A CA2678814A1 (en) | 2007-02-20 | 2008-02-20 | Thermo-mechanically controlled implants and methods of use |
EP08730274.1A EP2114301B1 (en) | 2007-02-20 | 2008-02-20 | Thermo-mechanically controlled implants |
PCT/US2008/054437 WO2008103741A1 (en) | 2007-02-20 | 2008-02-20 | Thermo-mechanically controlled implants and methods of use |
ES08730274T ES2762164T3 (en) | 2007-02-20 | 2008-02-20 | Thermomechanically controlled implants |
AU2008218719A AU2008218719A1 (en) | 2007-02-20 | 2008-02-20 | Thermo-mechanically controlled implants and methods of use |
US12/892,553 US8980297B2 (en) | 2007-02-20 | 2010-09-28 | Thermo-mechanically controlled implants and methods of use |
US14/607,944 US9457133B2 (en) | 2007-02-20 | 2015-01-28 | Thermo-mechanically controlled implants and methods of use |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US89070307P | 2007-02-20 | 2007-02-20 | |
US12/033,586 US20080199510A1 (en) | 2007-02-20 | 2008-02-19 | Thermo-mechanically controlled implants and methods of use |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/892,553 Continuation US8980297B2 (en) | 2007-02-20 | 2010-09-28 | Thermo-mechanically controlled implants and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
US20080199510A1 true US20080199510A1 (en) | 2008-08-21 |
Family
ID=39706863
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/033,586 Abandoned US20080199510A1 (en) | 2007-02-20 | 2008-02-19 | Thermo-mechanically controlled implants and methods of use |
US12/892,553 Active 2028-05-03 US8980297B2 (en) | 2007-02-20 | 2010-09-28 | Thermo-mechanically controlled implants and methods of use |
US14/607,944 Active US9457133B2 (en) | 2007-02-20 | 2015-01-28 | Thermo-mechanically controlled implants and methods of use |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/892,553 Active 2028-05-03 US8980297B2 (en) | 2007-02-20 | 2010-09-28 | Thermo-mechanically controlled implants and methods of use |
US14/607,944 Active US9457133B2 (en) | 2007-02-20 | 2015-01-28 | Thermo-mechanically controlled implants and methods of use |
Country Status (7)
Country | Link |
---|---|
US (3) | US20080199510A1 (en) |
EP (1) | EP2114301B1 (en) |
JP (1) | JP2010518980A (en) |
AU (1) | AU2008218719A1 (en) |
CA (1) | CA2678814A1 (en) |
ES (1) | ES2762164T3 (en) |
WO (1) | WO2008103741A1 (en) |
Cited By (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040249434A1 (en) * | 2001-12-03 | 2004-12-09 | Xtent, Inc. | Stent delivery for bifuricated vessels |
US20080099170A1 (en) * | 2006-10-31 | 2008-05-01 | The Procter & Gamble Company | Process of making wet-microcontracted paper |
US20090176193A1 (en) * | 2008-01-09 | 2009-07-09 | Kaigler Sr Darnell | Implant pellets and methods for performing bone augmentation and preservation |
US20090326654A1 (en) * | 2008-06-30 | 2009-12-31 | Allergan, Inc. | Fillable prosthetic implant with gel-like properties |
US7892274B2 (en) | 2001-12-03 | 2011-02-22 | Xtent, Inc. | Apparatus and methods for deployment of vascular prostheses |
US7892273B2 (en) | 2001-12-03 | 2011-02-22 | Xtent, Inc. | Custom length stent apparatus |
US7918881B2 (en) | 2003-06-09 | 2011-04-05 | Xtent, Inc. | Stent deployment systems and methods |
US7938852B2 (en) | 2001-12-03 | 2011-05-10 | Xtent, Inc. | Apparatus and methods for delivery of braided prostheses |
US8016870B2 (en) | 2001-12-03 | 2011-09-13 | Xtent, Inc. | Apparatus and methods for delivery of variable length stents |
US8016871B2 (en) | 2001-12-03 | 2011-09-13 | Xtent, Inc. | Apparatus and methods for delivery of multiple distributed stents |
EP2384725A1 (en) * | 2010-05-06 | 2011-11-09 | Biotronik AG | Biocorrodable implant in which corrosion may be triggered or accelerated after implantation by means of an external stimulus |
US8083788B2 (en) | 2001-12-03 | 2011-12-27 | Xtent, Inc. | Apparatus and methods for positioning prostheses for deployment from a catheter |
US8177831B2 (en) | 2001-12-03 | 2012-05-15 | Xtent, Inc. | Stent delivery apparatus and method |
US8257427B2 (en) | 2001-09-11 | 2012-09-04 | J.W. Medical Systems, Ltd. | Expandable stent |
US8273010B2 (en) | 2010-06-14 | 2012-09-25 | Coloplast A/S | Incontinence treatment device |
US8282680B2 (en) | 2003-01-17 | 2012-10-09 | J. W. Medical Systems Ltd. | Multiple independent nested stent structures and methods for their preparation and deployment |
US8317859B2 (en) | 2004-06-28 | 2012-11-27 | J.W. Medical Systems Ltd. | Devices and methods for controlling expandable prostheses during deployment |
US8460358B2 (en) | 2004-03-30 | 2013-06-11 | J.W. Medical Systems, Ltd. | Rapid exchange interventional devices and methods |
US8486132B2 (en) | 2007-03-22 | 2013-07-16 | J.W. Medical Systems Ltd. | Devices and methods for controlling expandable prostheses during deployment |
US20130245759A1 (en) * | 2012-03-09 | 2013-09-19 | The Florida International University Board Of Trustees | Medical devices incorporating silicone nanoparticles, and uses thereof |
CN103328034A (en) * | 2010-09-03 | 2013-09-25 | 塔夫茨大学/塔夫茨学院信托人 | Plasmonic nanoparticle-doped silk materials |
US8585747B2 (en) | 2003-12-23 | 2013-11-19 | J.W. Medical Systems Ltd. | Devices and methods for controlling and indicating the length of an interventional element |
US8652198B2 (en) | 2006-03-20 | 2014-02-18 | J.W. Medical Systems Ltd. | Apparatus and methods for deployment of linked prosthetic segments |
US8702781B2 (en) | 2001-12-03 | 2014-04-22 | J.W. Medical Systems Ltd. | Apparatus and methods for delivery of multiple distributed stents |
US8769796B2 (en) | 2008-09-25 | 2014-07-08 | Advanced Bifurcation Systems, Inc. | Selective stent crimping |
US8795347B2 (en) | 2008-09-25 | 2014-08-05 | Advanced Bifurcation Systems, Inc. | Methods and systems for treating a bifurcation with provisional side branch stenting |
US8808347B2 (en) | 2008-09-25 | 2014-08-19 | Advanced Bifurcation Systems, Inc. | Stent alignment during treatment of a bifurcation |
US8821562B2 (en) | 2008-09-25 | 2014-09-02 | Advanced Bifurcation Systems, Inc. | Partially crimped stent |
US8979917B2 (en) | 2008-09-25 | 2015-03-17 | Advanced Bifurcation Systems, Inc. | System and methods for treating a bifurcation |
US8980297B2 (en) | 2007-02-20 | 2015-03-17 | J.W. Medical Systems Ltd. | Thermo-mechanically controlled implants and methods of use |
US8986362B2 (en) | 2004-06-28 | 2015-03-24 | J.W. Medical Systems Ltd. | Devices and methods for controlling expandable prostheses during deployment |
US20150126615A1 (en) * | 2013-11-05 | 2015-05-07 | Tepha, Inc. | Compositions and devices of poly-4-hydroxybutyrate |
US9101503B2 (en) | 2008-03-06 | 2015-08-11 | J.W. Medical Systems Ltd. | Apparatus having variable strut length and methods of use |
US9254210B2 (en) | 2011-02-08 | 2016-02-09 | Advanced Bifurcation Systems, Inc. | Multi-stent and multi-balloon apparatus for treating bifurcations and methods of use |
US9364356B2 (en) | 2011-02-08 | 2016-06-14 | Advanced Bifurcation System, Inc. | System and methods for treating a bifurcation with a fully crimped stent |
US20160228267A1 (en) * | 2015-02-11 | 2016-08-11 | Abbott Cardiovascular Systems Inc. | Scaffolds having radiopaque markers |
US9737424B2 (en) | 2008-09-25 | 2017-08-22 | Advanced Bifurcation Systems, Inc. | Partially crimped stent |
US20180235750A1 (en) * | 2017-02-21 | 2018-08-23 | Biosense Webster (Israel) Ltd. | Heat expandable breast implant using induction heating |
US10610387B2 (en) | 2015-06-12 | 2020-04-07 | Abbott Cardiovascular Systems Inc. | Scaffolds having a radiopaque marker and methods for attaching a marker to a scaffold |
US10993834B2 (en) | 2013-01-15 | 2021-05-04 | The Regents Of The University Of Colorado, A Body Corporate | Lacrimal system drug delivery device |
CN113056295A (en) * | 2018-11-02 | 2021-06-29 | 波士顿科学国际有限公司 | Biodegradable stent |
US11207211B2 (en) | 2016-05-20 | 2021-12-28 | The Regents Of The University Of Colorado, A Body Corporate | Lacrimal drug delivery device |
US11857461B2 (en) * | 2015-11-23 | 2024-01-02 | The Regents Of The University Of Colorado, A Body Corporate | Lacrimal system for drug delivery |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7553324B2 (en) * | 2003-10-14 | 2009-06-30 | Xtent, Inc. | Fixed stent delivery devices and methods |
US20070281117A1 (en) * | 2006-06-02 | 2007-12-06 | Xtent, Inc. | Use of plasma in formation of biodegradable stent coating |
US20100249912A1 (en) * | 2009-03-30 | 2010-09-30 | Wilson-Cook Medical Inc. | Intraluminal device with controlled biodegradation |
US9525092B2 (en) | 2010-11-05 | 2016-12-20 | Pacific Light Technologies Corp. | Solar module employing quantum luminescent lateral transfer concentrator |
ES2632769T3 (en) * | 2011-03-09 | 2017-09-15 | Occlugel | Implantable inflatable bioresorbable polymer |
US9267889B1 (en) * | 2011-10-12 | 2016-02-23 | Stc.Unm | High efficiency light absorbing and light emitting nanostructures |
US20130112942A1 (en) | 2011-11-09 | 2013-05-09 | Juanita Kurtin | Composite having semiconductor structures embedded in a matrix |
US9277983B2 (en) * | 2013-03-13 | 2016-03-08 | Abbott Cardiovascular Systems Inc. | Drug delivery device for peripheral artery disease |
WO2014172572A1 (en) * | 2013-04-18 | 2014-10-23 | Board Of Regents, The University Of Texas System | Antimicrobial wraps for medical implants |
US9228420B2 (en) * | 2013-08-19 | 2016-01-05 | Baker Hughes Incorporated | Conformable materials containing heat transfer nanoparticles and devices made using same |
DK3391914T3 (en) | 2017-04-21 | 2021-10-18 | Safe Implant Tech Aps | GOLD PARTICLES FOR USE IN THERAPY TO PREVENT OR REDUCE CAPSULES CONTRACTURE |
GB201805484D0 (en) * | 2018-04-04 | 2018-05-16 | Gc Aesthetics Mfg Ltd | Implant |
KR102582064B1 (en) * | 2018-07-11 | 2023-09-25 | 한국과학기술연구원 | Nanoparticles comprising near infrared absorption dye, methods for manufacturing thereof, and uses thereof |
Citations (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4069825A (en) * | 1976-01-28 | 1978-01-24 | Taichiro Akiyama | Surgical thread and cutting apparatus for the same |
US4512338A (en) * | 1983-01-25 | 1985-04-23 | Balko Alexander B | Process for restoring patency to body vessels |
US4564014A (en) * | 1980-01-30 | 1986-01-14 | Thomas J. Fogarty | Variable length dilatation catheter apparatus and method |
US4580568A (en) * | 1984-10-01 | 1986-04-08 | Cook, Incorporated | Percutaneous endovascular stent and method for insertion thereof |
US4733665A (en) * | 1985-11-07 | 1988-03-29 | Expandable Grafts Partnership | Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft |
US4891225A (en) * | 1984-05-21 | 1990-01-02 | Massachusetts Institute Of Technology | Bioerodible polyanhydrides for controlled drug delivery |
US4988356A (en) * | 1987-02-27 | 1991-01-29 | C. R. Bard, Inc. | Catheter and guidewire exchange system |
US4994069A (en) * | 1988-11-02 | 1991-02-19 | Target Therapeutics | Vaso-occlusion coil and method |
US4994066A (en) * | 1988-10-07 | 1991-02-19 | Voss Gene A | Prostatic stent |
US5092877A (en) * | 1988-09-01 | 1992-03-03 | Corvita Corporation | Radially expandable endoprosthesis |
US5102417A (en) * | 1985-11-07 | 1992-04-07 | Expandable Grafts Partnership | Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft |
US5104404A (en) * | 1989-10-02 | 1992-04-14 | Medtronic, Inc. | Articulated stent |
US5195984A (en) * | 1988-10-04 | 1993-03-23 | Expandable Grafts Partnership | Expandable intraluminal graft |
US5282824A (en) * | 1990-10-09 | 1994-02-01 | Cook, Incorporated | Percutaneous stent assembly |
US5300085A (en) * | 1986-04-15 | 1994-04-05 | Advanced Cardiovascular Systems, Inc. | Angioplasty apparatus facilitating rapid exchanges and method |
US5490837A (en) * | 1991-07-05 | 1996-02-13 | Scimed Life Systems, Inc. | Single operator exchange catheter having a distal catheter shaft section |
US5496346A (en) * | 1987-01-06 | 1996-03-05 | Advanced Cardiovascular Systems, Inc. | Reinforced balloon dilatation catheter with slitted exchange sleeve and method |
US5507771A (en) * | 1992-06-15 | 1996-04-16 | Cook Incorporated | Stent assembly |
US5507768A (en) * | 1991-01-28 | 1996-04-16 | Advanced Cardiovascular Systems, Inc. | Stent delivery system |
US5593412A (en) * | 1994-03-01 | 1997-01-14 | Cordis Corporation | Stent delivery method and apparatus |
US5607444A (en) * | 1993-12-02 | 1997-03-04 | Advanced Cardiovascular Systems, Inc. | Ostial stent for bifurcations |
US5709701A (en) * | 1996-05-30 | 1998-01-20 | Parodi; Juan C. | Apparatus for implanting a prothesis within a body passageway |
US5716393A (en) * | 1994-05-26 | 1998-02-10 | Angiomed Gmbh & Co. Medizintechnik Kg | Stent with an end of greater diameter than its main body |
US5723003A (en) * | 1994-09-13 | 1998-03-03 | Ultrasonic Sensing And Monitoring Systems | Expandable graft assembly and method of use |
US5722669A (en) * | 1995-09-26 | 1998-03-03 | Keeper Co., Ltd. | Resin CVJ boot with distinct large and small crest portions |
US5735869A (en) * | 1994-11-30 | 1998-04-07 | Schneider (Europe) A.G. | Balloon catheter and stent delivery device |
US5741323A (en) * | 1993-04-28 | 1998-04-21 | Focal, Inc. | Polymeric article for intraluminal photothermoforming |
US5855563A (en) * | 1992-11-02 | 1999-01-05 | Localmed, Inc. | Method and apparatus for sequentially performing multiple intraluminal procedures |
US5870381A (en) * | 1995-07-10 | 1999-02-09 | Matsushita Electric Industrial Co., Ltd. | Method for transmitting signals from a plurality of transmitting units and receiving the signals |
US5879370A (en) * | 1994-02-25 | 1999-03-09 | Fischell; Robert E. | Stent having a multiplicity of undulating longitudinals |
US5891190A (en) * | 1989-08-24 | 1999-04-06 | Boneau; Michael D. | Endovascular support device and method |
US5895398A (en) * | 1996-02-02 | 1999-04-20 | The Regents Of The University Of California | Method of using a clot capture coil |
US6022374A (en) * | 1997-12-16 | 2000-02-08 | Cardiovasc, Inc. | Expandable stent having radiopaque marker and method |
US6022359A (en) * | 1999-01-13 | 2000-02-08 | Frantzen; John J. | Stent delivery system featuring a flexible balloon |
US6033434A (en) * | 1995-06-08 | 2000-03-07 | Ave Galway Limited | Bifurcated endovascular stent and methods for forming and placing |
US6036725A (en) * | 1998-06-10 | 2000-03-14 | General Science And Technology | Expandable endovascular support device |
US6039721A (en) * | 1996-07-24 | 2000-03-21 | Cordis Corporation | Method and catheter system for delivering medication with an everting balloon catheter |
US6042589A (en) * | 1998-03-17 | 2000-03-28 | Medicorp, S.A. | Reversible-action endoprosthesis delivery device |
US6179878B1 (en) * | 1996-10-22 | 2001-01-30 | Thomas Duerig | Composite self expanding stent device having a restraining element |
US6183509B1 (en) * | 1995-05-04 | 2001-02-06 | Alain Dibie | Endoprosthesis for the treatment of blood-vessel bifurcation stenosis and purpose-built installation device |
US6187034B1 (en) * | 1999-01-13 | 2001-02-13 | John J. Frantzen | Segmented stent for flexible stent delivery system |
US6190402B1 (en) * | 1996-06-21 | 2001-02-20 | Musc Foundation For Research Development | Insitu formable and self-forming intravascular flow modifier (IFM) and IFM assembly for deployment of same |
US6196995B1 (en) * | 1998-09-30 | 2001-03-06 | Medtronic Ave, Inc. | Reinforced edge exchange catheter |
US6200337B1 (en) * | 1996-03-10 | 2001-03-13 | Terumo Kabushiki Kaisha | Implanting stent |
US6344811B1 (en) * | 1999-03-16 | 2002-02-05 | Audio Logic, Inc. | Power supply compensation for noise shaped, digital amplifiers |
US6344272B1 (en) * | 1997-03-12 | 2002-02-05 | Wm. Marsh Rice University | Metal nanoshells |
US6357104B1 (en) * | 1993-08-18 | 2002-03-19 | David J. Myers | Method of making an intraluminal stent graft |
US20020037358A1 (en) * | 1997-08-13 | 2002-03-28 | Barry James J. | Loading and release of water-insoluble drugs |
US6375676B1 (en) * | 1999-05-17 | 2002-04-23 | Advanced Cardiovascular Systems, Inc. | Self-expanding stent with enhanced delivery precision and stent delivery system |
US6379365B1 (en) * | 1999-03-29 | 2002-04-30 | Alexis Diaz | Stent delivery catheter system having grooved shaft |
US6511468B1 (en) * | 1997-10-17 | 2003-01-28 | Micro Therapeutics, Inc. | Device and method for controlling injection of liquid embolic composition |
US6520986B2 (en) * | 1995-12-14 | 2003-02-18 | Gore Enterprise Holdings, Inc. | Kink resistant stent-graft |
US6520987B1 (en) * | 1997-02-25 | 2003-02-18 | Symbiotech Medical, Inc | Expandable intravascular stent |
US6527799B2 (en) * | 1998-10-29 | 2003-03-04 | Conor Medsystems, Inc. | Expandable medical device with ductile hinges |
US20030045923A1 (en) * | 2001-08-31 | 2003-03-06 | Mehran Bashiri | Hybrid balloon expandable/self expanding stent |
US6530944B2 (en) * | 2000-02-08 | 2003-03-11 | Rice University | Optically-active nanoparticles for use in therapeutic and diagnostic methods |
US6540777B2 (en) * | 2001-02-15 | 2003-04-01 | Scimed Life Systems, Inc. | Locking stent |
US6551350B1 (en) * | 1996-12-23 | 2003-04-22 | Gore Enterprise Holdings, Inc. | Kink resistant bifurcated prosthesis |
US6555157B1 (en) * | 2000-07-25 | 2003-04-29 | Advanced Cardiovascular Systems, Inc. | Method for coating an implantable device and system for performing the method |
US6676695B2 (en) * | 2001-05-30 | 2004-01-13 | Jan Otto Solem | Vascular instrument and method |
US6679909B2 (en) * | 2001-07-31 | 2004-01-20 | Advanced Cardiovascular Systems, Inc. | Rapid exchange delivery system for self-expanding stent |
US6685730B2 (en) * | 2001-09-26 | 2004-02-03 | Rice University | Optically-absorbing nanoparticles for enhanced tissue repair |
US20040024450A1 (en) * | 2002-04-24 | 2004-02-05 | Sun Biomedical, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
US20040030380A1 (en) * | 2002-04-24 | 2004-02-12 | Sun Biomedical, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
US6692465B2 (en) * | 1991-06-11 | 2004-02-17 | Advanced Cardiovascular Systems, Inc. | Catheter system with catheter and guidewire exchange |
US6699280B2 (en) * | 1999-04-15 | 2004-03-02 | Mayo Foundation For Medical Education And Research | Multi-section stent |
US6699724B1 (en) * | 1998-03-11 | 2004-03-02 | Wm. Marsh Rice University | Metal nanoshells for biosensing applications |
US20040044395A1 (en) * | 2002-09-03 | 2004-03-04 | Scimed Life Systems, Inc. | Elephant trunk thoracic endograft and delivery system |
US6702843B1 (en) * | 2000-04-12 | 2004-03-09 | Scimed Life Systems, Inc. | Stent delivery means with balloon retraction means |
US6709379B1 (en) * | 1998-11-02 | 2004-03-23 | Alcove Surfaces Gmbh | Implant with cavities containing therapeutic agents |
US6709440B2 (en) * | 2001-05-17 | 2004-03-23 | Advanced Cardiovascular Systems, Inc. | Stent and catheter assembly and method for treating bifurcations |
US6712827B2 (en) * | 1996-08-23 | 2004-03-30 | Scimed Life Systems, Inc. | Stent delivery system |
US6712845B2 (en) * | 2001-04-24 | 2004-03-30 | Advanced Cardiovascular Systems, Inc. | Coating for a stent and a method of forming the same |
US6837901B2 (en) * | 2001-04-27 | 2005-01-04 | Intek Technology L.L.C. | Methods for delivering, repositioning and/or retrieving self-expanding stents |
US20050010276A1 (en) * | 2001-12-03 | 2005-01-13 | Xtent, Inc. | Apparatus and methods for positioning prostheses for deployment from a catheter |
US6849084B2 (en) * | 2002-12-31 | 2005-02-01 | Intek Technology L.L.C. | Stent delivery system |
US6852252B2 (en) * | 1997-03-12 | 2005-02-08 | William Marsh Rice University | Use of metalnanoshells to impede the photo-oxidation of conjugated polymer |
US6855125B2 (en) * | 1999-05-20 | 2005-02-15 | Conor Medsystems, Inc. | Expandable medical device delivery system and method |
US20050038505A1 (en) * | 2001-11-05 | 2005-02-17 | Sun Biomedical Ltd. | Drug-delivery endovascular stent and method of forming the same |
US6858034B1 (en) * | 1999-05-20 | 2005-02-22 | Scimed Life Systems, Inc. | Stent delivery system for prevention of kinking, and method of loading and using same |
US20050049673A1 (en) * | 2001-12-03 | 2005-03-03 | Xtent, Inc. A Delaware Corporation | Apparatus and methods for delivery of braided prostheses |
US20060002852A1 (en) * | 2004-07-01 | 2006-01-05 | Yale University | Targeted and high density drug loaded polymeric materials |
US6994721B2 (en) * | 2002-10-21 | 2006-02-07 | Israel Henry M | Stent assembly |
US7005454B2 (en) * | 1995-07-28 | 2006-02-28 | Rutgers, The State University | Polymeric drug formulations |
US20060069424A1 (en) * | 2004-09-27 | 2006-03-30 | Xtent, Inc. | Self-constrained segmented stents and methods for their deployment |
US7169172B2 (en) * | 2002-11-01 | 2007-01-30 | Counter Clockwise, Inc. | Method and apparatus for caged stent delivery |
US20070027521A1 (en) * | 2005-06-08 | 2007-02-01 | Xtent, Inc., A Delaware Corporation | Apparatus and methods for deployment of multiple custom-length prostheses |
US7192440B2 (en) * | 2003-10-15 | 2007-03-20 | Xtent, Inc. | Implantable stent delivery devices and methods |
US20070067012A1 (en) * | 2001-12-03 | 2007-03-22 | Xtent, Inc. | Custom length stent apparatus |
US7314480B2 (en) * | 2003-02-27 | 2008-01-01 | Boston Scientific Scimed, Inc. | Rotating balloon expandable sheath bifurcation delivery |
US7323006B2 (en) * | 2004-03-30 | 2008-01-29 | Xtent, Inc. | Rapid exchange interventional devices and methods |
US7326236B2 (en) * | 2003-12-23 | 2008-02-05 | Xtent, Inc. | Devices and methods for controlling and indicating the length of an interventional element |
US20080077229A1 (en) * | 2004-06-28 | 2008-03-27 | Xtent, Inc. | Custom-length self-expanding stent delivery systems with stent bumpers |
Family Cites Families (380)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2002A (en) | 1841-03-12 | Tor and planter for plowing | ||
US4468224A (en) | 1982-01-28 | 1984-08-28 | Advanced Cardiovascular Systems, Inc. | System and method for catheter placement in blood vessels of a human patient |
US5693083A (en) | 1983-12-09 | 1997-12-02 | Endovascular Technologies, Inc. | Thoracic graft and delivery catheter |
DE3442736A1 (en) | 1984-11-23 | 1986-06-05 | Tassilo Dr.med. 7800 Freiburg Bonzel | DILATATION CATHETER |
US4690684A (en) | 1985-07-12 | 1987-09-01 | C. R. Bard, Inc. | Meltable stent for anastomosis |
US4770176A (en) | 1985-07-12 | 1988-09-13 | C. R. Bard, Inc. | Vessel anastomosis using meltable stent |
US4681110A (en) | 1985-12-02 | 1987-07-21 | Wiktor Dominik M | Catheter arrangement having a blood vessel liner, and method of using it |
US5061273A (en) | 1989-06-01 | 1991-10-29 | Yock Paul G | Angioplasty apparatus facilitating rapid exchanges |
US5040548A (en) | 1989-06-01 | 1991-08-20 | Yock Paul G | Angioplasty mehtod |
US4775337A (en) | 1986-12-02 | 1988-10-04 | Universal Manufacturing Corporation | Conductive wire with integral electrical terminal |
ES2043796T3 (en) | 1987-02-27 | 1994-01-01 | Bard Inc C R | CATHETER AND CHUCK EXCHANGE SYSTEM. |
US4886062A (en) | 1987-10-19 | 1989-12-12 | Medtronic, Inc. | Intravascular radially expandable stent and method of implant |
US5171222A (en) | 1988-03-10 | 1992-12-15 | Scimed Life Systems, Inc. | Interlocking peel-away dilation catheter |
US4994298A (en) | 1988-06-07 | 1991-02-19 | Biogold Inc. | Method of making a biocompatible prosthesis |
US6730105B2 (en) | 1988-07-29 | 2004-05-04 | Samuel Shiber | Clover leaf shaped tubular medical device |
US5226913A (en) | 1988-09-01 | 1993-07-13 | Corvita Corporation | Method of making a radially expandable prosthesis |
US4950227A (en) | 1988-11-07 | 1990-08-21 | Boston Scientific Corporation | Stent delivery system |
DE68915150T2 (en) | 1989-01-30 | 1994-10-13 | Bard Inc C R | Quickly replaceable coronary catheter. |
US5217495A (en) | 1989-05-10 | 1993-06-08 | United States Surgical Corporation | Synthetic semiabsorbable composite yarn |
DE9010130U1 (en) | 1989-07-13 | 1990-09-13 | American Medical Systems, Inc., Minnetonka, Minn., Us | |
US5035706A (en) | 1989-10-17 | 1991-07-30 | Cook Incorporated | Percutaneous stent and method for retrieval thereof |
US5158548A (en) | 1990-04-25 | 1992-10-27 | Advanced Cardiovascular Systems, Inc. | Method and system for stent delivery |
US5064435A (en) | 1990-06-28 | 1991-11-12 | Schneider (Usa) Inc. | Self-expanding prosthesis having stable axial length |
US5013318A (en) | 1990-07-31 | 1991-05-07 | Special Devices Incorporated | Medical instrument for measuring depth of fastener hold in bone |
US5122154A (en) | 1990-08-15 | 1992-06-16 | Rhodes Valentine J | Endovascular bypass graft |
AR246020A1 (en) | 1990-10-03 | 1994-03-30 | Hector Daniel Barone Juan Carl | A ball device for implanting an intraluminous aortic prosthesis, for repairing aneurysms. |
US5533968A (en) * | 1991-05-15 | 1996-07-09 | Advanced Cardiovascular Systems, Inc. | Low profile catheter with expandable outer tubular member |
US5527354A (en) | 1991-06-28 | 1996-06-18 | Cook Incorporated | Stent formed of half-round wire |
US5976107A (en) | 1991-07-05 | 1999-11-02 | Scimed Life Systems. Inc. | Catheter having extendable guide wire lumen |
ATE112847T1 (en) | 1991-07-29 | 1994-10-15 | Brandes Bernd | EQUIPMENT AND PROCEDURE FOR DETECTING LEAKS IN TUBES FOR LIQUID MEDIA. |
US5443498A (en) | 1991-10-01 | 1995-08-22 | Cook Incorporated | Vascular stent and method of making and implanting a vacsular stent |
US5456713A (en) | 1991-10-25 | 1995-10-10 | Cook Incorporated | Expandable transluminal graft prosthesis for repairs of aneurysm and method for implanting |
CA2079417C (en) | 1991-10-28 | 2003-01-07 | Lilip Lau | Expandable stents and method of making same |
US5628775A (en) | 1991-11-08 | 1997-05-13 | Ep Technologies, Inc. | Flexible bond for sleeves enclosing a bendable electrode tip assembly |
US5192297A (en) | 1991-12-31 | 1993-03-09 | Medtronic, Inc. | Apparatus and method for placement and implantation of a stent |
WO1993013827A1 (en) | 1992-01-09 | 1993-07-22 | Advanced Cardiovascular Systems, Inc. | Guidewire replacement device |
US5261887A (en) * | 1992-01-22 | 1993-11-16 | Baxter International Inc. | Easy-to-handle, self-guiding catheter stripper |
US5246421A (en) | 1992-02-12 | 1993-09-21 | Saab Mark A | Method of treating obstructed regions of bodily passages |
US5282823A (en) * | 1992-03-19 | 1994-02-01 | Medtronic, Inc. | Intravascular radially expandable stent |
US5273536A (en) | 1992-04-02 | 1993-12-28 | Vicky Savas | Tapered balloon catheter |
US5201757A (en) | 1992-04-03 | 1993-04-13 | Schneider (Usa) Inc. | Medial region deployment of radially self-expanding stents |
US5562725A (en) | 1992-09-14 | 1996-10-08 | Meadox Medicals Inc. | Radially self-expanding implantable intraluminal device |
US5312415A (en) | 1992-09-22 | 1994-05-17 | Target Therapeutics, Inc. | Assembly for placement of embolic coils using frictional placement |
ATE137656T1 (en) | 1992-10-31 | 1996-05-15 | Schneider Europ Ag | ARRANGEMENT FOR IMPLANTING SELF-EXPANDING ENDPROSTHESES |
WO1994015549A1 (en) | 1992-12-30 | 1994-07-21 | Schneider (Usa) Inc. | Apparatus for deploying body implantable stents |
US5328469A (en) * | 1993-03-19 | 1994-07-12 | Roger Coletti | Hybrid balloon angioplasty catheter and methods of use |
US5607463A (en) | 1993-03-30 | 1997-03-04 | Medtronic, Inc. | Intravascular medical device |
US5549553A (en) | 1993-04-29 | 1996-08-27 | Scimed Life Systems, Inc. | Dilation ballon for a single operator exchange intravascular catheter or similar device |
US5480423A (en) | 1993-05-20 | 1996-01-02 | Boston Scientific Corporation | Prosthesis delivery |
US5334187A (en) | 1993-05-21 | 1994-08-02 | Cathco, Inc. | Balloon catheter system with slit opening handle |
US5391172A (en) | 1993-05-24 | 1995-02-21 | Advanced Cardiovascular Systems, Inc. | Stent delivery system with coaxial catheter handle |
US5458615A (en) | 1993-07-06 | 1995-10-17 | Advanced Cardiovascular Systems, Inc. | Stent delivery system |
US5545209A (en) * | 1993-09-30 | 1996-08-13 | Texas Petrodet, Inc. | Controlled deployment of a medical device |
US5989280A (en) | 1993-10-22 | 1999-11-23 | Scimed Lifesystems, Inc | Stent delivery apparatus and method |
US5445646A (en) | 1993-10-22 | 1995-08-29 | Scimed Lifesystems, Inc. | Single layer hydraulic sheath stent delivery apparatus and method |
US5549635A (en) | 1994-01-24 | 1996-08-27 | Solar, Rita & Gaterud, Ltd. | Non-deformable self-expanding parallel flow endovascular stent and deployment apparatus therefore |
US6051020A (en) | 1994-02-09 | 2000-04-18 | Boston Scientific Technology, Inc. | Bifurcated endoluminal prosthesis |
US5449373A (en) | 1994-03-17 | 1995-09-12 | Medinol Ltd. | Articulated stent |
CA2499888C (en) | 1994-04-01 | 2010-05-25 | Gore Enterprise Holdings, Inc. | Self-expandable stent and stent-graft and method of using them |
US6165210A (en) | 1994-04-01 | 2000-12-26 | Gore Enterprise Holdings, Inc. | Self-expandable helical intravascular stent and stent-graft |
US5478349A (en) | 1994-04-28 | 1995-12-26 | Boston Scientific Corporation | Placement of endoprostheses and stents |
WO1995029646A1 (en) | 1994-04-29 | 1995-11-09 | Boston Scientific Corporation | Medical prosthetic stent and method of manufacture |
CA2188563C (en) | 1994-04-29 | 2005-08-02 | Andrew W. Buirge | Stent with collagen |
US5554181A (en) | 1994-05-04 | 1996-09-10 | Regents Of The University Of Minnesota | Stent |
US5456694A (en) | 1994-05-13 | 1995-10-10 | Stentco, Inc. | Device for delivering and deploying intraluminal devices |
US5514093A (en) | 1994-05-19 | 1996-05-07 | Scimed Life Systems, Inc. | Variable length balloon dilatation catheter |
US5824041A (en) | 1994-06-08 | 1998-10-20 | Medtronic, Inc. | Apparatus and methods for placement and repositioning of intraluminal prostheses |
US5683451A (en) | 1994-06-08 | 1997-11-04 | Cardiovascular Concepts, Inc. | Apparatus and methods for deployment release of intraluminal prostheses |
US5636641A (en) | 1994-07-25 | 1997-06-10 | Advanced Cardiovascular Systems, Inc. | High strength member for intracorporeal use |
US5575816A (en) | 1994-08-12 | 1996-11-19 | Meadox Medicals, Inc. | High strength and high density intraluminal wire stent |
US5470315A (en) | 1994-09-20 | 1995-11-28 | Scimed Life Systems, Inc. | Over-the-wire type balloon catheter with proximal hypotube |
US5702419A (en) * | 1994-09-21 | 1997-12-30 | Wake Forest University | Expandable, intraluminal stents |
US5531735A (en) | 1994-09-27 | 1996-07-02 | Hercules Incorporated | Medical devices containing triggerable disintegration agents |
US5549563A (en) | 1994-10-11 | 1996-08-27 | Kronner; Richard F. | Reinforcing insert for uterine manipulator |
US5522882A (en) * | 1994-10-21 | 1996-06-04 | Impra, Inc. | Method and apparatus for balloon expandable stent-graft delivery |
US5836964A (en) | 1996-10-30 | 1998-11-17 | Medinol Ltd. | Stent fabrication method |
EP0714640A1 (en) | 1994-11-28 | 1996-06-05 | Advanced Cardiovascular Systems, Inc. | System and method for delivering multiple stents |
US5628755A (en) | 1995-02-20 | 1997-05-13 | Schneider (Europe) A.G. | Balloon catheter and stent delivery system |
CA2163708C (en) | 1994-12-07 | 2007-08-07 | Robert E. Fischell | Integrated dual-function catheter system for balloon angioplasty and stent delivery |
US5549551A (en) | 1994-12-22 | 1996-08-27 | Advanced Cardiovascular Systems, Inc. | Adjustable length balloon catheter |
US5662675A (en) | 1995-02-24 | 1997-09-02 | Intervascular, Inc. | Delivery catheter assembly |
US7204848B1 (en) | 1995-03-01 | 2007-04-17 | Boston Scientific Scimed, Inc. | Longitudinally flexible expandable stent |
EP1163889B1 (en) | 1995-03-01 | 2008-05-14 | Boston Scientific Scimed, Inc. | Improved longitudinally flexible expandable stent |
US5709713A (en) | 1995-03-31 | 1998-01-20 | Cardiovascular Concepts, Inc. | Radially expansible vascular prosthesis having reversible and other locking structures |
WO1996032078A1 (en) * | 1995-04-14 | 1996-10-17 | Schneider (Usa) Inc. | Rolling membrane stent delivery device |
US5807398A (en) | 1995-04-28 | 1998-09-15 | Shaknovich; Alexander | Shuttle stent delivery catheter |
US5534007A (en) | 1995-05-18 | 1996-07-09 | Scimed Life Systems, Inc. | Stent deployment catheter with collapsible sheath |
US5681347A (en) | 1995-05-23 | 1997-10-28 | Boston Scientific Corporation | Vena cava filter delivery system |
JPH10503411A (en) | 1995-05-25 | 1998-03-31 | メドトロニック・インコーポレーテッド | Stent assembly and method of using the same |
US5639274A (en) | 1995-06-02 | 1997-06-17 | Fischell; Robert E. | Integrated catheter system for balloon angioplasty and stent delivery |
JPH11503056A (en) | 1995-06-06 | 1999-03-23 | コルヴィタ コーポレーション | Intravascular measurement device and introduction / placement means |
US6010530A (en) | 1995-06-07 | 2000-01-04 | Boston Scientific Technology, Inc. | Self-expanding endoluminal prosthesis |
US7611533B2 (en) | 1995-06-07 | 2009-11-03 | Cook Incorporated | Coated implantable medical device |
US5797951A (en) | 1995-08-09 | 1998-08-25 | Mueller; Edward Gene | Expandable support member |
US5776141A (en) | 1995-08-28 | 1998-07-07 | Localmed, Inc. | Method and apparatus for intraluminal prosthesis delivery |
DE19531659C2 (en) | 1995-08-29 | 1998-07-02 | Ernst Peter Prof Dr M Strecker | Stent |
US5769882A (en) | 1995-09-08 | 1998-06-23 | Medtronic, Inc. | Methods and apparatus for conformably sealing prostheses within body lumens |
US5702418A (en) | 1995-09-12 | 1997-12-30 | Boston Scientific Corporation | Stent delivery system |
US5868704A (en) * | 1995-09-18 | 1999-02-09 | W. L. Gore & Associates, Inc. | Balloon catheter device |
AU6862596A (en) | 1995-09-18 | 1997-04-09 | W.L. Gore & Associates, Inc. | A delivery system for intraluminal vascular grafts |
US5591195A (en) * | 1995-10-30 | 1997-01-07 | Taheri; Syde | Apparatus and method for engrafting a blood vessel |
US5749848A (en) | 1995-11-13 | 1998-05-12 | Cardiovascular Imaging Systems, Inc. | Catheter system having imaging, balloon angioplasty, and stent deployment capabilities, and method of use for guided stent deployment |
US5755697A (en) * | 1995-11-22 | 1998-05-26 | Jones; Calvin E. | Self-tunneling, self-securing percutaneous catheterization device and method of use thereof |
US6090063A (en) | 1995-12-01 | 2000-07-18 | C. R. Bard, Inc. | Device, system and method for implantation of filaments and particles in the body |
US5824040A (en) | 1995-12-01 | 1998-10-20 | Medtronic, Inc. | Endoluminal prostheses and therapies for highly variable body lumens |
US6579305B1 (en) | 1995-12-07 | 2003-06-17 | Medtronic Ave, Inc. | Method and apparatus for delivery deployment and retrieval of a stent comprising shape-memory material |
US6878161B2 (en) | 1996-01-05 | 2005-04-12 | Medtronic Vascular, Inc. | Stent graft loading and deployment device and method |
US5749921A (en) | 1996-02-20 | 1998-05-12 | Medtronic, Inc. | Apparatus and methods for compression of endoluminal prostheses |
US6334871B1 (en) | 1996-03-13 | 2002-01-01 | Medtronic, Inc. | Radiopaque stent markers |
CA2199890C (en) | 1996-03-26 | 2002-02-05 | Leonard Pinchuk | Stents and stent-grafts having enhanced hoop strength and methods of making the same |
US6533805B1 (en) | 1996-04-01 | 2003-03-18 | General Surgical Innovations, Inc. | Prosthesis and method for deployment within a body lumen |
US6783543B2 (en) | 2000-06-05 | 2004-08-31 | Scimed Life Systems, Inc. | Intravascular stent with increasing coating retaining capacity |
US5670161A (en) | 1996-05-28 | 1997-09-23 | Healy; Kevin E. | Biodegradable stent |
US6666883B1 (en) | 1996-06-06 | 2003-12-23 | Jacques Seguin | Endoprosthesis for vascular bifurcation |
US8728143B2 (en) | 1996-06-06 | 2014-05-20 | Biosensors International Group, Ltd. | Endoprosthesis deployment system for treating vascular bifurcations |
US7238197B2 (en) | 2000-05-30 | 2007-07-03 | Devax, Inc. | Endoprosthesis deployment system for treating vascular bifurcations |
FR2749500B1 (en) | 1996-06-06 | 1998-11-20 | Jacques Seguin | DEVICE ALLOWING THE TREATMENT OF BODY DUCTS AT THE LEVEL OF A BIFURCATION |
US5697971A (en) | 1996-06-11 | 1997-12-16 | Fischell; Robert E. | Multi-cell stent with cells having differing characteristics |
US5980514A (en) | 1996-07-26 | 1999-11-09 | Target Therapeutics, Inc. | Aneurysm closure device assembly |
DE19630469C2 (en) | 1996-07-27 | 2000-12-21 | Michael Betzler | Vascular endoprosthesis, especially for the endovascular treatment of aortic aneurysms |
US6090136A (en) | 1996-07-29 | 2000-07-18 | Radiance Medical Systems, Inc. | Self expandable tubular support |
US5922020A (en) | 1996-08-02 | 1999-07-13 | Localmed, Inc. | Tubular prosthesis having improved expansion and imaging characteristics |
US5755781A (en) | 1996-08-06 | 1998-05-26 | Iowa-India Investments Company Limited | Embodiments of multiple interconnected stents |
US6217585B1 (en) * | 1996-08-16 | 2001-04-17 | Converge Medical, Inc. | Mechanical stent and graft delivery system |
US6007517A (en) | 1996-08-19 | 1999-12-28 | Anderson; R. David | Rapid exchange/perfusion angioplasty catheter |
US6123712A (en) | 1996-08-23 | 2000-09-26 | Scimed Life Systems, Inc. | Balloon catheter with stent securement means |
JP3968444B2 (en) | 1996-08-23 | 2007-08-29 | ボストン サイエンティフィック サイムド,インコーポレイテッド | Stent delivery mechanism with stent fixation device |
US20030093143A1 (en) | 1999-03-01 | 2003-05-15 | Yiju Zhao | Medical device having surface depressions containing nitric oxide releasing compound |
US5921971A (en) | 1996-09-13 | 1999-07-13 | Boston Scientific Corporation | Single operator exchange biliary catheter |
US6254628B1 (en) | 1996-12-09 | 2001-07-03 | Micro Therapeutics, Inc. | Intracranial stent |
US5772669A (en) | 1996-09-27 | 1998-06-30 | Scimed Life Systems, Inc. | Stent deployment catheter with retractable sheath |
US5755776A (en) | 1996-10-04 | 1998-05-26 | Al-Saadon; Khalid | Permanent expandable intraluminal tubular stent |
US5843119A (en) * | 1996-10-23 | 1998-12-01 | United States Surgical Corporation | Apparatus and method for dilatation of a body lumen and delivery of a prothesis therein |
US7341598B2 (en) | 1999-01-13 | 2008-03-11 | Boston Scientific Scimed, Inc. | Stent with protruding branch portion for bifurcated vessels |
US7220275B2 (en) * | 1996-11-04 | 2007-05-22 | Advanced Stent Technologies, Inc. | Stent with protruding branch portion for bifurcated vessels |
US5843090A (en) * | 1996-11-05 | 1998-12-01 | Schneider (Usa) Inc. | Stent delivery device |
WO1998020810A1 (en) | 1996-11-12 | 1998-05-22 | Medtronic, Inc. | Flexible, radially expansible luminal prostheses |
DE59610631D1 (en) | 1996-11-15 | 2003-09-04 | Schneider Europ Gmbh Buelach | Balloon catheter and stent delivery device |
US5749890A (en) | 1996-12-03 | 1998-05-12 | Shaknovich; Alexander | Method and system for stent placement in ostial lesions |
US5858556A (en) | 1997-01-21 | 1999-01-12 | Uti Corporation | Multilayer composite tubular structure and method of making |
EP0961597B8 (en) | 1997-01-24 | 2005-12-28 | Paragon Intellectual Properties, LLC | Bistable spring construction for a stent |
JP3523765B2 (en) | 1997-01-24 | 2004-04-26 | テルモ株式会社 | Living organ dilator |
US5882329A (en) | 1997-02-12 | 1999-03-16 | Prolifix Medical, Inc. | Apparatus and method for removing stenotic material from stents |
US5814064A (en) | 1997-03-06 | 1998-09-29 | Scimed Life Systems, Inc. | Distal protection device |
US6035856A (en) | 1997-03-06 | 2000-03-14 | Scimed Life Systems | Percutaneous bypass with branching vessel |
IL128261A0 (en) | 1999-01-27 | 1999-11-30 | Disc O Tech Medical Tech Ltd | Expandable element |
US5817101A (en) | 1997-03-13 | 1998-10-06 | Schneider (Usa) Inc | Fluid actuated stent delivery system |
US5792144A (en) * | 1997-03-31 | 1998-08-11 | Cathco, Inc. | Stent delivery catheter system |
US5843172A (en) | 1997-04-15 | 1998-12-01 | Advanced Cardiovascular Systems, Inc. | Porous medicated stent |
US8172897B2 (en) * | 1997-04-15 | 2012-05-08 | Advanced Cardiovascular Systems, Inc. | Polymer and metal composite implantable medical devices |
US6273913B1 (en) | 1997-04-18 | 2001-08-14 | Cordis Corporation | Modified stent useful for delivery of drugs along stent strut |
US6143016A (en) | 1997-04-21 | 2000-11-07 | Advanced Cardiovascular Systems, Inc. | Sheath and method of use for a stent delivery system |
US5965879A (en) * | 1997-05-07 | 1999-10-12 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Method and apparatus for ultra-high-sensitivity, incremental and absolute optical encoding |
EP0884063B1 (en) | 1997-06-10 | 2004-04-28 | Schneider ( Europe) GmbH | Catheter system |
US6004328A (en) | 1997-06-19 | 1999-12-21 | Solar; Ronald J. | Radially expandable intraluminal stent and delivery catheter therefore and method of using the same |
FR2764794B1 (en) | 1997-06-20 | 1999-11-12 | Nycomed Lab Sa | EXPANDED TUBULAR DEVICE WITH VARIABLE THICKNESS |
DE19728337A1 (en) | 1997-07-03 | 1999-01-07 | Inst Mikrotechnik Mainz Gmbh | Implantable stent |
US6500174B1 (en) | 1997-07-08 | 2002-12-31 | Atrionix, Inc. | Circumferential ablation device assembly and methods of use and manufacture providing an ablative circumferential band along an expandable member |
US6070589A (en) | 1997-08-01 | 2000-06-06 | Teramed, Inc. | Methods for deploying bypass graft stents |
US5899935A (en) | 1997-08-04 | 1999-05-04 | Schneider (Usa) Inc. | Balloon expandable braided stent with restraint |
US5984957A (en) | 1997-08-12 | 1999-11-16 | Schneider (Usa) Inc | Radially expanded prostheses with axial diameter control |
US6056722A (en) | 1997-09-18 | 2000-05-02 | Iowa-India Investments Company Limited Of Douglas | Delivery mechanism for balloons, drugs, stents and other physical/mechanical agents and methods of use |
AU738502B2 (en) | 1997-09-24 | 2001-09-20 | Cook Medical Technologies Llc | Radially expandable stent |
US5972027A (en) | 1997-09-30 | 1999-10-26 | Scimed Life Systems, Inc | Porous stent drug delivery system |
US5961536A (en) | 1997-10-14 | 1999-10-05 | Scimed Life Systems, Inc. | Catheter having a variable length balloon and method of using the same |
NO311781B1 (en) | 1997-11-13 | 2002-01-28 | Medinol Ltd | Metal multilayer stents |
US6241691B1 (en) | 1997-12-05 | 2001-06-05 | Micrus Corporation | Coated superelastic stent |
US6027519A (en) * | 1997-12-15 | 2000-02-22 | Stanford; Ulf Harry | Catheter with expandable multiband segment |
US6050999A (en) * | 1997-12-18 | 2000-04-18 | Keravision, Inc. | Corneal implant introducer and method of use |
US6159178A (en) | 1998-01-23 | 2000-12-12 | Heartport, Inc. | Methods and devices for occluding the ascending aorta and maintaining circulation of oxygenated blood in the patient when the patient's heart is arrested |
CA2318890C (en) * | 1998-01-26 | 2007-05-22 | Anson Medical Limited | Reinforced graft |
US7371210B2 (en) * | 1998-02-24 | 2008-05-13 | Hansen Medical, Inc. | Flexible instrument |
US6280467B1 (en) | 1998-02-26 | 2001-08-28 | World Medical Manufacturing Corporation | Delivery system for deployment and endovascular assembly of a multi-stage stented graft |
US6428811B1 (en) | 1998-03-11 | 2002-08-06 | Wm. Marsh Rice University | Temperature-sensitive polymer/nanoshell composites for photothermally modulated drug delivery |
US6425898B1 (en) | 1998-03-13 | 2002-07-30 | Cordis Corporation | Delivery apparatus for a self-expanding stent |
US7491232B2 (en) | 1998-09-18 | 2009-02-17 | Aptus Endosystems, Inc. | Catheter-based fastener implantation apparatus and methods with implantation force resolution |
US6129756A (en) | 1998-03-16 | 2000-10-10 | Teramed, Inc. | Biluminal endovascular graft system |
US6132460A (en) | 1998-03-27 | 2000-10-17 | Intratherapeutics, Inc. | Stent |
US6558415B2 (en) | 1998-03-27 | 2003-05-06 | Intratherapeutics, Inc. | Stent |
US6102942A (en) | 1998-03-30 | 2000-08-15 | Endovascular Technologies, Inc. | Stent/graft deployment catheter with a stent/graft attachment mechanism |
US6063111A (en) | 1998-03-31 | 2000-05-16 | Cordis Corporation | Stent aneurysm treatment system and method |
IE980241A1 (en) * | 1998-04-02 | 1999-10-20 | Salviac Ltd | Delivery catheter with split sheath |
US6037647A (en) | 1998-05-08 | 2000-03-14 | Fujitsu Limited | Semiconductor device having an epitaxial substrate and a fabrication process thereof |
WO1999059667A1 (en) * | 1998-05-15 | 1999-11-25 | Medgination, Inc. | Enhanced balloon dilatation system |
US6171334B1 (en) | 1998-06-17 | 2001-01-09 | Advanced Cardiovascular Systems, Inc. | Expandable stent and method of use |
DE19829702C1 (en) | 1998-07-03 | 2000-03-16 | Heraeus Gmbh W C | Radially expandable support device V |
WO2000012832A2 (en) | 1998-08-26 | 2000-03-09 | Molecular Geodesics, Inc. | Radially expandable device |
US6120522A (en) | 1998-08-27 | 2000-09-19 | Scimed Life Systems, Inc. | Self-expanding stent delivery catheter |
AU6144599A (en) | 1998-09-16 | 2000-04-03 | Isostent, Inc. | Linkage stent |
US5997563A (en) | 1998-09-28 | 1999-12-07 | Medtronic, Inc. | Implantable stent having variable diameter |
US6254612B1 (en) | 1998-10-22 | 2001-07-03 | Cordis Neurovascular, Inc. | Hydraulic stent deployment system |
US6214036B1 (en) | 1998-11-09 | 2001-04-10 | Cordis Corporation | Stent which is easily recaptured and repositioned within the body |
SG75982A1 (en) | 1998-12-03 | 2000-10-24 | Medinol Ltd | Controlled detachment stents |
US6340366B2 (en) | 1998-12-08 | 2002-01-22 | Bandula Wijay | Stent with nested or overlapping rings |
US6350277B1 (en) | 1999-01-15 | 2002-02-26 | Scimed Life Systems, Inc. | Stents with temporary retaining bands |
US6558414B2 (en) | 1999-02-02 | 2003-05-06 | Impra, Inc. | Partial encapsulation of stents using strips and bands |
US6248122B1 (en) | 1999-02-26 | 2001-06-19 | Vascular Architects, Inc. | Catheter with controlled release endoluminal prosthesis |
AU758027B2 (en) | 1999-02-26 | 2003-03-13 | Lemaitre Vascular, Inc. | Catheter assembly with endoluminal prosthesis and method for placing |
US6251134B1 (en) | 1999-02-28 | 2001-06-26 | Inflow Dynamics Inc. | Stent with high longitudinal flexibility |
US5976155A (en) | 1999-03-05 | 1999-11-02 | Advanced Cardiovascular Systems, Inc. | System for removably securing a stent on a catheter assembly and method of use |
US6613074B1 (en) * | 1999-03-10 | 2003-09-02 | Cordis Corporation | Endovascular aneurysm embolization device |
US6730116B1 (en) | 1999-04-16 | 2004-05-04 | Medtronic, Inc. | Medical device for intraluminal endovascular stenting |
US6273911B1 (en) | 1999-04-22 | 2001-08-14 | Advanced Cardiovascular Systems, Inc. | Variable strength stent |
US6585756B1 (en) | 1999-05-14 | 2003-07-01 | Ernst P. Strecker | Implantable lumen prosthesis |
US6241758B1 (en) | 1999-05-28 | 2001-06-05 | Advanced Cardiovascular Systems, Inc. | Self-expanding stent delivery system and method of use |
DE19938377A1 (en) | 1999-08-06 | 2001-03-01 | Biotronik Mess & Therapieg | Stent for vascular branching |
US6415696B1 (en) | 1999-09-01 | 2002-07-09 | Kennametal Pc Inc. | Toolholder assembly |
US6605062B1 (en) | 1999-09-02 | 2003-08-12 | Advanced Cardiovascular Systems, Inc. | Catheter for guidewire support or exchange |
US6203551B1 (en) * | 1999-10-04 | 2001-03-20 | Advanced Cardiovascular Systems, Inc. | Chamber for applying therapeutic substances to an implant device |
AU1083101A (en) | 1999-10-12 | 2001-04-23 | Allan R. Will | Methods and devices for protecting a passageway in a body |
US6383171B1 (en) | 1999-10-12 | 2002-05-07 | Allan Will | Methods and devices for protecting a passageway in a body when advancing devices through the passageway |
US6409753B1 (en) | 1999-10-26 | 2002-06-25 | Scimed Life Systems, Inc. | Flexible stent |
US6325823B1 (en) | 1999-10-29 | 2001-12-04 | Revasc Corporation | Endovascular prosthesis accommodating torsional and longitudinal displacements and methods of use |
US6428569B1 (en) | 1999-11-09 | 2002-08-06 | Scimed Life Systems Inc. | Micro structure stent configurations |
US6287291B1 (en) | 1999-11-09 | 2001-09-11 | Advanced Cardiovascular Systems, Inc. | Protective sheath for catheters |
US6908624B2 (en) | 1999-12-23 | 2005-06-21 | Advanced Cardiovascular Systems, Inc. | Coating for implantable devices and a method of forming the same |
JP4473390B2 (en) | 2000-01-07 | 2010-06-02 | 川澄化学工業株式会社 | Stent and stent graft |
US6322586B1 (en) | 2000-01-10 | 2001-11-27 | Scimed Life Systems, Inc. | Catheter tip designs and method of manufacture |
US6312458B1 (en) | 2000-01-19 | 2001-11-06 | Scimed Life Systems, Inc. | Tubular structure/stent/stent securement member |
JP2003521334A (en) | 2000-02-04 | 2003-07-15 | ウィルソン−クック メディカル インコーポレイテッド | Stent introducer device |
US7373197B2 (en) | 2000-03-03 | 2008-05-13 | Intramedical Imaging, Llc | Methods and devices to expand applications of intraoperative radiation probes |
IL177381A0 (en) | 2000-03-08 | 2006-12-10 | Given Imaging Ltd | A device for in vivo imaging |
DE10012460A1 (en) | 2000-03-15 | 2001-09-20 | Biotronik Mess & Therapieg | Stent consists of several adjacent lengthwise tubular sections joined by first and second connections consisting of cell-type elements of one orientation. |
US6264683B1 (en) | 2000-03-17 | 2001-07-24 | Advanced Cardiovascular Systems, Inc. | Stent delivery catheter with bumpers for improved retention of balloon expandable stents |
AUPQ641400A0 (en) | 2000-03-23 | 2000-04-15 | Kleiner, Daniel E. | A device incorporating a hollow member for being positioned along a body cavity of a patient and method of positioning same |
US6315708B1 (en) | 2000-03-31 | 2001-11-13 | Cordis Corporation | Stent with self-expanding end sections |
US6964676B1 (en) | 2000-04-14 | 2005-11-15 | Scimed Life Systems, Inc. | Stent securement system |
US6451050B1 (en) | 2000-04-28 | 2002-09-17 | Cardiovasc, Inc. | Stent graft and method |
IL152473A0 (en) | 2000-04-28 | 2003-05-29 | Sloan Kettering Inst Cancer | Topical anesthetic/opioid formulations and uses thereof |
WO2001083017A1 (en) | 2000-05-02 | 2001-11-08 | Wilson-Cook Medical, Inc. | Introducer device for catheters o.t.l. with eversible sleeve |
US6602282B1 (en) | 2000-05-04 | 2003-08-05 | Avantec Vascular Corporation | Flexible stent structure |
AU2001265238A1 (en) | 2000-05-31 | 2001-12-11 | Advanced Cardiovascular Systems Inc. | An apparatus and method for forming a coating onto a surface of a prosthesis |
JP4754714B2 (en) * | 2000-06-01 | 2011-08-24 | テルモ株式会社 | Intraluminal indwelling |
US6554848B2 (en) * | 2000-06-02 | 2003-04-29 | Advanced Cardiovascular Systems, Inc. | Marker device for rotationally orienting a stent delivery system prior to deploying a curved self-expanding stent |
US6569180B1 (en) | 2000-06-02 | 2003-05-27 | Avantec Vascular Corporation | Catheter having exchangeable balloon |
US6540775B1 (en) | 2000-06-30 | 2003-04-01 | Cordis Corporation | Ultraflexible open cell stent |
US6773446B1 (en) | 2000-08-02 | 2004-08-10 | Cordis Corporation | Delivery apparatus for a self-expanding stent |
US6629992B2 (en) | 2000-08-04 | 2003-10-07 | Advanced Cardiovascular Systems, Inc. | Sheath for self-expanding stent |
AU2002212621A1 (en) * | 2000-09-14 | 2002-03-26 | Tuborg Engineering Nv | Adaptive balloon with improved flexibility |
US6945989B1 (en) | 2000-09-18 | 2005-09-20 | Endotex Interventional Systems, Inc. | Apparatus for delivering endoluminal prostheses and methods of making and using them |
WO2002060344A2 (en) | 2000-09-22 | 2002-08-08 | Scimed Life Systems, Inc. | Flexible and expandable stent |
US6589273B1 (en) * | 2000-10-02 | 2003-07-08 | Impra, Inc. | Apparatus and method for relining a blood vessel |
US6602226B1 (en) | 2000-10-12 | 2003-08-05 | Scimed Life Systems, Inc. | Low-profile stent delivery system and apparatus |
US6613089B1 (en) * | 2000-10-25 | 2003-09-02 | Sdgi Holdings, Inc. | Laterally expanding intervertebral fusion device |
WO2002059226A2 (en) | 2000-11-03 | 2002-08-01 | Wm. Marsh Rice University | Partial coverage metal nanoshells and method of making same |
US6582394B1 (en) | 2000-11-14 | 2003-06-24 | Advanced Cardiovascular Systems, Inc. | Stent and catheter assembly and method for treating bifurcated vessels |
US6743251B1 (en) | 2000-11-15 | 2004-06-01 | Scimed Life Systems, Inc. | Implantable devices with polymeric detachment junction |
US6607553B1 (en) | 2000-11-17 | 2003-08-19 | B. Braun Medical, Inc. | Method for deploying a thermo-mechanically expandable stent |
US6582460B1 (en) | 2000-11-20 | 2003-06-24 | Advanced Cardiovascular Systems, Inc. | System and method for accurately deploying a stent |
US6884257B1 (en) | 2000-11-28 | 2005-04-26 | Advanced Cardiovascular Systems, Inc. | Stent delivery system with adjustable length balloon |
US6565599B1 (en) * | 2000-12-28 | 2003-05-20 | Advanced Cardiovascular Systems, Inc. | Hybrid stent |
US6468298B1 (en) | 2000-12-28 | 2002-10-22 | Advanced Cardiovascular Systems, Inc. | Gripping delivery system for self-expanding stents and method of using the same |
US7208002B2 (en) * | 2001-01-04 | 2007-04-24 | Boston Scientific Scimed, Inc. | Expansion-assisting delivery system for self-expanding stent |
DE10103000B4 (en) | 2001-01-24 | 2007-08-30 | Qualimed Innovative Medizinprodukte Gmbh | Radially re-expandable vascular support |
DE10105160B4 (en) | 2001-02-06 | 2005-09-01 | Osypka, Peter, Dr.-Ing. | Implantable vascular support |
WO2002065947A2 (en) | 2001-02-16 | 2002-08-29 | Abbott Laboratories Vascular Enterprises Limited | Implants with fk506 for prophylaxis and treatment of restonoses |
AU2002250189A1 (en) | 2001-02-26 | 2002-09-12 | Scimed Life Systems, Inc. | Bifurcated stent and delivery system |
US7799064B2 (en) | 2001-02-26 | 2010-09-21 | Boston Scientific Scimed, Inc. | Bifurcated stent and delivery system |
US6790227B2 (en) * | 2001-03-01 | 2004-09-14 | Cordis Corporation | Flexible stent |
US20020123786A1 (en) | 2001-03-02 | 2002-09-05 | Ventrica, Inc. | Methods and devices for bypassing an obstructed target vessel by placing the vessel in communication with a heart chamber containing blood |
CA2708603C (en) | 2001-03-13 | 2015-02-17 | Yoram Richter | Method and apparatus for stenting |
US6592549B2 (en) | 2001-03-14 | 2003-07-15 | Scimed Life Systems, Inc. | Rapid exchange stent delivery system and associated components |
EP1258230A3 (en) | 2001-03-29 | 2003-12-10 | CardioSafe Ltd | Balloon catheter device |
US6660031B2 (en) | 2001-04-11 | 2003-12-09 | Scimed Life Systems, Inc. | Multi-length delivery system |
WO2002085253A1 (en) | 2001-04-20 | 2002-10-31 | The Board Of Trustees Of The Leland Stanford Junior University | Drug delivery platform and methods for the inhibition of neointima formation |
GB0110551D0 (en) | 2001-04-30 | 2001-06-20 | Angiomed Ag | Self-expanding stent delivery service |
EP1254644A1 (en) | 2001-05-01 | 2002-11-06 | Pan Medical Limited | Variable form stent and deployment arrangement for use therewith |
US8337540B2 (en) | 2001-05-17 | 2012-12-25 | Advanced Cardiovascular Systems, Inc. | Stent for treating bifurcations and method of use |
US6599314B2 (en) | 2001-06-08 | 2003-07-29 | Cordis Corporation | Apparatus and method for stenting a vessel using balloon-actuated stent with interlocking elements |
US6676693B1 (en) | 2001-06-27 | 2004-01-13 | Advanced Cardiovascular Systems, Inc. | Apparatus and method for delivering a self-expanding stent |
ATE330564T1 (en) | 2001-07-20 | 2006-07-15 | Sorin Biomedica Cardio Srl | STENT |
US6599296B1 (en) | 2001-07-27 | 2003-07-29 | Advanced Cardiovascular Systems, Inc. | Ratcheting handle for intraluminal catheter systems |
JP4525958B2 (en) * | 2001-08-27 | 2010-08-18 | 独立行政法人産業技術総合研究所 | Manufacturing method of semiconductor device |
US6796999B2 (en) | 2001-09-06 | 2004-09-28 | Medinol Ltd. | Self articulating stent |
GB0121980D0 (en) | 2001-09-11 | 2001-10-31 | Cathnet Science Holding As | Expandable stent |
US20030055485A1 (en) * | 2001-09-17 | 2003-03-20 | Intra Therapeutics, Inc. | Stent with offset cell geometry |
US6778316B2 (en) | 2001-10-24 | 2004-08-17 | William Marsh Rice University | Nanoparticle-based all-optical sensors |
JP4043216B2 (en) | 2001-10-30 | 2008-02-06 | オリンパス株式会社 | Stent |
US7014654B2 (en) * | 2001-11-30 | 2006-03-21 | Scimed Life Systems, Inc. | Stent designed for the delivery of therapeutic substance or other agents |
US20030135266A1 (en) | 2001-12-03 | 2003-07-17 | Xtent, Inc. | Apparatus and methods for delivery of multiple distributed stents |
US7309350B2 (en) | 2001-12-03 | 2007-12-18 | Xtent, Inc. | Apparatus and methods for deployment of vascular prostheses |
US7270668B2 (en) | 2001-12-03 | 2007-09-18 | Xtent, Inc. | Apparatus and methods for delivering coiled prostheses |
US7294146B2 (en) * | 2001-12-03 | 2007-11-13 | Xtent, Inc. | Apparatus and methods for delivery of variable length stents |
US7137993B2 (en) | 2001-12-03 | 2006-11-21 | Xtent, Inc. | Apparatus and methods for delivery of multiple distributed stents |
US20040186551A1 (en) * | 2003-01-17 | 2004-09-23 | Xtent, Inc. | Multiple independent nested stent structures and methods for their preparation and deployment |
US8080048B2 (en) | 2001-12-03 | 2011-12-20 | Xtent, Inc. | Stent delivery for bifurcated vessels |
US7351255B2 (en) | 2001-12-03 | 2008-04-01 | Xtent, Inc. | Stent delivery apparatus and method |
WO2007136946A2 (en) | 2001-12-03 | 2007-11-29 | Xtent, Inc. | Delivery catheter having active engagement mechanism for prosthesis |
US20030114919A1 (en) | 2001-12-10 | 2003-06-19 | Mcquiston Jesse | Polymeric stent with metallic rings |
US6991646B2 (en) | 2001-12-18 | 2006-01-31 | Linvatec Biomaterials, Inc. | Method and apparatus for delivering a stent into a body lumen |
US20050182477A1 (en) * | 2001-12-20 | 2005-08-18 | White Geoffrey H. | Intraluminal stent and graft |
US7537607B2 (en) | 2001-12-21 | 2009-05-26 | Boston Scientific Scimed, Inc. | Stent geometry for improved flexibility |
AU2003205148A1 (en) | 2002-01-16 | 2003-09-02 | Eva Corporation | Catheter hand-piece apparatus and method of using the same |
US6939368B2 (en) | 2002-01-17 | 2005-09-06 | Scimed Life Systems, Inc. | Delivery system for self expanding stents for use in bifurcated vessels |
US6981985B2 (en) | 2002-01-22 | 2006-01-03 | Boston Scientific Scimed, Inc. | Stent bumper struts |
US6911040B2 (en) | 2002-01-24 | 2005-06-28 | Cordis Corporation | Covered segmented stent |
US7029493B2 (en) * | 2002-01-25 | 2006-04-18 | Cordis Corporation | Stent with enhanced crossability |
US7004964B2 (en) * | 2002-02-22 | 2006-02-28 | Scimed Life Systems, Inc. | Apparatus and method for deployment of an endoluminal device |
US7887573B2 (en) * | 2002-02-22 | 2011-02-15 | Boston Scientific Scimed, Inc. | Method and apparatus for deployment of an endoluminal device |
US6866679B2 (en) * | 2002-03-12 | 2005-03-15 | Ev3 Inc. | Everting stent and stent delivery system |
GB0206061D0 (en) | 2002-03-14 | 2002-04-24 | Angiomed Ag | Metal structure compatible with MRI imaging, and method of manufacturing such a structure |
US7052511B2 (en) | 2002-04-04 | 2006-05-30 | Scimed Life Systems, Inc. | Delivery system and method for deployment of foreshortening endoluminal devices |
US6800065B2 (en) | 2002-04-04 | 2004-10-05 | Medtronic Ave, Inc. | Catheter and guide wire exchange system |
US20030195609A1 (en) | 2002-04-10 | 2003-10-16 | Scimed Life Systems, Inc. | Hybrid stent |
US7648515B2 (en) | 2002-04-16 | 2010-01-19 | Tyco Healthcare Group Lp | Method and apparatus for anastomosis including an expandable anchor |
US7470281B2 (en) | 2002-04-26 | 2008-12-30 | Medtronic Vascular, Inc. | Coated stent with crimpable coating |
US6645547B1 (en) | 2002-05-02 | 2003-11-11 | Labcoat Ltd. | Stent coating device |
US20030225446A1 (en) | 2002-05-29 | 2003-12-04 | William A. Cook Australia Pty Ltd. | Multi-piece prosthesis deployment apparatus |
US7056523B1 (en) | 2002-06-21 | 2006-06-06 | Advanced Cardiovascular Systems, Inc. | Implantable medical devices incorporating chemically conjugated polymers and oligomers of L-arginine |
US6761734B2 (en) | 2002-07-22 | 2004-07-13 | William S. Suhr | Segmented balloon catheter for stenting bifurcation lesions |
US20040015224A1 (en) * | 2002-07-22 | 2004-01-22 | Armstrong Joseph R. | Endoluminal expansion system |
US7141063B2 (en) * | 2002-08-06 | 2006-11-28 | Icon Medical Corp. | Stent with micro-latching hinge joints |
US6945995B2 (en) | 2002-08-29 | 2005-09-20 | Boston Scientific Scimed, Inc. | Stent overlap point markers |
US6951053B2 (en) | 2002-09-04 | 2005-10-04 | Reva Medical, Inc. | Method of manufacturing a prosthesis |
US6893417B2 (en) | 2002-09-20 | 2005-05-17 | Medtronic Vascular, Inc. | Catheter and guide wire exchange system with improved proximal shaft and transition section |
JP4033747B2 (en) | 2002-09-30 | 2008-01-16 | テルモ株式会社 | Biological organ expansion device |
US7223283B2 (en) | 2002-10-09 | 2007-05-29 | Boston Scientific Scimed, Inc. | Stent with improved flexibility |
US6733536B1 (en) | 2002-10-22 | 2004-05-11 | Scimed Life Systems | Male urethral stent device |
AU2003290675A1 (en) | 2002-11-07 | 2004-06-03 | Abbott Laboratories | Method of loading beneficial agent to a prosthesis by fluid-jet application |
KR20050086440A (en) | 2002-11-08 | 2005-08-30 | 코너 메드시스템즈, 인코포레이티드 | Method and apparatus for reducing tissue damage after ischemic injury |
ITRM20020596A1 (en) | 2002-11-27 | 2004-05-28 | Mauro Ferrari | IMPLANT VASCULAR PROSTHESIS WITH COMBINED, LAPAROSCOPIC AND ENDOVASCULAR TECHNIQUES, FOR THE TREATMENT OF ABDOMINAL AORTIC ANEURYSMS, AND OPERATIONAL EQUIPMENT FOR THE RELEASE OF A PROSTHESIS EQUIPPED WITH ANCHORING STENTS. |
DE60326000D1 (en) | 2002-12-04 | 2009-03-12 | Cook Inc | METHOD AND DEVICE FOR TREATMENT IN AORTASE ACTION |
WO2004052237A2 (en) | 2002-12-09 | 2004-06-24 | Medtronic Vascular | Modular stent having polymer bridges at modular unit contact sites |
US7044981B2 (en) | 2003-01-22 | 2006-05-16 | Boston Scientific Scimed, Inc. | Ureteral stent configured for improved patient comfort and aftercare |
ES2346059T3 (en) | 2003-03-26 | 2010-10-08 | Biosensors International Group Ltd. | IMPLANT SUPPLY CATHETER WITH ELECTROLYTICALLY EROSIONABLE JOINTS. |
EP1613242B1 (en) | 2003-03-26 | 2013-02-20 | The Foundry, LLC | Devices for treatment of abdominal aortic aneurysms |
US20050079132A1 (en) * | 2003-04-08 | 2005-04-14 | Xingwu Wang | Medical device with low magnetic susceptibility |
US7208001B2 (en) * | 2003-04-24 | 2007-04-24 | Medtronic Vascular, Inc. | Catheter with detached proximal inflation and guidewire shafts |
US7279003B2 (en) | 2003-04-24 | 2007-10-09 | Medtronic Vascular, Inc. | Stent graft tapered spring |
US7241308B2 (en) * | 2003-06-09 | 2007-07-10 | Xtent, Inc. | Stent deployment systems and methods |
US7131993B2 (en) | 2003-06-25 | 2006-11-07 | Boston Scientific Scimed, Inc. | Varying circumferential spanned connectors in a stent |
US7744620B2 (en) | 2003-07-18 | 2010-06-29 | Intervalve, Inc. | Valvuloplasty catheter |
US8784472B2 (en) | 2003-08-15 | 2014-07-22 | Boston Scientific Scimed, Inc. | Clutch driven stent delivery system |
US20050055077A1 (en) * | 2003-09-05 | 2005-03-10 | Doron Marco | Very low profile medical device system having an adjustable balloon |
US20050209674A1 (en) | 2003-09-05 | 2005-09-22 | Kutscher Tuvia D | Balloon assembly (V) |
US20070219613A1 (en) | 2003-10-06 | 2007-09-20 | Xtent, Inc. | Apparatus and methods for interlocking stent segments |
US7553324B2 (en) | 2003-10-14 | 2009-06-30 | Xtent, Inc. | Fixed stent delivery devices and methods |
US20050080475A1 (en) | 2003-10-14 | 2005-04-14 | Xtent, Inc. A Delaware Corporation | Stent delivery devices and methods |
US7175654B2 (en) | 2003-10-16 | 2007-02-13 | Cordis Corporation | Stent design having stent segments which uncouple upon deployment |
US20050085897A1 (en) | 2003-10-17 | 2005-04-21 | Craig Bonsignore | Stent design having independent stent segments which uncouple upon deployment |
WO2005043123A2 (en) | 2003-10-31 | 2005-05-12 | Queststar Medical, Inc. | System and apparatus for body fluid analysis using surface-textured optical materials |
US7220755B2 (en) | 2003-11-12 | 2007-05-22 | Biosensors International Group, Ltd. | 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same |
US7090694B1 (en) | 2003-11-19 | 2006-08-15 | Advanced Cardiovascular Systems, Inc. | Portal design for stent for treating bifurcated vessels |
US8157855B2 (en) | 2003-12-05 | 2012-04-17 | Boston Scientific Scimed, Inc. | Detachable segment stent |
US7244336B2 (en) * | 2003-12-17 | 2007-07-17 | Lam Research Corporation | Temperature controlled hot edge ring assembly for reducing plasma reactor etch rate drift |
US7529722B2 (en) * | 2003-12-22 | 2009-05-05 | Dintecom, Inc. | Automatic creation of neuro-fuzzy expert system from online anlytical processing (OLAP) tools |
US20070156225A1 (en) | 2003-12-23 | 2007-07-05 | Xtent, Inc. | Automated control mechanisms and methods for custom length stent apparatus |
US9232948B2 (en) * | 2003-12-23 | 2016-01-12 | Stryker Corporation | Catheter with distal occlusion apparatus |
US20050149168A1 (en) | 2003-12-30 | 2005-07-07 | Daniel Gregorich | Stent to be deployed on a bend |
GB0400571D0 (en) | 2004-01-12 | 2004-02-11 | Angiomed Gmbh & Co | Implant |
US20050171568A1 (en) * | 2004-01-30 | 2005-08-04 | Niall Duffy | Catheter and guidewire exchange system with improved catheter design |
US20050222671A1 (en) | 2004-03-31 | 2005-10-06 | Schaeffer Darin G | Partially biodegradable stent |
US20050228477A1 (en) | 2004-04-09 | 2005-10-13 | Xtent, Inc. | Topographic coatings and coating methods for medical devices |
US7820732B2 (en) * | 2004-04-30 | 2010-10-26 | Advanced Cardiovascular Systems, Inc. | Methods for modulating thermal and mechanical properties of coatings on implantable devices |
US20050278011A1 (en) * | 2004-06-10 | 2005-12-15 | Peckham John E | Stent delivery system |
US7824439B2 (en) * | 2004-06-25 | 2010-11-02 | Zeon Corporation | Zigzag-shaped stent configured to produce less wall damage |
US8317859B2 (en) * | 2004-06-28 | 2012-11-27 | J.W. Medical Systems Ltd. | Devices and methods for controlling expandable prostheses during deployment |
ATE506029T1 (en) | 2004-10-25 | 2011-05-15 | Merit Medical Systems Inc | DEVICE FOR REMOVAL AND REPLACEMENT OF A STENT |
US9050393B2 (en) * | 2005-02-08 | 2015-06-09 | Bruce N. Saffran | Medical devices and methods for modulation of physiology using device-based surface chemistry |
US7402168B2 (en) * | 2005-04-11 | 2008-07-22 | Xtent, Inc. | Custom-length stent delivery system with independently operable expansion elements |
US8460357B2 (en) | 2005-05-31 | 2013-06-11 | J.W. Medical Systems Ltd. | In situ stent formation |
US7938851B2 (en) | 2005-06-08 | 2011-05-10 | Xtent, Inc. | Devices and methods for operating and controlling interventional apparatus |
US8021426B2 (en) | 2005-06-15 | 2011-09-20 | Ouroboros Medical, Inc. | Mechanical apparatus and method for artificial disc replacement |
JP4797473B2 (en) * | 2005-07-11 | 2011-10-19 | ニプロ株式会社 | Flexible stent with excellent expandability |
WO2007035805A2 (en) | 2005-09-20 | 2007-03-29 | Purdue Research Foundation | Biocompatable nanophase materials |
US7465489B2 (en) | 2005-11-15 | 2008-12-16 | Poly-Med, Inc. | Inorganic-organic melted-extruded hybrid filaments and medical applications thereof |
US20070179587A1 (en) | 2006-01-30 | 2007-08-02 | Xtent, Inc. | Apparatus and methods for deployment of custom-length prostheses |
US8652198B2 (en) | 2006-03-20 | 2014-02-18 | J.W. Medical Systems Ltd. | Apparatus and methods for deployment of linked prosthetic segments |
US20070265637A1 (en) | 2006-04-21 | 2007-11-15 | Xtent, Inc. | Devices and methods for controlling and counting interventional elements |
US20070281117A1 (en) * | 2006-06-02 | 2007-12-06 | Xtent, Inc. | Use of plasma in formation of biodegradable stent coating |
US8603530B2 (en) | 2006-06-14 | 2013-12-10 | Abbott Cardiovascular Systems Inc. | Nanoshell therapy |
US8236044B2 (en) | 2006-06-30 | 2012-08-07 | Boston Scientific Scimed, Inc. | Stent design with variable expansion columns along circumference |
US20080269865A1 (en) | 2006-08-07 | 2008-10-30 | Xtent, Inc. | Custom Length Stent Apparatus |
FR2911063B1 (en) * | 2007-01-09 | 2009-03-20 | Stentys S A S Soc Par Actions | RUPTIBLE BRIDGE STRUCTURE FOR STENT, AND STENT INCLUDING SUCH BRIDGE STRUCTURES. |
US20080199510A1 (en) | 2007-02-20 | 2008-08-21 | Xtent, Inc. | Thermo-mechanically controlled implants and methods of use |
US8486132B2 (en) * | 2007-03-22 | 2013-07-16 | J.W. Medical Systems Ltd. | Devices and methods for controlling expandable prostheses during deployment |
US9370642B2 (en) | 2007-06-29 | 2016-06-21 | J.W. Medical Systems Ltd. | Adjustable-length drug delivery balloon |
US20090076584A1 (en) | 2007-09-19 | 2009-03-19 | Xtent, Inc. | Apparatus and methods for deployment of multiple custom-length prostheses |
US9101503B2 (en) * | 2008-03-06 | 2015-08-11 | J.W. Medical Systems Ltd. | Apparatus having variable strut length and methods of use |
US8280680B2 (en) * | 2009-12-07 | 2012-10-02 | Pitney Bowes Inc. | Method and apparatus for detecting mailpiece thickness in an inserter system |
-
2008
- 2008-02-19 US US12/033,586 patent/US20080199510A1/en not_active Abandoned
- 2008-02-20 ES ES08730274T patent/ES2762164T3/en active Active
- 2008-02-20 AU AU2008218719A patent/AU2008218719A1/en not_active Abandoned
- 2008-02-20 WO PCT/US2008/054437 patent/WO2008103741A1/en active Application Filing
- 2008-02-20 CA CA002678814A patent/CA2678814A1/en not_active Abandoned
- 2008-02-20 JP JP2009550987A patent/JP2010518980A/en active Pending
- 2008-02-20 EP EP08730274.1A patent/EP2114301B1/en active Active
-
2010
- 2010-09-28 US US12/892,553 patent/US8980297B2/en active Active
-
2015
- 2015-01-28 US US14/607,944 patent/US9457133B2/en active Active
Patent Citations (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4069825A (en) * | 1976-01-28 | 1978-01-24 | Taichiro Akiyama | Surgical thread and cutting apparatus for the same |
US4564014A (en) * | 1980-01-30 | 1986-01-14 | Thomas J. Fogarty | Variable length dilatation catheter apparatus and method |
US4512338A (en) * | 1983-01-25 | 1985-04-23 | Balko Alexander B | Process for restoring patency to body vessels |
US4891225A (en) * | 1984-05-21 | 1990-01-02 | Massachusetts Institute Of Technology | Bioerodible polyanhydrides for controlled drug delivery |
US4580568A (en) * | 1984-10-01 | 1986-04-08 | Cook, Incorporated | Percutaneous endovascular stent and method for insertion thereof |
US5102417A (en) * | 1985-11-07 | 1992-04-07 | Expandable Grafts Partnership | Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft |
US4733665A (en) * | 1985-11-07 | 1988-03-29 | Expandable Grafts Partnership | Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft |
US4739762A (en) * | 1985-11-07 | 1988-04-26 | Expandable Grafts Partnership | Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft |
US4739762B1 (en) * | 1985-11-07 | 1998-10-27 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
US4733665C2 (en) * | 1985-11-07 | 2002-01-29 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
US4733665B1 (en) * | 1985-11-07 | 1994-01-11 | Expandable Grafts Partnership | Expandable intraluminal graft,and method and apparatus for implanting an expandable intraluminal graft |
US5300085A (en) * | 1986-04-15 | 1994-04-05 | Advanced Cardiovascular Systems, Inc. | Angioplasty apparatus facilitating rapid exchanges and method |
US5501227A (en) * | 1986-04-15 | 1996-03-26 | Yock; Paul G. | Angioplasty apparatus facilitating rapid exchange and method |
US5496346A (en) * | 1987-01-06 | 1996-03-05 | Advanced Cardiovascular Systems, Inc. | Reinforced balloon dilatation catheter with slitted exchange sleeve and method |
US4988356A (en) * | 1987-02-27 | 1991-01-29 | C. R. Bard, Inc. | Catheter and guidewire exchange system |
US5092877A (en) * | 1988-09-01 | 1992-03-03 | Corvita Corporation | Radially expandable endoprosthesis |
US5195984A (en) * | 1988-10-04 | 1993-03-23 | Expandable Grafts Partnership | Expandable intraluminal graft |
US4994066A (en) * | 1988-10-07 | 1991-02-19 | Voss Gene A | Prostatic stent |
US4994069A (en) * | 1988-11-02 | 1991-02-19 | Target Therapeutics | Vaso-occlusion coil and method |
US5891190A (en) * | 1989-08-24 | 1999-04-06 | Boneau; Michael D. | Endovascular support device and method |
US5104404A (en) * | 1989-10-02 | 1992-04-14 | Medtronic, Inc. | Articulated stent |
US5282824A (en) * | 1990-10-09 | 1994-02-01 | Cook, Incorporated | Percutaneous stent assembly |
US6527789B1 (en) * | 1991-01-28 | 2003-03-04 | Advanced Cardiovascular Systems, Inc. | Stent delivery system |
US5507768A (en) * | 1991-01-28 | 1996-04-16 | Advanced Cardiovascular Systems, Inc. | Stent delivery system |
US6692465B2 (en) * | 1991-06-11 | 2004-02-17 | Advanced Cardiovascular Systems, Inc. | Catheter system with catheter and guidewire exchange |
US5490837A (en) * | 1991-07-05 | 1996-02-13 | Scimed Life Systems, Inc. | Single operator exchange catheter having a distal catheter shaft section |
US5507771A (en) * | 1992-06-15 | 1996-04-16 | Cook Incorporated | Stent assembly |
US5855563A (en) * | 1992-11-02 | 1999-01-05 | Localmed, Inc. | Method and apparatus for sequentially performing multiple intraluminal procedures |
US5741323A (en) * | 1993-04-28 | 1998-04-21 | Focal, Inc. | Polymeric article for intraluminal photothermoforming |
US6357104B1 (en) * | 1993-08-18 | 2002-03-19 | David J. Myers | Method of making an intraluminal stent graft |
US5607444A (en) * | 1993-12-02 | 1997-03-04 | Advanced Cardiovascular Systems, Inc. | Ostial stent for bifurcations |
US5879370A (en) * | 1994-02-25 | 1999-03-09 | Fischell; Robert E. | Stent having a multiplicity of undulating longitudinals |
US5593412A (en) * | 1994-03-01 | 1997-01-14 | Cordis Corporation | Stent delivery method and apparatus |
US5716393A (en) * | 1994-05-26 | 1998-02-10 | Angiomed Gmbh & Co. Medizintechnik Kg | Stent with an end of greater diameter than its main body |
US5723003A (en) * | 1994-09-13 | 1998-03-03 | Ultrasonic Sensing And Monitoring Systems | Expandable graft assembly and method of use |
US5735869A (en) * | 1994-11-30 | 1998-04-07 | Schneider (Europe) A.G. | Balloon catheter and stent delivery device |
US6183509B1 (en) * | 1995-05-04 | 2001-02-06 | Alain Dibie | Endoprosthesis for the treatment of blood-vessel bifurcation stenosis and purpose-built installation device |
US6033434A (en) * | 1995-06-08 | 2000-03-07 | Ave Galway Limited | Bifurcated endovascular stent and methods for forming and placing |
US5870381A (en) * | 1995-07-10 | 1999-02-09 | Matsushita Electric Industrial Co., Ltd. | Method for transmitting signals from a plurality of transmitting units and receiving the signals |
US7005454B2 (en) * | 1995-07-28 | 2006-02-28 | Rutgers, The State University | Polymeric drug formulations |
US5722669A (en) * | 1995-09-26 | 1998-03-03 | Keeper Co., Ltd. | Resin CVJ boot with distinct large and small crest portions |
US6520986B2 (en) * | 1995-12-14 | 2003-02-18 | Gore Enterprise Holdings, Inc. | Kink resistant stent-graft |
US5895398A (en) * | 1996-02-02 | 1999-04-20 | The Regents Of The University Of California | Method of using a clot capture coil |
US6200337B1 (en) * | 1996-03-10 | 2001-03-13 | Terumo Kabushiki Kaisha | Implanting stent |
US5709701A (en) * | 1996-05-30 | 1998-01-20 | Parodi; Juan C. | Apparatus for implanting a prothesis within a body passageway |
US6190402B1 (en) * | 1996-06-21 | 2001-02-20 | Musc Foundation For Research Development | Insitu formable and self-forming intravascular flow modifier (IFM) and IFM assembly for deployment of same |
US6039721A (en) * | 1996-07-24 | 2000-03-21 | Cordis Corporation | Method and catheter system for delivering medication with an everting balloon catheter |
US6712827B2 (en) * | 1996-08-23 | 2004-03-30 | Scimed Life Systems, Inc. | Stent delivery system |
US6179878B1 (en) * | 1996-10-22 | 2001-01-30 | Thomas Duerig | Composite self expanding stent device having a restraining element |
US6551350B1 (en) * | 1996-12-23 | 2003-04-22 | Gore Enterprise Holdings, Inc. | Kink resistant bifurcated prosthesis |
US6520987B1 (en) * | 1997-02-25 | 2003-02-18 | Symbiotech Medical, Inc | Expandable intravascular stent |
US6344272B1 (en) * | 1997-03-12 | 2002-02-05 | Wm. Marsh Rice University | Metal nanoshells |
US6852252B2 (en) * | 1997-03-12 | 2005-02-08 | William Marsh Rice University | Use of metalnanoshells to impede the photo-oxidation of conjugated polymer |
US20020037358A1 (en) * | 1997-08-13 | 2002-03-28 | Barry James J. | Loading and release of water-insoluble drugs |
US6511468B1 (en) * | 1997-10-17 | 2003-01-28 | Micro Therapeutics, Inc. | Device and method for controlling injection of liquid embolic composition |
US6022374A (en) * | 1997-12-16 | 2000-02-08 | Cardiovasc, Inc. | Expandable stent having radiopaque marker and method |
US6699724B1 (en) * | 1998-03-11 | 2004-03-02 | Wm. Marsh Rice University | Metal nanoshells for biosensing applications |
US6042589A (en) * | 1998-03-17 | 2000-03-28 | Medicorp, S.A. | Reversible-action endoprosthesis delivery device |
US6036725A (en) * | 1998-06-10 | 2000-03-14 | General Science And Technology | Expandable endovascular support device |
US6196995B1 (en) * | 1998-09-30 | 2001-03-06 | Medtronic Ave, Inc. | Reinforced edge exchange catheter |
US6527799B2 (en) * | 1998-10-29 | 2003-03-04 | Conor Medsystems, Inc. | Expandable medical device with ductile hinges |
US6709379B1 (en) * | 1998-11-02 | 2004-03-23 | Alcove Surfaces Gmbh | Implant with cavities containing therapeutic agents |
US6022359A (en) * | 1999-01-13 | 2000-02-08 | Frantzen; John J. | Stent delivery system featuring a flexible balloon |
US6187034B1 (en) * | 1999-01-13 | 2001-02-13 | John J. Frantzen | Segmented stent for flexible stent delivery system |
US6344811B1 (en) * | 1999-03-16 | 2002-02-05 | Audio Logic, Inc. | Power supply compensation for noise shaped, digital amplifiers |
US6379365B1 (en) * | 1999-03-29 | 2002-04-30 | Alexis Diaz | Stent delivery catheter system having grooved shaft |
US6699280B2 (en) * | 1999-04-15 | 2004-03-02 | Mayo Foundation For Medical Education And Research | Multi-section stent |
US6375676B1 (en) * | 1999-05-17 | 2002-04-23 | Advanced Cardiovascular Systems, Inc. | Self-expanding stent with enhanced delivery precision and stent delivery system |
US6858034B1 (en) * | 1999-05-20 | 2005-02-22 | Scimed Life Systems, Inc. | Stent delivery system for prevention of kinking, and method of loading and using same |
US6855125B2 (en) * | 1999-05-20 | 2005-02-15 | Conor Medsystems, Inc. | Expandable medical device delivery system and method |
US6530944B2 (en) * | 2000-02-08 | 2003-03-11 | Rice University | Optically-active nanoparticles for use in therapeutic and diagnostic methods |
US6702843B1 (en) * | 2000-04-12 | 2004-03-09 | Scimed Life Systems, Inc. | Stent delivery means with balloon retraction means |
US6555157B1 (en) * | 2000-07-25 | 2003-04-29 | Advanced Cardiovascular Systems, Inc. | Method for coating an implantable device and system for performing the method |
US6540777B2 (en) * | 2001-02-15 | 2003-04-01 | Scimed Life Systems, Inc. | Locking stent |
US6712845B2 (en) * | 2001-04-24 | 2004-03-30 | Advanced Cardiovascular Systems, Inc. | Coating for a stent and a method of forming the same |
US6837901B2 (en) * | 2001-04-27 | 2005-01-04 | Intek Technology L.L.C. | Methods for delivering, repositioning and/or retrieving self-expanding stents |
US6709440B2 (en) * | 2001-05-17 | 2004-03-23 | Advanced Cardiovascular Systems, Inc. | Stent and catheter assembly and method for treating bifurcations |
US6676695B2 (en) * | 2001-05-30 | 2004-01-13 | Jan Otto Solem | Vascular instrument and method |
US6679909B2 (en) * | 2001-07-31 | 2004-01-20 | Advanced Cardiovascular Systems, Inc. | Rapid exchange delivery system for self-expanding stent |
US20030045923A1 (en) * | 2001-08-31 | 2003-03-06 | Mehran Bashiri | Hybrid balloon expandable/self expanding stent |
US6685730B2 (en) * | 2001-09-26 | 2004-02-03 | Rice University | Optically-absorbing nanoparticles for enhanced tissue repair |
US20050038505A1 (en) * | 2001-11-05 | 2005-02-17 | Sun Biomedical Ltd. | Drug-delivery endovascular stent and method of forming the same |
US20050010276A1 (en) * | 2001-12-03 | 2005-01-13 | Xtent, Inc. | Apparatus and methods for positioning prostheses for deployment from a catheter |
US7182779B2 (en) * | 2001-12-03 | 2007-02-27 | Xtent, Inc. | Apparatus and methods for positioning prostheses for deployment from a catheter |
US20050049673A1 (en) * | 2001-12-03 | 2005-03-03 | Xtent, Inc. A Delaware Corporation | Apparatus and methods for delivery of braided prostheses |
US20070067012A1 (en) * | 2001-12-03 | 2007-03-22 | Xtent, Inc. | Custom length stent apparatus |
US20040030380A1 (en) * | 2002-04-24 | 2004-02-12 | Sun Biomedical, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
US20040024450A1 (en) * | 2002-04-24 | 2004-02-05 | Sun Biomedical, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
US20040044395A1 (en) * | 2002-09-03 | 2004-03-04 | Scimed Life Systems, Inc. | Elephant trunk thoracic endograft and delivery system |
US6994721B2 (en) * | 2002-10-21 | 2006-02-07 | Israel Henry M | Stent assembly |
US7169172B2 (en) * | 2002-11-01 | 2007-01-30 | Counter Clockwise, Inc. | Method and apparatus for caged stent delivery |
US6849084B2 (en) * | 2002-12-31 | 2005-02-01 | Intek Technology L.L.C. | Stent delivery system |
US7314480B2 (en) * | 2003-02-27 | 2008-01-01 | Boston Scientific Scimed, Inc. | Rotating balloon expandable sheath bifurcation delivery |
US7192440B2 (en) * | 2003-10-15 | 2007-03-20 | Xtent, Inc. | Implantable stent delivery devices and methods |
US7326236B2 (en) * | 2003-12-23 | 2008-02-05 | Xtent, Inc. | Devices and methods for controlling and indicating the length of an interventional element |
US7323006B2 (en) * | 2004-03-30 | 2008-01-29 | Xtent, Inc. | Rapid exchange interventional devices and methods |
US20080077229A1 (en) * | 2004-06-28 | 2008-03-27 | Xtent, Inc. | Custom-length self-expanding stent delivery systems with stent bumpers |
US20060002852A1 (en) * | 2004-07-01 | 2006-01-05 | Yale University | Targeted and high density drug loaded polymeric materials |
US20060069424A1 (en) * | 2004-09-27 | 2006-03-30 | Xtent, Inc. | Self-constrained segmented stents and methods for their deployment |
US20070027521A1 (en) * | 2005-06-08 | 2007-02-01 | Xtent, Inc., A Delaware Corporation | Apparatus and methods for deployment of multiple custom-length prostheses |
US7320702B2 (en) * | 2005-06-08 | 2008-01-22 | Xtent, Inc. | Apparatus and methods for deployment of multiple custom-length prostheses (III) |
US20080071345A1 (en) * | 2005-06-08 | 2008-03-20 | Xtent, Inc. | Apparatus and methods for deployment of multiple custom-length prostheses (iii) |
Cited By (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8257427B2 (en) | 2001-09-11 | 2012-09-04 | J.W. Medical Systems, Ltd. | Expandable stent |
US8702781B2 (en) | 2001-12-03 | 2014-04-22 | J.W. Medical Systems Ltd. | Apparatus and methods for delivery of multiple distributed stents |
US8016870B2 (en) | 2001-12-03 | 2011-09-13 | Xtent, Inc. | Apparatus and methods for delivery of variable length stents |
US9326876B2 (en) | 2001-12-03 | 2016-05-03 | J.W. Medical Systems Ltd. | Apparatus and methods for delivery of multiple distributed stents |
US7892274B2 (en) | 2001-12-03 | 2011-02-22 | Xtent, Inc. | Apparatus and methods for deployment of vascular prostheses |
US7892273B2 (en) | 2001-12-03 | 2011-02-22 | Xtent, Inc. | Custom length stent apparatus |
US8177831B2 (en) | 2001-12-03 | 2012-05-15 | Xtent, Inc. | Stent delivery apparatus and method |
US7938852B2 (en) | 2001-12-03 | 2011-05-10 | Xtent, Inc. | Apparatus and methods for delivery of braided prostheses |
US20040249434A1 (en) * | 2001-12-03 | 2004-12-09 | Xtent, Inc. | Stent delivery for bifuricated vessels |
US8016871B2 (en) | 2001-12-03 | 2011-09-13 | Xtent, Inc. | Apparatus and methods for delivery of multiple distributed stents |
US8574282B2 (en) | 2001-12-03 | 2013-11-05 | J.W. Medical Systems Ltd. | Apparatus and methods for delivery of braided prostheses |
US8070789B2 (en) | 2001-12-03 | 2011-12-06 | Xtent, Inc. | Apparatus and methods for deployment of vascular prostheses |
US8080048B2 (en) | 2001-12-03 | 2011-12-20 | Xtent, Inc. | Stent delivery for bifurcated vessels |
US8083788B2 (en) | 2001-12-03 | 2011-12-27 | Xtent, Inc. | Apparatus and methods for positioning prostheses for deployment from a catheter |
US8956398B2 (en) | 2001-12-03 | 2015-02-17 | J.W. Medical Systems Ltd. | Custom length stent apparatus |
US8282680B2 (en) | 2003-01-17 | 2012-10-09 | J. W. Medical Systems Ltd. | Multiple independent nested stent structures and methods for their preparation and deployment |
US8740968B2 (en) | 2003-01-17 | 2014-06-03 | J.W. Medical Systems Ltd. | Multiple independent nested stent structures and methods for their preparation and deployment |
US7918881B2 (en) | 2003-06-09 | 2011-04-05 | Xtent, Inc. | Stent deployment systems and methods |
US8585747B2 (en) | 2003-12-23 | 2013-11-19 | J.W. Medical Systems Ltd. | Devices and methods for controlling and indicating the length of an interventional element |
US9566179B2 (en) | 2003-12-23 | 2017-02-14 | J.W. Medical Systems Ltd. | Devices and methods for controlling and indicating the length of an interventional element |
US8460358B2 (en) | 2004-03-30 | 2013-06-11 | J.W. Medical Systems, Ltd. | Rapid exchange interventional devices and methods |
US9700448B2 (en) | 2004-06-28 | 2017-07-11 | J.W. Medical Systems Ltd. | Devices and methods for controlling expandable prostheses during deployment |
US8986362B2 (en) | 2004-06-28 | 2015-03-24 | J.W. Medical Systems Ltd. | Devices and methods for controlling expandable prostheses during deployment |
US8317859B2 (en) | 2004-06-28 | 2012-11-27 | J.W. Medical Systems Ltd. | Devices and methods for controlling expandable prostheses during deployment |
US9883957B2 (en) | 2006-03-20 | 2018-02-06 | J.W. Medical Systems Ltd. | Apparatus and methods for deployment of linked prosthetic segments |
US8652198B2 (en) | 2006-03-20 | 2014-02-18 | J.W. Medical Systems Ltd. | Apparatus and methods for deployment of linked prosthetic segments |
US20080099170A1 (en) * | 2006-10-31 | 2008-05-01 | The Procter & Gamble Company | Process of making wet-microcontracted paper |
US9457133B2 (en) | 2007-02-20 | 2016-10-04 | J.W. Medical Systems Ltd. | Thermo-mechanically controlled implants and methods of use |
US8980297B2 (en) | 2007-02-20 | 2015-03-17 | J.W. Medical Systems Ltd. | Thermo-mechanically controlled implants and methods of use |
US8486132B2 (en) | 2007-03-22 | 2013-07-16 | J.W. Medical Systems Ltd. | Devices and methods for controlling expandable prostheses during deployment |
US9339404B2 (en) | 2007-03-22 | 2016-05-17 | J.W. Medical Systems Ltd. | Devices and methods for controlling expandable prostheses during deployment |
US9814544B2 (en) * | 2008-01-09 | 2017-11-14 | Innovative Health Technologies, Llc | Implant pellets and methods for performing bone augmentation and preservation |
US20160213449A1 (en) * | 2008-01-09 | 2016-07-28 | Innovative Health Technologies, Llc | Implant Pellets and Methods for Performing Bone Augmentation and Preservation |
US8128706B2 (en) * | 2008-01-09 | 2012-03-06 | Innovative Health Technologies, Llc | Implant pellets and methods for performing bone augmentation and preservation |
US9301816B2 (en) | 2008-01-09 | 2016-04-05 | Innovative Health Technologies, Llc | Implant pellets and methods for performing bone augmentation and preservation |
US20090176193A1 (en) * | 2008-01-09 | 2009-07-09 | Kaigler Sr Darnell | Implant pellets and methods for performing bone augmentation and preservation |
US9101503B2 (en) | 2008-03-06 | 2015-08-11 | J.W. Medical Systems Ltd. | Apparatus having variable strut length and methods of use |
US20090326654A1 (en) * | 2008-06-30 | 2009-12-31 | Allergan, Inc. | Fillable prosthetic implant with gel-like properties |
US10610391B2 (en) | 2008-09-25 | 2020-04-07 | Advanced Bifurcation Systems Inc. | Stent alignment during treatment of a bifurcation |
US11000392B2 (en) | 2008-09-25 | 2021-05-11 | Advanced Bifurcation Systems Inc. | Partially crimped stent |
US9724218B2 (en) | 2008-09-25 | 2017-08-08 | Advanced Bifurcation Systems, Inc. | Methods and systems for ostial stenting of a bifurcation |
US8821562B2 (en) | 2008-09-25 | 2014-09-02 | Advanced Bifurcation Systems, Inc. | Partially crimped stent |
US10219926B2 (en) | 2008-09-25 | 2019-03-05 | Advanced Bifurcation Systems Inc. | Selective stent crimping |
US8808347B2 (en) | 2008-09-25 | 2014-08-19 | Advanced Bifurcation Systems, Inc. | Stent alignment during treatment of a bifurcation |
US8795347B2 (en) | 2008-09-25 | 2014-08-05 | Advanced Bifurcation Systems, Inc. | Methods and systems for treating a bifurcation with provisional side branch stenting |
US8769796B2 (en) | 2008-09-25 | 2014-07-08 | Advanced Bifurcation Systems, Inc. | Selective stent crimping |
US8979917B2 (en) | 2008-09-25 | 2015-03-17 | Advanced Bifurcation Systems, Inc. | System and methods for treating a bifurcation |
US8828071B2 (en) | 2008-09-25 | 2014-09-09 | Advanced Bifurcation Systems, Inc. | Methods and systems for ostial stenting of a bifurcation |
US11839562B2 (en) | 2008-09-25 | 2023-12-12 | Advanced Bifurcation Systems Inc. | Partially crimped stent |
US9855158B2 (en) | 2008-09-25 | 2018-01-02 | Advanced Bifurcation Systems, Inc. | Stent alignment during treatment of a bifurcation |
US10219927B2 (en) | 2008-09-25 | 2019-03-05 | Advanced Bifurcation Systems Inc. | System and methods for treating a bifurcation |
US9737424B2 (en) | 2008-09-25 | 2017-08-22 | Advanced Bifurcation Systems, Inc. | Partially crimped stent |
US10918506B2 (en) | 2008-09-25 | 2021-02-16 | Advanced Bifurcation Systems Inc. | System and methods for treating a bifurcation |
US9730821B2 (en) | 2008-09-25 | 2017-08-15 | Advanced Bifurcation Systems, Inc. | Methods and systems for treating a bifurcation with provisional side branch stenting |
US11857442B2 (en) | 2008-09-25 | 2024-01-02 | Advanced Bifurcation Systems Inc. | System and methods for treating a bifurcation |
EP2384725A1 (en) * | 2010-05-06 | 2011-11-09 | Biotronik AG | Biocorrodable implant in which corrosion may be triggered or accelerated after implantation by means of an external stimulus |
US9072618B2 (en) | 2010-05-06 | 2015-07-07 | Biotronik Ag | Biocorrodable implant in which corrosion may be triggered or accelerated after implantation by means of an external stimulus |
US8273010B2 (en) | 2010-06-14 | 2012-09-25 | Coloplast A/S | Incontinence treatment device |
US8550979B2 (en) | 2010-06-15 | 2013-10-08 | Coloplast A/S | Method of treating incontinence |
US9517357B2 (en) | 2010-09-03 | 2016-12-13 | Tufts University | Plasmonic nanoparticle-doped silk materials |
CN103328034A (en) * | 2010-09-03 | 2013-09-25 | 塔夫茨大学/塔夫茨学院信托人 | Plasmonic nanoparticle-doped silk materials |
US9364356B2 (en) | 2011-02-08 | 2016-06-14 | Advanced Bifurcation System, Inc. | System and methods for treating a bifurcation with a fully crimped stent |
US11000393B2 (en) | 2011-02-08 | 2021-05-11 | Advanced Bifurcation Systems Inc. | System and methods for treating a bifurcation with a fully crimped stent |
US11717428B2 (en) | 2011-02-08 | 2023-08-08 | Advanced Bifurcation Systems Inc. | System and methods for treating a bifurcation with a fully crimped stent |
US9254210B2 (en) | 2011-02-08 | 2016-02-09 | Advanced Bifurcation Systems, Inc. | Multi-stent and multi-balloon apparatus for treating bifurcations and methods of use |
US10285832B2 (en) | 2011-02-08 | 2019-05-14 | Advanced Bifurcation Systems Inc. | System and methods for treating a bifurcation with a fully crimped stent |
US10406010B2 (en) | 2011-02-08 | 2019-09-10 | Advanced Bifurcation Systems Inc. | Multi-stent and multi-balloon apparatus for treating bifurcations and methods of use |
US20130245759A1 (en) * | 2012-03-09 | 2013-09-19 | The Florida International University Board Of Trustees | Medical devices incorporating silicone nanoparticles, and uses thereof |
US10993834B2 (en) | 2013-01-15 | 2021-05-04 | The Regents Of The University Of Colorado, A Body Corporate | Lacrimal system drug delivery device |
US11806447B2 (en) | 2013-11-05 | 2023-11-07 | Tepha, Inc. | Compositions and devices of poly-4-hydroxybutyrate |
US20150126615A1 (en) * | 2013-11-05 | 2015-05-07 | Tepha, Inc. | Compositions and devices of poly-4-hydroxybutyrate |
US9480780B2 (en) * | 2013-11-05 | 2016-11-01 | Tepha, Inc. | Compositions and devices of poly-4-hydroxybutyrate |
US9999527B2 (en) * | 2015-02-11 | 2018-06-19 | Abbott Cardiovascular Systems Inc. | Scaffolds having radiopaque markers |
US20160228267A1 (en) * | 2015-02-11 | 2016-08-11 | Abbott Cardiovascular Systems Inc. | Scaffolds having radiopaque markers |
US10610387B2 (en) | 2015-06-12 | 2020-04-07 | Abbott Cardiovascular Systems Inc. | Scaffolds having a radiopaque marker and methods for attaching a marker to a scaffold |
US11478370B2 (en) | 2015-06-12 | 2022-10-25 | Abbott Cardiovascular Systems Inc. | Scaffolds having a radiopaque marker and methods for attaching a marker to a scaffold |
US11857461B2 (en) * | 2015-11-23 | 2024-01-02 | The Regents Of The University Of Colorado, A Body Corporate | Lacrimal system for drug delivery |
US11207211B2 (en) | 2016-05-20 | 2021-12-28 | The Regents Of The University Of Colorado, A Body Corporate | Lacrimal drug delivery device |
US20180235750A1 (en) * | 2017-02-21 | 2018-08-23 | Biosense Webster (Israel) Ltd. | Heat expandable breast implant using induction heating |
WO2018154419A1 (en) * | 2017-02-21 | 2018-08-30 | Biosense Webster (Israel) Ltd. | Heat expandable breast implant using induction heating |
US10182904B2 (en) * | 2017-02-21 | 2019-01-22 | Biosense Webster (Israel) Ltd. | Heat expandable breast implant using induction heating |
CN110312493A (en) * | 2017-02-21 | 2019-10-08 | 韦伯斯特生物官能(以色列)有限公司 | It may expand breast implant using the heat of induction heating |
CN113056295A (en) * | 2018-11-02 | 2021-06-29 | 波士顿科学国际有限公司 | Biodegradable stent |
US11497595B2 (en) * | 2018-11-02 | 2022-11-15 | Boston Scientific Scimed, Inc. | Biodegradable stent |
Also Published As
Publication number | Publication date |
---|---|
US20150142098A1 (en) | 2015-05-21 |
AU2008218719A1 (en) | 2008-08-28 |
EP2114301A1 (en) | 2009-11-11 |
US20110022148A1 (en) | 2011-01-27 |
JP2010518980A (en) | 2010-06-03 |
EP2114301B1 (en) | 2019-10-02 |
ES2762164T3 (en) | 2020-05-22 |
US9457133B2 (en) | 2016-10-04 |
EP2114301A4 (en) | 2017-06-07 |
WO2008103741A1 (en) | 2008-08-28 |
CA2678814A1 (en) | 2008-08-28 |
US8980297B2 (en) | 2015-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9457133B2 (en) | Thermo-mechanically controlled implants and methods of use | |
US11577055B2 (en) | Adjustable-length drug delivery balloon | |
US5849035A (en) | Methods for intraluminal photothermoforming | |
ES2251012T3 (en) | BIODEGRADABLE STENT. | |
JP4067274B2 (en) | Stent with programmed pattern of in vivo degradation | |
JP4387670B2 (en) | Thermomechanically expandable stent | |
US5551954A (en) | Biodegradable drug delivery vascular stent | |
JP4665109B2 (en) | Polymer-based stent assembly | |
JP2940859B2 (en) | Shape memory lock mechanism for intravascular stent | |
AU2014400542B2 (en) | Thin strut stent from bioabsorbable polymer with high fatigue and radial strength and method to manufacture thereof | |
AU2003272529A1 (en) | Drawn expanded stent | |
JP2008296041A (en) | Stent for vascular channel | |
JP2004522494A (en) | Stent for in-stent restenosis | |
US20180344991A1 (en) | Balloon catheter device for in vivo polymerization of bioresorbable scaffolds | |
KR101686628B1 (en) | Drug and photothermal therapy capable hybrid stent and a method of manufacturing the same | |
JP2005052419A (en) | Stent | |
JP2013046829A (en) | Polymer base stent assembly |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: XTENT, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RUANE, PATRICK H.;WILSON, CAMERON L.;REEL/FRAME:020887/0499 Effective date: 20080430 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |